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ABSTRACT 
 
Parkinson’s disease (PD) is the second most common neurodegenerative disease, 
characterised by a typical movement disorder, accompanied by a number of non-motor 
manifestations including cognitive impairment, neuropsychiatric symptoms, autonomic 
features and sleep disturbance.   The aetiology of PD is incompletely understood, but 
there has been growing interest in the role of genetic risk factors contributing to the 
development of PD. 
 
Mutations in the GBA1 gene have been identified as numerically the most important in 
PD, being found in approximately 5 % to 10 % of patients, and increasing the risk of 
developing PD by up to 20- to 30-fold. However, there is correlation between the severity 
of the genetic variant and the degree to which PD risk is increased, with milder variants 
only increasing the risk by approximately two-fold. Furthermore, as well as being 
relatively common, GBA1 mutations have also been reported to adversely affect 
prognosis, in terms of motor progression and risk of dementia, though questions remain 
about the incidence of these outcomes and the contribution of “non-pathogenic” variants 
in the GBA1 gene. GBA1 mutation-associated PD (GBA1-PD) therefore constitutes an 
important subgroup of the PD population, and one in which novel therapies could 
significantly reduce the burden of PD. The pathogenesis of GBA1-PD seems to be related 
to dysfunction of the lysosome-autophagy system, making this system a prime therapeutic 
target in this group. 
 
This project consists of a combined epidemiological and in vitro study of GBA1-PD, with 
a focus on better characterisation of the clinical aspects of GBA1-PD, and establishing a 
novel disease model using directly reprogrammed induced neurons (iNs) in which to test 
putative disease-modifying treatments. Firstly, long-term data from two incident PD 
clinical cohorts is presented, which constitutes the longest follow-up study of GBA1-PD 
to date. Consistent with previous studies, GBA1 abnormalities were found to increase the 
risk of dementia and motor progression, and also to increase the risk of death – an 
outcome which few studies have previously reported on. Additionally, it was found that 
carrying “non-pathogenic” GBA1 variants also adversely affected disease course. 
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In order to set up a novel drug-screening model, iNs were generated from healthy 
controls, and PD patients with and without GBA1 abnormalities. The use of iNs means 
that the age signature is preserved in the cells, such that they retain factors potentially 
important in pathogenesis, that are lost in similar in vitro models in which induced 
pluripotent stem cell-derived neurons are employed.  The iNs were treated with pre-
formed fibrils of pathogenic α-synuclein to induce formation of α-synuclein aggregates, 
which were formed in greater numbers in diseased cell lines compared to healthy controls. 
Additionally, PD iNs in particular developed a reduction in mitochondrial membrane 
potential following treatment with PFFs, suggesting that they were more susceptible to 
relevant downstream pathology. This system was then used to study the effects of two 
drugs previously suggested to enhance activity in the lysosome-autophagy system – 
trehalose and nortriptyline. Trehalose was found to alter autophagy activity in carriers 
and non-carriers of GBA1 mutations, which resulted in a reduction in α-synuclein-induced 
pathology. In contrast, nortriptyline was ineffective in GBA1-PD patient-derived neurons, 
suggesting that it is not able to overcome the autophagy dysfunction seen in this subgroup, 
but was able to reduce pathology in PD patient cells without GBA1 abnormalities. 
 
In conclusion, this project describes the long-term clinical course in GBA1-PD, as well as 
a novel in vitro model for studying pathogenesis and drug-screening in this PD patient 
group. Two drugs tested were identified to reduce pathology in different PD subgroups, 
highlighting the power of this work to the future development of personalised therapies 
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1 INTRODUCTION 
1.1 Introduction to Parkinson’s disease and project 
 
Parkinson’s disease (PD) is the second most common neurodegenerative disorder after 
Alzheimer’s disease. It is characterised clinically by a motor syndrome consisting of 
bradykinesia, rest tremor, rigidity and as disease progresses, postural instability (Kalia 
and Lang 2015). In addition to the Parkinsonian movement disorder, non-motor features 
are common and include cognitive impairment and dementia, neuropsychiatric features 
such as depression, anxiety and hallucinations, anosmia, autonomic dysfunction and 
sleep-disturbance (Khoo et al. 2013). There are currently no disease-modifying treatments 
for PD, and the disorder generally follows a slowly progressive course with deterioration 
over years. However, clinical heterogeneity is seen, with some patients following a 
relatively benign course dominated by motor features, whilst in others non-motor features 
including cognitive impairment may predominate (Williams-Gray et al. 2013, Greenland, 
Williams-Gray and Barker 2019). 
 
A number of novel and existing drugs have been purported as potential disease-modifying 
treatments in PD, based on their ability to act on the dysfunctional mechanisms that 
contribute to pathogenesis. There is increasing interest in the possibility of drug 
repurposing – the use of drugs that are already used for other conditions for a new 
indication – as this potentially offers an expedited route to clinic, given that safety data 
will already be available. Furthermore, as the pathogenic basis of clinical heterogeneity 
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is determined, different treatment approaches may be employed for different subgroups 
of patients – precision medicine. As such, there is therefore a rationale for studying the 
pathogenic mechanisms and treatment effects in specific populations of PD patients. 
 
One important subpopulation of PD patients that has recently emerged are those carrying 
mutations in the GBA1 gene (Migdalska-Richards and Schapira 2016). This group is 
characterised by distinct clinical features and specific pathological mechanisms, making 
it an interesting group to study the effects of putative disease-modifying treatments. The 
aim of this project has been to establish a novel in vitro model of PD pathology in which 
drugs can be screened for potential disease-modifying effects in this group of patients. 
This has involved the use of the novel technique of direct lineage conversion to generate 
adult patient-derived neurons, without passage through a stem cell stage and its associated 
problems. In this model four drugs have been screened for their ability to reverse 
pathology. A second aim of this project has been to detail the natural history of PD 
patients carrying GBA1 mutations using long-term follow-up data from two cohorts of 
incident PD patients. 
 
1.2 Aetiology of Parkinson’s disease 
 
The aetiology of PD remains poorly understood, and there are clearly genetic and 
environmental influences. The discovery that the toxin MPTP could cause selective death 
of dopaminergic neurons prompted interest in a potential environmental toxic cause of 
PD (Langston et al. 1983, Langston and Ballard 1983). One such putative toxin includes 
the herbicide paraquat, of which the molecular structure is similar to that of MPTP 
(McCormack et al. 2002). A meta-analysis of thirty potential risk factors found 11 to alter 
the risk of PD, with pesticide exposure bearing the strongest to be associated with the 
disease (Noyce et al. 2012). Other factors including cigarette smoking were reported to 
be protective, though it is possible that this observation is explained by the fact that PD 
patients more readily give up smoking than healthy controls – perhaps explained by a 
reduced reward mechanism due to dopamine depletion (Ritz et al. 2014). Similarly, 
caffeine consumption has been reported to reduce the risk of PD in several studies, though 
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the basis of this relationship is not known (Hernán et al. 2002). The environmental factors 
that contribute to PD remain poorly defined, and their significance remains unknown. 
 
Mutations in several genes have been identified to cause rare forms of PD or Parkinsonian 
syndromes. These include syndromes inherited in autosomal dominant (e.g. mutations in 
SNCA and LRRK2) and autosomal recessive (e.g. mutations in PRKN, PINK-1, and 
PARK7) patterns, most of which are associated with early disease-onset (Klein and 
Westenberger 2012). Identification of these mutations has yielded useful insight into the 
pathogenic mechanisms of PD, but they account for only a very small proportion of PD 
patients, and most are characterised by distinct clinical syndromes, separating them from 
cases of sporadic PD.  
 
It has more recently become increasingly clear that a number of genetic susceptibility 
factors contribute to the risk of developing PD, and indeed alter its clinical course. For 
example, individuals that carry the H2 haplotype of the MAPT gene have a reduced risk 
of PD (Goris et al. 2007). Additionally, the H2 allele is protective against development 
of dementia within PD patients (Evans et al. 2011). Genome-wide association studies 
have identified several genetic loci associated with an increased risk of PD, and it now 
seems likely that an individual’s propensity for development of PD is determined by a 
polygenic risk profile, with or without superadded environmental exposures (Nalls et al. 
2011, Nalls et al. 2014, Verstraeten et al. 2015). Mutations and low-frequency 
polymorphisms in the aforementioned GBA1 gene have been identified as a particularly 
important genetic risk factor for PD (Sidransky et al. 2009), which will be discussed 
further below. 
 
1.3 Pathogenesis of Parkinson’s disease 
 
The movement disorder of PD occurs in part due to the relatively selective loss of 
dopaminergic neurons of the substantia pars compacta, resulting in reduced delivery of 
dopamine to the striatum, though features such as tremor and gait disturbance have a 
largely non-dopaminergic basis. Non-motor features occur due to extra-nigral PD 
pathology with widespread neurodegeneration in the cortex and a number of brainstem 
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nuclei (Selikhova et al. 2009, Kalia and Lang 2015). Here, the mechanisms thought to 
contribute to neurodegeneration in PD are discussed. 
 
1.3.1 The role of α-synuclein in Parkinson’s disease 
 
Whilst the pathogenesis of PD is not completely understood, it is clear that the neuronal 
protein α-synuclein plays a role. This association was first suggested after the description 
of a familial autosomal dominant form of PD occurring due to mutations in its gene, 
SNCA (Polymeropoulos et al. 1997). Since then, α-synuclein has been identified as the 
main constituent of the abnormal collections of protein (Lewy bodies and Lewy neurites) 
which represent the pathological hallmark of PD (Spillantini et al. 1997). Aggregates of 
α-synuclein are also found in other related neurodegenerative conditions (α-
synucleinopathies) including Lewy body dementia and multiple system atrophy, and are 
thought also to play a role in the pathogenesis of these conditions (Spillantini et al. 1998a, 
Spillantini et al. 1998b). The native biological function of α-synuclein is poorly 
understood, but it has been suggested to play a role in the regulation of synaptic vesicles 
and release of neurotransmitters (Burré, Sharma and Südhof 2014). 
 
Although some mutations in the SNCA gene result in the expression of aggregation-prone 
α-synuclein, these only account for rare familial forms of PD (Polymeropoulos et al. 
1997), and the mechanisms by which accumulation and aggregation of α-synuclein occur 
in sporadic PD are not understood. It is known that the cell’s major protein clearance 
pathways, the ubiquitin-proteasome system and lysosome-autophagy system are involved 
in the clearance of α-synuclein (Webb et al. 2003, Tofaris, Layfield and Spillantini 2001, 
Cuervo et al. 2004), and dysfunction of these systems have been implicated in PD 
development. This is supported by the fact that mutations in genes encoding some 
proteins involved in the proteasome pathway or the lysosome-autophagy system (e.g. 
ATP13A2, VPS35) cause familial forms of PD (Zimprich et al. 2011, Leroy et al. 1998, 
Ramirez et al. 2006, Gan-Or, Dion and Rouleau 2015). Additionally, the functional 
capacity of these pathways is known to decline with age, which could explain in part why 
PD incidence increases with age (Gray, Tsirigotis and Woulfe 2003). Of these two 
systems, the lysosome-autophagy pathway seems to be the most important for the 
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clearance of α-synuclein, as inhibition of this system (but not the ubiquitin-proteasome 
system) results in accumulation of α-synuclein (Vogiatzi et al. 2008). Mutations in the 
GBA1 gene, which are discussed in detail below, result in dysfunction of the lysosome-
autophagy system, which is thought to account for their association with development of 
PD (Fernandes et al. 2016, Schöndorf et al. 2014). 
 
It is thought that α-synuclein accumulation and aggregation probably contributes to 
neuronal death in PD, though the mechanisms leading to neurodegeneration are not clear. 
In addition to the visible Lewy body aggregates, α-synuclein also accumulates in other 
forms such as oligomers, which are precursors for aggregate development, and are 
thought to be the more toxic form of α-synuclein (Kalia et al. 2013a). Neuronal pathology 
and clinical abnormalities occur in models in which α-synuclein aggregates are induced 
through the administration of pathogenic pre-formed fibrils (PFFs) of α-synuclein or 
expression of aggregate-prone forms of α-synuclein, suggesting that α-synuclein 
aggregation does indeed have potential neurotoxic effects (Luk et al. 2012a, Luk et al. 
2012b, Giasson et al. 2002). However, Lewy bodies are absent in some forms of familial 
PD, including in some cases associated with mutations in the relatively common LRRK2 
gene (Kalia et al. 2015), and a degree of uncertainty remains regarding their significance 
in patients. 
 
It has been postulated that the progression of PD occurs due to transmission of α-
synuclein pathology, with intercellular transmission of toxic species of α-synuclein 
resulting in propagation of pathology in a prion-like fashion, following a predictable 
anatomical sequence (See Table 1.1) (Braak et al. 2003). In the early stages of disease, 
Lewy body pathology occurs in the dorsal motor nucleus of the glossopharyngeal and 
vagus nerves and the olfactory system, before being seen in other brainstem structures 
such as the locus coeruleus, caudal raphe nuclei, and gigantocellular reticular nucleus. 
Pathology then progresses to involve the substantia nigra, before the cortex is affected 
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Pathological Stage Brain Region Structures Involved 




Peripheral nervous system 
Dorsal IX/X motor nucleus 
Intermediate reticular zone 
Olfactory bulb 
Anterior olfactory nucleus 
Autonomic neurons 
Stage 2 Medulla oblongata 
 
Pons 
Caudal raphe nuclei 
Gigantocellular reticular nucleus 
Locus coeruleus 




Substantia nigra pars compacta 
Nucleus basalis of Meynert 






Accessory cortical and basolateral nuclei of 
amygdala 
Ventral claustrum 
Interstitial nucleus of stria terminalis 
Intralaminar nuclei of thalamus 
Anteromedial temporal mesocortex 
CA2 region of hippocampus 
Stage 5 Neocortex High order sensory association areas 
Prefrontal cortex 
Stage 6 Neocortex First order sensory association areas 
Premotor areas 
Table 1.1 – Braak staging of Parkinson’s disease pathology. 
 
The natural history of PD reflects this proposed spread of pathology. Motor symptoms 
are often preceded by a number of non-motor features including anosmia, rapid eye 
movement (REM) sleep behaviour disorder (RBD), and gastrointestinal dysfunction, 
whilst dementia develops later in the disease course. Further supportive evidence for this 
hypothesis first emerged when typical Lewy body pathology was found in fetal 
mesencephalic neurons grafted into the brains of some PD patients (Li et al. 2016, 
Kordower et al. 2008). Additionally, the administration of exogenous α-synuclein PFFs 
and Lewy body fractionate from brain homogenates of PD patients to animals results in 
α-synuclein accumulation and neurodegeneration (Recasens et al. 2014, Luk et al. 2012a, 
Luk et al. 2012b). However, it should be noted that many patients do not develop the 
aforementioned prodromal features, and in another α-synucleinopathy, dementia with 
Lewy bodies (DLB), cognitive impairment develops early, suggesting that the 
development of α-synuclein pathology does not always follow this sequential 
propagation. 
 
The processes through which α-synuclein may spread between cells are poorly defined, 
but it has been suggested that exosomal release of α-synuclein oligomers may allow for 
transmission (Danzer et al. 2012). This process may be of particular relevance in cases of 
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PD associated with GBA1 mutations, as lysosomal dysfunction has been shown to 
increase the release of α-synuclein via exocytosis (Alvarez-Erviti et al. 2011, Bae et al. 
2014). 
 
1.3.2 Mitochondrial dysfunction in Parkinson’s disease 
 
Mitochondrial dysfunction has frequently been implicated in PD, and is thought to be 
important in its pathogenesis. This was initially highlighted by the fact that inadvertent 
inoculation with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), which is 
converted to the neurotoxin 1-methyl-4-phenylpyridinium (MPP+), resulted in a 
Parkinsonian syndrome in a cohort of individuals (Langston et al. 1983, Langston and 
Ballard 1983). MPP+ is an inhibitor of the mitochondrial complex I and also leads to the 
generation of free radicals (Chiueh et al. 1992, Ramsay et al. 1991). Similarly the 
pesticide rotenone (another complex I inhibitor) results in nigrostriatal degeneration, with 
some reports of Lewy body-like pathology in rodents treated with this toxin (Betarbet et 
al. 2000). Mitochondrial toxins such as MPTP and rotenone have formed the basis of in 
vivo and in vitro models which have been employed to study the pathogenesis of PD, and 
the potential effects of treatments (Testa, Sherer and Greenamyre 2005, Bayliss et al. 
2016b). Additionally, mitochondrial complex I activity has been reported to be reduced 
in the substantia nigra from PD patients in comparison to healthy controls, with similar 
results subsequently seen in other cell types (Schapira et al. 1989, Parker, Boyson and 
Parks 1989).  
 
Additionally, many of the familial forms of PD-like syndromes occur due to mutations in 
genes encoding proteins involved in mitochondrial homeostasis. Mutations in the PRKN, 
PINK1 and FBXO7 genes for example result in early-onset autosomal recessive 
Parkinsonian syndromes, albeit with distinct clinical features to sporadic PD (Kitada et 
al. 1998, Valente et al. 2004, Di Fonzo et al. 2009). The proteins encoded by these genes, 
Parkin, PTEN-induced putative kinase-1 (PINK-1) and F-box only protein 7 (Fbxo7) are 
involved in a common pathway which is important in the initiation of mitophagy – 
clearance of dysfunctional mitochondria through the lysosome-autophagy system (Chen 
and Dorn 2013). In mitophagy, Parkin (an E3 ubiquitin-ligase) is recruited to 
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mitochondria, in a process dependent on PINK-1 and Fbxo7 (Narendra et al. 2008, 
Narendra et al. 2010, Burchell et al 2014). The recruitment of Parkin to mitochondria 
results in ubiquitination of several targets including mitochondrial fusion proteins (Zivani 
et al. 2010, Gegg et al. 2010). Clearance of mitochondria via this pathway appears to be 
dependent on P62/SQSTM1, which co-localises to Parkin on depolarised mitochondria, 
with knockout of P62/SQSTM1 resulting in loss of mitochondrial clearance following 
treatment with carbonyl cyanide 3-chloroyphenylhydrazone (CCCP) (Geisler et al. 2010). 
There is therefore considerable interest in the role that dysfunction of the mitophagy 
system may play in sporadic PD (Ryan et al. 2015).Similarly, mutations in PARK7 which 
encodes DJ-1 result in an autosomal recessive familial Parkinsonian syndrome (Bonifati 
et al. 2003). This protein is involved in sustaining mitophagy and mitochondrial function 
under conditions of oxidant stress, and is thought to act in parallel to PINK-1 (Thomas et 
al. 2011). Dysfunction in these pathways therefore leads to persistence of abnormal 
mitochondria, and accumulation of reactive oxygen species with subsequent oxidative 
stress (Joselin et al. 2012). 
 
The relationship between α-synuclein aggregation and mitochondrial dysfunction is not 
clear, but it has been suggested that mitochondrial deficits can occur as a downstream 
consequence of α-synuclein pathology. α-synuclein has been reported to co-localise with 
mitochondria in cell and animal models of PD (Martin et al. 2006, Devi et al. 2008). 
Similarly, at post-mortem α-synuclein has been seen to accumulate in mitochondria in 
nigral neurons of PD patients, which is associated with a reduction in complex I activity, 
thought to be due to a direct interaction between α-synuclein and complex I (Devi et al. 
2008). This association of α-synuclein with mitochondria appears to be dependent on a 
32 amino-acid N-terminal targeting signal (Devi et al. 2008). Mitochondrial 
deoxyribonucleic acid (DNA) damage and degeneration occurs to a greater extent in the 
nervous system of mice expressing the aggregate-prone A53T and A30P α-synuclein, in 
comparison to wild-type controls (Martin et al. 2006). Overexpression of α-synuclein in 
neuronal cell models has also been seen to alter mitochondrial morphology, and lead to 
increases in free-radical levels and reduced mitochondrial activity (Hsu et al. 2000, Kamp 
et al. 2010, Parihar et al. 2009), suggesting that mitochondrial dysfunction occurs 
secondary to α-synuclein pathology. However, it has also been suggested that instead of 
occurring downstream of α-synuclein pathology, mitochondrial oxidant stress is an early 
step in a sequential pathogenic pathway, in which increased levels of oxidised dopamine 
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result in lysosomal dysfunction and accumulation of α-synuclein (Burbulla et al. 2017). 
So whilst both α-synuclein aggregation and mitochondrial dysfunction are important in 
PD pathogenesis, the way in which these cell autonomous pathogenic processes 
interrelate appears to be complex, and is not fully understood. 
 
1.3.3 Neuroinflammation in Parkinson’s disease 
 
The pathological processes discussed so far involve dysfunction of intracellular pathways 
or altered protein homeostasis within the degenerative cells themselves. However, non-
cell-autonomous processes are also thought to play a role in PD pathogenesis, including 
a neuroinflammatory response involving microglia and astrocytes (Tansey and Goldberg 
2010, Hirsch and Hunot 2009). This is supported by the fact that a single nucleotide 
polymorphism in the human leukocyte antigen DQ1b (HLA-DQ1b) region has been 
identified as a risk factor for PD (Saiki et al. 2010, Nalls et al. 2014). Neurotoxin-based 
animal models used to study PD are often associated with a glial response, though in some 
cases, toxins (e.g. 6-hydroxydopamine) are introduced intracerebrally, with disruption of 
the blood-brain-barrier. This may in itself herald an inflammatory response, which should 
be taken into account when interpreting results of such studies (Akiyama and McGeer 
1989, McGeer et al. 2003). Additionally, in the case of MPTP, though acute exposure is 
often associated with an inflammatory response this is not seen with chronic exposure 
(Furuya et al. 2004). However, activated microglia have been observed in the substantia 
nigra of PD patients at autopsy suggesting that a neuroinflammatory response does occur 
(McGeer et al. 1988, Imamura et al. 2003). Additionally, an increased density of 
astrocytes has been observed in the substantia nigra of PD patients, though it is not known 
whether these findings constitute a protective response, or whether they contribute to 
neurodegeneration (Damier et al. 1993). Nevertheless, the neuroinflammatory response 
is considered an interesting potential therapeutic target for treatment of PD. 
 
1.4 Introduction to GBA1 mutation-associated Parkinson’s disease 
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It has recently become clear that variants in the GBA1 gene are an important risk factor 
for the development of PD (Sidransky et al. 2009). As well as being relatively prevalent 
in the PD population, GBA1 abnormalities are also associated with an accelerated clinical 
course, making these patients an important clinical group to study. 
 
1.4.1 Glucocerebrosidase and the GBA1 gene 
 
The GBA1 gene consists of 11 exons and 10 introns in a 7.6 kb sequence, situated on the 
long arm of chromosome one (Horowitz et al. 1989). Its product, glucocerebrosidase 
(GCase) is a lysosomal enzyme responsible for the hydrolysis of glucosylceramide (also 
referred to as glucocerebroside) glycosphingolipids to ceramide and glucose (Beutler 
1992). Transcription of the GBA1 gene yields at least two mRNA sequences, dependent 
on alternate polyadenylation sites. The amino acid peptide products are then processed to 
form the 496 amino acid mature protein (Sorge et al. 1987, Migdalska-Richards and 
Schapira 2016). Genetic sequencing of the GBA1 gene is complicated by the presence of 
a 5.7 kb pseudogene, which has sometimes impeded the identification of novel mutations. 
This pseudogene is situated 17 kb downstream of the GBA1 gene and shares high 
sequence homology with the gene (Horowitz et al. 1989). 
 
The GCase protein consists of three domains, the third of which has a triose phosphate 
isomerase barrel structure, and contains the catalytic site (Dvir et al. 2003). It is 
synthesised in the rough endoplasmic reticulum (ER), before transit across the Golgi 
apparatus via a phosphatidylinositol-4-kinase (PI4K)-dependent pathway and delivery to 
the lysosome. In contrast to most other lysosomal enzymes, for which delivery to the 
lysosome is dependent on mannose-6-phosphate receptors, transit of GCase to the 
lysosome is mediated by a specific transporter – lysosomal membrane protein-2 (LIMP-
2), encoded by the SCARB2 gene (Jović et al. 2012, Reczek et al. 2007, Ludwig, Le 
Borgne and Hoflack 1995). GCase and LIMP-2 become associated in the ER, before 
traversing the Golgi apparatus as a complex. The low pH environment of the lysosome 
results in dissociation of GCase from LIMP-2 (Reczek et al. 2007) Figure 1.1). Saposin 
C, cleaved from prosaposin, acts as a substrate-presenting co-factor and is required for 
enzymatic activity (O'Brien and Kishimoto 1991).  
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Figure 1.1 – Processing of GCase and LIMP-2. GCase is synthesised in the rough ER 
where it becomes associated with LIMP-2. The GCase-LIMP-2 complex is processed as 
it traverses the Golgi apparatus, before it reaches the lysosome. The acidic lysosomal 
environment causes dissociation of GCase from LIMP-2. Abbreviations: ER = 
endoplasmic reticulum; GCase = glucocerebrosidase; LIMP-2 = lysosomal membrane 
protein-2; mRNA = messenger ribonucleic acid. Adapted from (Stoker, Torsney and 
Barker 2018a). 
 
1.4.2 Association between GBA1 mutations and Parkinson’s disease 
 
Biallelic mutations in the GBA1 gene result in the autosomal recessive storage disorder 
Gaucher disease (GD), in which there is negligible GCase enzymatic activity and 
accumulation of glucosylceramide in a number of cell types, particularly macrophages 
(Hruska et al. 2008). The classification of GD is determined by the presence or absence 
of neurodegenerative features, and the rate of progression (Grabowski 2008). Type one 
(non-neuronopathic) GD manifests with hepatosplenomegaly, bone lesions, 
thrombocytopaenia, and anaemia. Types two and three (neuronopathic) GD are 
characterised by progressive neurological decline in addition to peripheral features, with 
rapid progression in type three GD (Grabowski 2008). Over 300 mutations in the GBA1 
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gene have been reported, including point mutations, deletions and insertions, splice-site 
mutations and recombinations (Hruska et al. 2008, Lesage et al. 2011). There is a degree 
of genotype-phenotype correlation, with some mutations (e.g. L444P) being associated 
with neuronopathic disease and others (e.g. N370S) being associated with the more 
benign type one GD (Gan-Or et al. 2008). 
 
At the end of the twentieth century, reports started to emerge linking PD to GD. It was 
initially noted that an adult-onset Parkinsonian syndrome developed in a proportion of 
type one GD patients (Neudorfer et al. 1996, Sidransky 2005, Tayebi et al. 2003). The 
subsequent observation that PD was prevalent in first-degree relatives of GD patients 
suggested that carrying a single GBA1 mutation was a risk factor for the development of 
PD (Goker-Alpan et al. 2004, Halperin, Elstein and Zimran 2006). Approximately 10 % 
of type one GD patients develop PD by the age of 80 years, which is in comparison to 
about 3 to 4 % in the normal population (Rosenbloom et al. 2011). The prevalence of 
GBA1 mutations in the PD population has been reported to be as high as 21 % (Lwin et 
al. 2004), though post-mortem studies, in which cohorts may be more likely to include 
early-onset or atypical forms of PD, have probably overestimated this figure, which is 
generally considered to be closer to 5 % (Winder-Rhodes et al. 2013, Kumar et al. 2013, 
Bras et al. 2009, Sidransky et al. 2009). This compares to a less than 1 % carrier rate in 
most healthy populations, though the prevalence varies in different ethnic groups 
(Sidransky et al. 2009). Mutations are particularly common in people of Ashkenazi 
Jewish origin, where there is carrier frequency of 15 to 20 % in the PD population, with 
the N370S mutation being by far the most common (Gan-Or et al. 2008, Sidransky et al. 
2009). GBA1 variants are overrepresented in early-onset PD, with about a 25 % carrier 
rate in those with disease onset under 50 years of age (Duran et al. 2013). 
 
Mutations in the GBA1 gene have also been associated with DLB, providing further 
support that there is a pathogenic link between this gene and α-synuclein pathology (Nalls 
et al. 2013, Goker-Alpan et al. 2006, Mata et al. 2008). Although an important genetic 
risk factor for PD, penetrance associated with GBA1 mutations is low, with about 30% of 
carriers estimated to develop PD before age 80 years (Migdalska-Richards and Schapira 
2016). Nevertheless, overall GBA1 mutations increase the risk of PD by 20- to 30-fold, 
and taking into account their prevalence, they represent numerically the most significant 
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known genetic risk factor for PD (Lesage et al. 2011, Lesage and Brice 2009, Sidransky 
et al. 2009).  
 
1.4.3 Pathogenesis and clinical features of GBA1 mutation-associated 
Parkinson’s disease  
 
The clinical features and pathogenesis of GBA1 mutation-associated PD are discussed in 
detail in chapters 2 and 4 respectively, but the general principals are introduced here. 
 
The mechanisms through which GBA1 variants predispose to PD are complex. Clinical 
manifestations of GD arise due to a reduction in GCase enzyme activity and accumulation 
of it substrates (Grabowski 2008). Similarly, GCase activity has been reported to be 
reduced in brains and blood spots of individuals with GBA1 mutation-associated PD 
(hereafter referred to as GBA1-PD) (Rocha et al. 2015a, Alcalay et al. 2015). 
Additionally, chemical suppression of GCase activity results in accumulation of α-
synuclein in cell and animal models, supporting the idea that a reduction in GCase activity 
can precipitate PD pathology (Rocha et al. 2015b, Manning-Boğ, Schüle and Langston 
2009). Reduced GCase activity has also been noted in PD patients with “idiopathic” PD 
(with no GBA1 mutations – hereafter referred to as iPD), and indeed in association with 
normal aging (Rocha et al. 2015a, Murphy et al. 2014) Furthermore, augmentation of 
GCase activity has been observed to reduce α-synuclein pathology in animal models and 
in induced pluripotent stem cell (iPSC)-derived neurons (Sardi et al. 2013, Osellame et 
al. 2013, Mazzulli et al. 2016). It is possible that reduced GCase activity allows for 
accumulation of sphingolipids (Schöndorf et al. 2014, Rocha et al. 2015a, Xu et al. 2011) 
which potentially stabilise the pathogenic forms of α-synuclein, facilitating its 
accumulation and aggregation (Mazzulli et al. 2011, Zunke et al. 2017). However, the 
role of sphingolipid accumulation in GBA1-PD is unclear. Higher glycosphingolipid 
levels have been correlated with reduced GCase enzyme activity in the brains of patients 
with iPD (Rocha et al. 2015a). However, in another post-mortem study there were no 
differences between the levels of glycosphingolipids in healthy controls, and patients with 
iPD or GBA1-PD (Gegg et al. 2015). Whilst reduced GCase enzyme activity may result 
in elevated glycosphingolipid levels, the importance of this in the pathogenesis of GBA1-
PD is uncertain. 
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However, several observations are inconsistent with a primary loss-of-function 
mechanism in GBA1-PD. Firstly, PD only occurs in a minority of GD patients, where 
GCase activity is negligible (Rosenbloom et al. 2011). If the risk associated with 
heterozygous GBA1 mutations could be attributed to loss of enzyme activity, a much 
higher incidence of PD within the GD population would be expected. Additionally, GBA1 
variants which are not associated with a significant reduction in enzyme activity (and are 
hence not associated with GD) are common in PD (Duran et al. 2013). The risk conveyed 
by GBA1 mutations are therefore not completely explained by a reduction in GCase 
activity. 
 
Alternatively, it has been argued that GBA1 mutations may confer a deleterious gain-of-
function effect. Most pathogenic GBA1 mutations result in misfolding of GCase, such 
that it is retained in the ER, causing ER stress and subsequent activation of the unfolded 
protein response (Fernandes et al. 2016). Additionally, mutant GCase is more likely to be 
identified in Lewy bodies than wild-type GCase, suggesting that there is potentially a 
direct interaction between α-synuclein and toxic forms of GCase (Goker-Alpan et al. 
2010). However, null mutations may be associated with increased risk of PD, and 
reduction in enzyme activity (through genetic knock-down or chemical inhibition) can 
recapitulate some aspects of PD pathology as discussed above (Mazzulli et al. 2011, 
Rocha et al. 2015b, Manning-Boğ et al. 2009, Cleeter et al. 2013). Hence, the 
pathogenesis of GBA1-PD cannot be fully accounted for by a toxic effect of mutant GBA1. 
 
GBA1 mutations may therefore act through more than one mechanism to predispose to 
the development of PD. Dysfunction of the lysosome-autophagy system has been well 
established as a feature of GBA1-PD (Mazzulli et al. 2011, Li et al. 2018), and a smaller 
number of studies have identified mitochondrial dysfunction and ER stress (Fernandes et 
al. 2016, Cleeter et al. 2013, Osellame et al. 2013, Xu et al. 2014). The evidence for these 
pathogenic mechanisms are discussed in detail in chapter 4. 
 
At an individual level, GBA1-PD is indistinguishable from iPD. However, at a population 
level, GBA1 mutations confer an earlier age of onset by about five years, and a more 
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aggressive clinical course (Brockmann et al. 2015, Clark et al. 2007, Nichols et al. 2009, 
Jesús et al. 2016). Several epidemiological studies have identified an increased risk of 
cognitive impairment and PD dementia in the context of GBA1 mutations (Setó-Salvia et 
al. 2012, Winder-Rhodes et al. 2013, Brockmann et al. 2015, Cilia et al. 2016, Lunde et 
al. 2018, Oeda et al. 2015). Additionally, motor progression seems to take a more rapid 
course in GBA1-PD (Winder-Rhodes et al. 2013, Davis et al. 2016b, Brockmann et al. 
2015). A number of non-motor features including depression and rapid eye movement 
RBD are also said to be more common in GBA1-PD, potentially reflecting more 
widespread pathology (Neumann et al. 2009, Beavan et al. 2015, Goker-Alpan et al. 
2008). Some of these features are also more prevalent in healthy carriers of GBA1 
mutations compared to non-carriers, potentially reflecting a prodromal stage of PD 
(Beavan et al. 2015). Clinical aspects of GBA1-PD are discussed further in chapter 2. 
 
1.5 Current and emerging treatments for Parkinson’s disease 
 
There are no established disease-modifying treatments for PD, with current management 
being symptomatic. The mainstay of PD treatments are dopaminergic drugs, used to 
replenish striatal dopamine levels. Most patients ultimately require treatment with 
preparations containing the dopamine precursor, levodopa. Other commonly used drugs 
include dopamine receptor agonists and inhibitors of the enzymes responsible for 
dopamine metabolism (monoamine oxidase B (MAO-B) and catechol-O-
methyltransferase (COMT)). These drugs can be effective in controlling the motor 
symptoms, but can be associated with significant adverse effects and they do not alter the 
course of disease (Jenner 2003). An alternative approach to the treatment of motor 
symptoms, particularly in patients that experience significant adverse effects from 
levodopa, is the use of deep brain stimulation, which again does not alter disease 
progression (Kalia, Sankar and Lozano 2013b). None of these approaches help with the, 
often disabling, non-motor aspects of PD which have a significant impact on quality of 
life. 
 
A number of experimental treatment approaches are emerging, some of which are 
designed to control the motor symptoms in a more physiological manner than is achieved 
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by existing treatments, while others target the underlying pathogenic processes, with the 
aim of slowing disease progression. The former category includes cell-replacement 
therapies, such as embryonic stem cell- and iPSC-derived neural progenitors which are 
beginning to enter clinical trials (Barker et al. 2017). Gene therapies have also entered 
clinical trials, in which enzymes involved in the synthesis of dopamine are introduced 
into striatal cells, boosting striatal dopamine levels (Palfi et al. 2014). Theoretically, more 
physiological and targeted release of dopamine would allow for treatment of the motor 
aspects of PD with a reduced risk of the significant adverse effects associated with current 
treatments. 
 
Putative disease-modifying approaches include the use of immunotherapies against α-
synuclein, which aim to reduce α-synuclein levels and potentially propagation of 
pathology, and a number of these have entered clinical trials (Brundin, Dave and 
Kordower 2017, Stoker, Torsney and Barker 2018b). Other drugs targeting pathogenic 
mechanisms associated with PD (e.g. nilotinib a tyrosine kinase inhibitor which facilitates 
delivery of α-synuclein to lysosomes, and ambroxol hydrochloride which acts as a 
chaperone molecule facilitating the folding of GCase) have also entered clinical trials 
(Hebron, Lonskaya and Moussa 2013, Pagan et al. 2016, Silveira et al. 2019). 
 
However, no agents so far have been able to translate promising pre-clinical results to 
clinical efficacy (Kieburtz and Ravina 2007). The detection of disease-modifying agents 
has been hindered by a lack of truly representative disease models of PD, which generally 
involve animals receiving acute treatment with nigral toxins such as MPTP or rotenone, 
introduction of aggregate-prone forms of α-synuclein which only occur in rare forms of 
familial PD, or overexpression of α-synuclein to supra-physiological levels (Beal 2001). 
These models are discussed further in chapter 5. The novel technique of direct 
reprogramming to generate induced neurons (iNs) potentially offers a more faithful 
disease model, and in this project iNs have been used to test drugs for potential disease-
modifying effects. 
 
1.6 Introduction to direct neuronal reprogramming 
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Given the limitations of the aforementioned experimental models used to study PD and 
other neurodegenerative diseases, a platform which better represents the pathological 
mechanisms and risk profiles that contribute to PD in patients is needed. It is desirable 
for such a model to involve adult human neurons from patients, which possess the (as yet 
poorly understood) polygenic risk factor profile that contributes to PD development. 
Additionally, given that PD is a disease of aged neurons, it would also be beneficial for 
such a model to retain the effects of age on cells, which may precipitate the development 
of, or increase vulnerability to PD pathology. 
 
Direct conversion of patient-derived somatic cells into iNs is potentially a method of 
achieving these aims. Generation of iNs was first achieved in 2010 using mouse 
fibroblasts (Vierbuchen et al. 2010). Derivation of iNs from human cells proved more 
challenging, particularly from adult cells, but novel reprogramming protocols have 
allowed for the generation of aged, human iNs (Pang et al. 2011, Pfisterer et al. 2011b). 
However, the use of iNs for disease-modelling has been limited to only a small number 
of studies to date, which are discussed in chapter 3. 
 
1.6.1 Transcription factor driven reprogramming 
 
The first iN protocols involved the forced expression of proneural transcription factors in 
fibroblasts (Vierbuchen et al. 2010). In this study 19 candidate genes were initially 
investigated for their ability to drive conversion of fibroblasts into iNs, and a combination 
of three factors was found to achieve efficient conversion. These included achaete-scute 
homolog 1 (Ascl1 – a basic helix-loop-helix (bHLH) transcription factor expressed in 
neural progenitor cells (Lo et al. 1991)), Brn2 (a POU-homeodomain family transcription 
factor) and Myt1-L (a zinc finger superfamily transcription factor) – a combination 
termed the “BAM factors” (Vierbuchen et al. 2010). These factors were also capable of 
driving conversion of endodermal cells (e.g. hepatocytes) to iNs (Marro et al. 2011). 
  
After the initial report of iN generation in murine fibroblasts, it was demonstrated that 
this technique could also be applied to human fetal fibroblasts (from gestational age 8 to 
10 weeks), and to post-natal human fibroblasts (aged up to 11 years) (Pang et al. 2011). 
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However, whilst reprogramming using the BAM factors resulted in neuronal morphology 
and expression of the neuronal marker β3-tubulin, these cells were functionally immature. 
A further 20 factors were tested for their ability to improve the reprogramming, and it 
was found that the addition of NeuroD1 (another bHLH transcription factor) improved 
conversion efficiency by two to three-fold, as well as neuronal maturity (Pang et al. 2011). 
The BAM factors were also shown to drive the conversion of human adult lung fibroblasts 
(from donors aged up to 65 years) to functional iNs, at a conversion efficiency comparable 
to that achieved with human fetal and post-natal fibroblasts (Pfisterer et al. 2011b). 
 
1.6.1.1 Direct conversion to neuronal subtypes 
 
Early protocols for direct conversion generally yielded non-specific neuronal types, 
expressing a number of pan-neuronal markers such as microtubule-associated protein two 
(MAP2) and β3-tubulin (Pfisterer et al. 2011b, Pang et al. 2011, Vierbuchen et al. 2010). 
Given that many neurological diseases predominantly affect a specific type of neuron, it 
was therefore desirable to demonstrate that direct conversion could be used to generate 
populations of subtype-specific neurons. Caiazzo et al employed Ascl1 in combination 
with nuclear receptor-related-1 (Nurr1) and LIM homeobox transcription factor one α 
(Lmx1a – a transcription factors known to be expressed in nigral dopaminergic neurons) 
to generate dopaminergic neurons from murine and human fibroblasts (Caiazzo et al. 
2011). In mouse embryonic fibroblasts, a relatively high purity of tyrosine hydroxylase- 
(TH-) positive, dopamine-releasing cells was generated (85 % of converted cells) 
(Caiazzo et al. 2011). In human fetal and adult fibroblasts, TH-positive cells could be 
produced, albeit at a much lower efficiency (6 % and 3 % of cells that were successfully 
transfected for fetal and adult fibroblasts respectively (Caiazzo et al. 2011)). It should be 
noted that the way in which conversion efficiency has been defined varies between 
studies, with some quoting the number of iNs as a proportion of the transfected cells, and 
others reporting the number of iNs as a proportion of the total number of cells in the 
starting population. Given that not all cells are successfully transfected with the viral 
vector, the absolute conversion efficiencies are therefore likely to be lower than the 
reported figures in some studies. 
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Around the same time, Pfisterer et al also attempted to generate subtype dopaminergic 
iNs from human embryonic fibroblasts (Pfisterer et al. 2011a). A pool of 10 genes 
involved in midbrain and dopaminergic neuron patterning were tested, which were used 
in combination with the BAM factors. The combination of all 10 factors resulted in the 
emergence of small numbers of TH-positive cells. The yield of TH-positive iNs was 
greatest when the transcription factor pool was limited to just two of these factors (Lmx1a 
and forkhead box protein A two (FoxA2)) in combination with the BAM factors. With 
this combination of transcription factors, approximately 5 to 10 % of the iNs were TH-
positive (Pfisterer et al. 2011a). 
 
Other studies have focused on the generation of striatal medium spiny neurons, which are 
particularly vulnerable in Huntington’s disease (Walker 2007). The addition of the 
transcription factors CTIP2, DLX1, DLX2, and Myt1-L (“CDM” factors) to microRNA-
mediated conversion protocols (discussed in section 1.6.2) has been shown to yield a high 
purity of medium spiny neurons (Huh et al. 2016, Victor et al. 2014), which when grafted 
into mice survive for long periods and integrate into functional circuits (Victor et al. 
2014). 
 
The addition of motor neuron specification factors (Lhx3, Hb9, Isl1 and Ngn2) to the 
BAM factors allowed for the generation of spinal motor neurons from mouse fibroblasts, 
which resembled embryonic motor neurons morphologically, electrophysiologically, and 
in terms of the transcriptome (Son et al. 2011). The addition of NeuroD1 to this 
combination of transcription factors allowed for the generation of cholinergic motor iNs 
from human fibroblasts. Sensory neurons have also been directly generated from 
fibroblasts, using the BAM factors, in combination with Isl1, Ngn1, and Klf7 (Wainger 
et al. 2015). Derivation of sensory neurons can also be achieved independently of Ascl1 
expression, through the expression of Brn3a in combination with Ngn1 or Ngn2 
(Blanchard et al. 2015). 
 
1.6.1.2 Mechanisms of transcription factor driven direct reprogramming 
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BAM factor driven reprogramming has been shown to be dependent on a short period of 
transgene expression at the start of the conversion process. Withdrawal of inducible 
transgene expression at day three, does not significantly alter conversion efficiency 
(Pfisterer et al. 2011a). This observation suggests that, whilst it is important that defined 
factors are expressed early during a conversion, subsequent changes are mediated by 
endogenous downstream events. In the early stages of BAM-driven reprogramming, the 
majority of transcriptional changes represent upregulation of neuronal genes, with 
downregulation of the parent cell-type programme occurring later (Wapinski et al. 2013). 
 
Several of the early iN studies showed that forced expression of Ascl1 alone is sufficient 
to induce conversion to iNs, albeit with less complex neuronal morphology and low 
efficiency when compared to reprogramming in combination with other factors (Pfisterer 
et al. 2011a, Pang et al. 2011, Vierbuchen et al. 2010, Liu et al. 2013). Chromatin 
immunoprecipitation and high-throughput sequencing analysis at 48 hours post-
transduction with the BAM factors showed that Ascl1 had bound to a large number of 
sites across the genome, and it did so independent of Brn2 or Myt1-L expression 
(Wapinski et al. 2013). The Ascl1 binding sites in fibroblasts strongly overlapped with 
those in neural precursor cells, and were predominantly in regions deplete of open 
chromatin, suggesting that it acts as a pioneer factor (Wapinski et al. 2013). 
 
There were fewer Brn2 binding sites in comparison to those for Ascl1, and these were 
predominantly in regions of accessible chromatin. About a quarter of the Brn2 sites were 
also bound by Ascl1, suggesting that Ascl1 recruits Brn2 to a proportion of its binding 
sites (Wapinski et al. 2013). Similarly, Myt1-L preferentially bound to open chromatin 
sites. In contrast to Ascl1 and Brn2 the function of Myt1-L in neuronal reprogramming is 
to down-regulate genes (Mall et al. 2017). Down-regulated genes include those important 
in differentiation programs of multiple non-neuronal systems (e.g. cartilage, heart and 
lung development) as well as negative-regulators of neuronal differentiation (such as 
those involved in the Notch and Wnt pathways) (Mall et al. 2017). This suggests that it is 
acting as a repressor of “all-but-one” cell fates, and its expression is important in 
suppressing the parent cell phenotype during direct reprogramming. 
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The mechanism of BAM factor-driven reprogramming therefore, appears to be dependent 
on two predominant processes. Firstly, Ascl1 accesses closed chromatin sites, causing 
upregulation of a number of transcription factors (including Zfp238, Lmo2, Rfx1, and 
Tcfl5), as well as recruiting Brn2 to its target sites, with subsequent expression of 
neuronal genes (Wapinski et al. 2013). Secondly, Myt1-L binds to a number of sites, 
which result in downregulation of non-neuronal programmes, and suppression of original 
parent cell properties (Figure 1.2) (Mall et al. 2017). 
 
Figure 1.2 – Mechanisms of BAM factor-driven reprogramming. The proneural 
transcription factors Ascl1 and Brn2 bind to target sites on DNA resulting in upregulation 
of proneural transcription factors and neuronal genes. Ascl1 acts as a pioneer factor, 
binding to closed chromatin sites, and is involved in recruiting Brn2 to its target sites. 
Myt1-L acts through an alternative mechanism, resulting in the downregulation of non-
neuronal transcripts. 
 
1.6.2 The RE1-silencing transcription factor complex and microRNA-
mediated reprogramming 
 
Whilst it is possible to generate iNs from human cells through expression of proneural 
transcription factors, conversion efficiency is much lower than that seen when 
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reprogramming murine cells. However, the use of specific microRNA molecules in 
reprogramming protocols has been shown to enhance the direct reprogramming of human 
somatic cells into iNs (Huh et al. 2016, Victor et al. 2014, Yoo et al. 2011, Ambasudhan 
et al. 2011). 
 
Neuronal differentiation is dependent on a conformational shift in Brg1-like-associated 
factor (BAF) chromatin remodelling complexes (the human analogues of SWItch/Sucrose 
Non-Fermentable- (SWI/SNF-) complexes). These are large multi-unit complexes in 
which different homologues and splice variants confer functional specificity (Zheng et al. 
2012, Wu, Lessard and Crabtree 2009). For example neuronal cells contain the 
components BAF53B and BAF45B, while their progenitors contain BAF53A and 
BAF45A (Olave et al. 2002, Lessard et al. 2007). The microRNA molecules, microRNA-
9/9* (miR-9/9*) and microRNA-124 (miR-124) have been shown to be particularly 
important in driving this switch (Yoo et al. 2009). Additionally, miR-124 has been shown 
to reduce non-neuronal transcripts, suggesting that it has a permissive function for 
neuronal differentiation (Conaco et al. 2006, Lim et al. 2005). Expression of these 
microRNA molecules alone is sufficient for fibroblasts to be reprogrammed into iNs, but 
neuronal purity improves when combined with the bHLH transcription factor, neuroD2 
as well as Ascl1 and Myt1-L (Yoo et al. 2011). 
 
The RE1-silencing transcription factor (REST) complex is known to prevent expression 
of these neuron-specific microRNAs, as well as neuronal genes containing the 23 bp 
repressor element RE-1 (Conaco et al. 2006, Johnson et al. 2007). As such, REST 
prevents expression of the neuronal programme in early neural progenitors, and in non-
neuronal cells, in which it is highly expressed (Chong et al. 1995). As a cell transitions 
from an immature progenitor to a post-mitotic neuron, REST is downregulated, 
permitting expression of neuronal genes and microRNAs (Ballas et al. 2005). REST 
levels are higher in adult fibroblasts compared to fetal fibroblasts, posing a specific barrier 
to the reprogramming of human adult cells (Drouin-Ouellet et al. 2017). An alternative 
approach to improving the efficiency of direct conversion in adult human cells therefore, 
is to suppress the REST complex, which in turn allows for the expression of miR-9/9*, 
miR-124 and other neuronal genes (Drouin-Ouellet et al. 2017, Villanueva-Paz et al. 
2019, Xue et al. 2013, Masserdotti et al. 2015). Additionally, miR-9/9* and miR-124 have 
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been shown to impair the pathway leading to the REST complex accessing DNA, so that 
they prevent its neurorepressive effect (Lee et al. 2018). 
 
 
Figure 1.3 – MicroRNAs and the REST complex in neuronal differentiation. Neuron-
specific microRNAs (miR-9/9* and miR-124) cause a switch in SWI/SNF-like chromatin 
remodelling complexes, allowing for neuronal differentiation to occur. In non-neuronal 
cells, the REST complex prevents expression of these microRNAs, preventing neuronal 
differentiation. Downregulation of, or suppression of REST, allows for the expression of 
these microRNAs, and differentiation to a neuronal phenotype. Abbreviations: miR-9/9* 
= microRNA-9/9*; miR-124 = microRNA-124; REST = RE1-silencing transcription 
factor complex. 
 
1.6.3 Small molecules used in direct neuronal reprogramming 
 
The use of specific small molecules and growth factors can significantly enhance the 
efficiency of direct reprograming protocols. The use of SMAD inhibition (using 
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SB431542 and noggin), in combination with the glycogen synthase kinase three β (GSK-
3β) inhibitor CHIR99021 for up to two weeks significantly enhances transcription factor-
driven direct reprograming of human cells (Ladewig et al. 2012). Prolongation of 
exposure to these factors beyond two weeks, does not enhance conversion any further, 
but impairs the acquisition of neuronal morphology, which is thought to be due to the 
effect of GSK-3β inhibition on neurite development (Ladewig et al. 2012). 
 
It has also been shown to be possible to generate iNs using a set of small molecules, 
without introducing proneural transcription factors or microRNAs (Hu et al. 2015). This 
required induction using a cocktail of seven factors (valproic acid, CHIR99021, repsox, 
forsokolin, SP600125, GO6983, Y-27632), before switching to a maturation medium 
containing CHIR99021, forsokolin and doromorphin, along with the neurotrophic growth 
factors glial cell line-derived neurotrophic factor (GDNF), brain-derived neurotrophic 
factor (BDNF) and neurotrophin three (NT3), after eight days. Other small molecule 
targets including cyclic adenosine monophosphate- (cAMP) and bone morphogenic 
protein (BMP) signalling have also been shown to enhance reprogramming (Liu et al. 
2013). Combinations of these factors are therefore now routinely incorporated into direct 
conversion protocols. 
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Study Reprogramming Methods Parent Cell Type Neuronal Subtype Efficiency and Purity 
Vierbuchen et 
al. 2010 
Ascl1, Brn2, Myt1-L Mouse embryonic fibroblasts 
Mouse tail-tip fibroblasts 
Glutamatergic and GABAergic Conversion efficiency 3.6-23.1 % 
Neuronal purity ~45 % 
Pang et al. 
2011 
Ascl1, Brn2, Myt1-L, 
neuroD1 
Human fetal fibroblasts 
 
Glutamatergic (53.7 %), TH (9 
%); forebrain (17%), peripheral 
neuron (21%) 
Conversion efficiency 2-4 % 
Human post-natal fibroblasts (up 
to age 11) 
Glutamatergic (72.5 %), 
forebrain (81 %), peripheral 
neuron (15 %) 
Pfisterer et al. 
2011b 
Ascl1, Brn2, Myt1-L Adult human lung fibroblasts (age 
23 to 65 years) 
Not reported Conversion efficiency ~1-4 % 
Ambasudhan 
et al. 2011 
miR-124, Brn2, Myt1-L Human post-natal fibroblasts Glutamatergic and GABAergic Conversion efficiency 4-8 % 
Human adult fibroblasts Glutamatergic Conversion efficiency ~6 % 
Son et al. 2011 Ascl1, Brn2, Myt1-L, 
Lhx3, Hb9, Isl1, Ngn2 
Mouse embryonic  fibroblasts 
Mouse tail-tip fibroblasts 
Spinal motor neurons Conversion efficiency 5-10 % for spinal motor 
neurons 
Ascl1, Brn2, Myt1-L, 
Lhx3, Hb9, Isl1, Ngn2, 
NeuroD1 
Human embryonic fibroblasts Cholinergic motor neurons 10-15 % of infected cells converted to spinal motor 
neurons 
Caiazzo et al. 
2011 
Ascl1, Nurr1, Lmx1a Mouse embryonic fibroblasts Dopaminergic (85 % of iNs) 18 % neuronal purity 
Human fetal fibroblasts Dopaminergic 10 % of infected cells converted to iNs 
6 % of infected cells converted to TH-positive iNs 
Human adult fibroblasts Dopaminergic 5 % of infected cells converted to iNs 
3 % of infected cells converted to TH-positive iNs 
Pfisterer et al. 
2011a 
Ascl1, Brn2, Myt1-L Human embryonic fibroblasts (5.5 
to 7 week gestation) 
Not reported Conversion efficiency 16 % at day 24 
Human post-natal fibroblasts Glutamatergic and GABAergic Conversion efficiency 4.3 % at day 12 
Ascl1, Brn2, Myt1-L, 
Lmx1a2, FoxA2 
Human embryonic fibroblasts (5.5 
to 7 week gestation) 
Dopaminergic ~5-10 % of iNs positive for TH 
Yoo et al. 
2011 
miR-9/9*, miR-124,  
NeuroD2, Ascl1, Myt1-L 
Human post-natal fibroblasts Glutamatergic and GABAergic Neuronal purity ~ 80% at day 30 
Conversion efficiency ~ 5% at day 30 
Human adult fibroblasts Not reported Not reported 
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Ladewig et al. 
2012 
Ascl1, Ngn2, SB431542, 
noggin, LDN-193189, 
CHIR99021 
Human post-natal fibroblasts Glutamatergic, GABAergic, 
serotoninergic 
Neuronal purity 75 % 
Conversion efficiency 168.5 % 
 
Liu et al. 2013 NGN2, forskolin, 
dorsomorphin 
Human fetal lung fibroblasts Glutamatergic 
Cholinergic 
95 % of transduced cells MAP2 positive 
Human post-natal and adult 
fibroblasts 
Cholinergic 95 % of transduced cells β3-tubulin-positive 
Victor et al. 
2014 
miR-9/9*, miR-124, 
CTIP2, DLX1, DLX2, 
Myt1-L, Bcl-xL 
Human post-natal fibroblasts Striatal medium spiny neurons Neuronal purity ~90 % at five weeks (70 % purity 
for DARPP-32-positive GABAergic neurons) 
Human adult fibroblasts Not reported 
Hu et al. 2015 Small molecules and 
growth factors (see above) 
Human adult fibroblasts Glutamatergic Conversion efficiency ~15 % 
Neuronal purity ~20-25 % 
Huh et al. 
2016 
miR-9/9*, miR-124, 
CTIP2, DLX1, DLX2, 
Myt1-L, Bcl-xL 
 Striatal medium spiny neurons Neuronal purity ~70-80 % at day 30 
Drouin-
Ouellet et al. 
2017 
Ascl1, Brn2, REST 
suppression 
Human adult fibroblasts  Conversion efficiency ~ 35 % to 45 % 
Neuronal purity ~60 % 
Villanueva-
paz 2019 
Ascl1, Brn2, REST 
suppression 
Human adult fibroblasts  Conversion efficiency and neuronal purity ~50 % in 
healthy controls and ~70 % in MERRF patients 
Table 1.2 – Summary of published iN conversion protocols. Abbreviations: GABA = gamma-aminobutyric acid; MERRF = myoclonic epilepsy 
with ragged red fibres; REST = RE1-silencing transcription factor complex; TH = tyrosine hydroxylase
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1.7 Overview of project 
 
The following chapters detail the studies that have been performed as part of my thesis. 
Broadly, these can be divided into a clinical study of the natural history of GBA1-PD, and 
an in vitro study in which patient-derived fibroblasts and iNs have been used to 
investigate pathology and as a screening tool for drugs in GBA1-PD. 
 
In chapter 2, the results of a clinical study are described in which two locally acquired 
community-based cohorts of incident PD patients have been analysed, with a view to 
better characterisation of the natural history of GBA1-PD, in contrast to iPD. This study 
was perhaps better positioned to do this than most previous epidemiological studies of 
GBA1-PD given that all patients were incident, with most being followed up from the 
time of diagnosis to the onset of adverse outcomes including development of dementia, 
development of postural instability, and death. Additionally, the long duration of follow-
up meant that most patients reached these outcomes. 
 
Chapters 3 to 5 focus on the generation of iNs from patients with GBA1-PD, as well as 
those with iPD and healthy controls. iNs, and the parent fibroblasts have been used to 
establish baseline pathology of GBA1-PD. Treatment with PFFs of α-synuclein were used 
to induce PD-relevant pathology in this system, which was greatest in the GBA1-PD 
group. This model was then used as the basis for initial drug-screening studies for four 
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GBA1 mutations are considered an important risk factor for PD, being found in 
approximately 5 % to 10 % of patients with so called sporadic disease. Furthermore, they 
have previously been reported to adversely affect clinical course, with increased risk of 
dementia, and potentially increased rate of motor progression. Previous observational 
studies have been limited by relatively short follow-up periods, and in some cases, small 
sample sizes. The impact of GBA1 mutations on mortality in PD has not been established. 
Additionally, a number of polymorphisms in the GBA1 gene have been associated with 
PD, though their role in terms of altering disease course is disputed. In this study, two 
cohorts of incident PD patients have been investigated to determine the effect of GBA1 
mutations and polymorphisms on key disease milestones, including development of 
dementia, progression to postural instability, and time to death. Additionally, the effect 
of concomitant genetic risk factors in GBA1-PD has also been studied. GBA1 mutations 
and polymorphisms were found to significantly adversely alter the natural history of PD, 
which included a shorter time to death in both groups of patients. 
 
2.2 Introduction to chapter 
 
Several epidemiological studies have been performed, aiming to characterise the natural 
history of GBA1-PD in patient cohorts. Whilst it has become clear that GBA1 mutations 
adversely affect the clinical course of PD, there remain questions about the degree to 
which GBA1-PD differs clinically from iPD, and about the importance of some “non-
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pathogenic” GBA1 variants. The epidemiological study of GBA1-PD has been limited by 
the fact that most studies have been performed in prevalent cohorts of PD patients, with 
a relatively short follow up period, often meaning that only a small proportion of patients 
reach outcome measures. In order to get a clearer picture of the natural history of PD, it 
would be preferable to follow up incident PD patients longitudinally, from diagnosis to 
the development of relevant disease milestones such as dementia or death. 
 
Prospective follow up of incident PD patients has been limited to only a small number of 
studies to date (Winder-Rhodes et al. 2013, Lunde et al. 2018). This chapter discusses the 
analysis of the long-term follow up from two incident PD cohorts, including the 
CamPaIGN cohort which now has a longer follow up time than any previously published 
epidemiological study of GBA1-PD. GBA1 variants seen in PD include mutations known 
to cause GD (e.g. N370S, L444P) and polymorphisms that have not been associated with 
GD (e.g. E326K and T369M), with most studies either focussing on one or other of these 
groups, or analysing them separately. In this study, data is presented for carriers of 
pathogenic mutations, “non-pathogenic” polymorphisms, as well as all variant carriers 
(combining the first two groups).  
 
2.2.1 Cognitive decline and dementia in GBA1 variant-associated 
Parkinson’s disease 
 
The most consistent finding in clinical studies of GBA1-PD has been an increased risk of 
cognitive impairment and dementia, which has been demonstrated in a number of studies 
in European (Setó-Salvia et al. 2012, Winder-Rhodes et al. 2013, Brockmann et al. 2015, 
Cilia et al. 2016, Lunde et al. 2018) and Japanese (Oeda et al. 2015) cohorts. Carriers of 
pathogenic GBA1 mutations have been shown to have an approximately three- to eight-
fold increased risk of development of dementia, in comparison to non-carriers in 
longitudinal studies (Winder-Rhodes et al. 2013, Lunde et al. 2018, Oeda et al. 2015, 
Cilia et al. 2016). Additionally, pathogenic mutations have also been associated with 
accelerated decline in cognitive function as defined by Montreal Cognitive Assessment 
(MOCA) (Brockmann et al. 2015) and Mini-Mental State Examination (MMSE) scores 
(Cilia et al. 2016).  
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The impact of GBA1 polymorphisms, such as E326K and T369M is less clear, but in most 
studies in which carriers of such variants have been included, these have been associated 
with a trend towards an increased risk of dementia. In incident cohorts from the United 
Kingdom (Winder-Rhodes et al. 2013) and Northern Europe (Lunde et al. 2018), carriers 
of these GBA1 polymorphisms had an increased risk of dementia in comparison to 
patients with no GBA1 abnormality, with hazard ratios of 3.3 and 2.0 respectively. 
However, a Japanese study (in which 29 PD patients carrying GBA1 abnormalities not 
known to cause GD were followed up) found that these polymorphism carriers had no 
increase in dementia risk in comparison to non-carriers (Oeda et al. 2015). It should be 
noted that in this study, the polymorphisms identified did not include the common E326K 
or T369M variants, so the authors could not comment on the significance of these (Oeda 
et al. 2015). In a longitudinal multi-centre study of 32 E326K carriers in the USA, this 
polymorphism was found to confer an approximately three-fold greater risk of 
progression to mild cognitive impairment and dementia in comparison to non-carriers, 
with almost 50 % of E326K carriers reaching these outcomes within the three year follow 
up (Davis et al. 2016b). It should be noted that in this study there was no increase in risk 
of mild cognitive impairment or dementia in the carriers of pathogenic mutations, even 
despite a particularly high frequency of the aggressive L444P mutation (Davis et al. 
2016b). These longitudinal studies have been performed in small cohorts, with relatively 
short follow-up times, which probably accounts for the inter-study variability. 
 
As well as conveying an increased risk of dementia in PD patients, one study of healthy 
carriers of GBA1 mutations with no symptoms of PD found an accelerated rate of decline 
in cognitive scores (MMSE and MOCA) in comparison to non-carriers, after a two year 
follow up period (Beavan et al. 2015). The authors postulated that this decline may 
represent an increased frequency of mild cognitive impairment as a prodromal feature of 
PD in carriers of GBA1 mutation, though it is not known how many of these patients 
subsequently went on to develop PD. 
 
A large meta-analysis of seven longitudinal cohorts, investigated the clinical 
heterogeneity seen in patients with different GBA1-variants, grouping patients into those 
with no GBA1 abnormality, those with polymorphisms not known to cause GD, those 
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with the common non-neuronopathic N370S GD mutation, and those with aggressive 
neuronopathic GD-causing mutations. In the latter group, there was a significant increase 
in the risk of global cognitive impairment compared to non-carriers, with non-significant 
trends towards increased cognitive impairment in N370S carriers, and carriers of 
polymorphisms not causative of GD (Liu et al. 2016a). Taking this and the prior literature 
into account, it seems that the clinical impact of GBA1 abnormalities lies on a genotype-
dependent spectrum, with carriers of severe GD-causing mutations (such as L444P)  
having a more aggressive course than those with less severe GD-causing mutations (such 
as N370S) and polymorphisms. 
 
2.2.2 Motor progression in GBA1 variant-associated Parkinson’s disease 
 
Most epidemiological studies of GBA1-PD have found that GBA1 variants are associated 
with an increased rate of motor progression, compared to that in non-carriers, though the 
association is less clear than that with cognitive decline. Longitudinal follow-up in an 
incident cohort found that median time to the development of postural instability (Hoehn 
and Yahr stage three) was approximately halved in carriers of pathogenic GBA1 
mutations in comparison to patients with wild-type GBA1 (23.5 months versus 49.0 
months respectively). Median time to development of postural instability in 
polymorphism carriers was intermediate between these groups (32.0 months), which was 
statistically significant when controlled for age. Relative risk of progression to Hoehn and 
Yahr stage three was 3.2 in polymorphism carriers and 4.2 in pathogenic mutation 
carriers, in comparison to non-carriers (Winder-Rhodes et al. 2013). The same pattern 
was seen in an American cohort, which found pathogenic mutation carriers and carriers 
of the common E326K polymorphism to have a significantly higher rate of progression 
in the Unified Parkinson’s Disease Rating Scale (UPDRS) part III score, compared to 
non-carriers (Davis et al. 2016b). This supports the fact that the clinical severity of GBA1-
PD lies on a spectrum in which polymorphisms have an adverse effect, but to a lesser 
extent than pathological mutations. Increased rate of motor progression has also been 
observed in other longitudinal cohort studies (Brockmann et al. 2015, Davis et al. 2016a). 
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However, other longitudinal studies have found there to be no differences in motor 
progression in association with GBA1 abnormalities (Setó-Salvia et al. 2012, Lunde et al. 
2018). In one of these studies females (who have been reported to have reduced motor 
progression (Lyons et al. 1998)) were overrepresented in the GBA1 mutation group (72.7 
%), which may account for this finding (Setó-Salvia et al. 2012). Additionally, a large 
meta-analysis involving seven cohorts also found that neither pathogenic mutation 
carriers nor polymorphism carriers had an increased rate of motor progression, though it 
should be noted that the maximum follow-up time was relatively short in most of these 
cohorts (Liu et al. 2016a). The natural history of motor features in GBA1-PD remains 
somewhat unclear. 
 
Dyskinesias and motor fluctuations are reported to occur more commonly in GBA1-PD 
(Jesús et al. 2016). This is possibly explained by the fact that patients with GBA1-PD 
require higher levodopa doses due to more severe symptoms, rather than an underlying 
increased susceptibility to these complications. Nevertheless, their increased incidence 
contributes to the overall picture of more severe disease in GBA1-variant carriers 
compared to non-carriers. 
 
2.2.3 Other non-motor features of GBA1 variant-associated Parkinson’s 
disease 
 
Non-motor features may also be more common in GBA1-PD when compared to iPD. 
RBD has been reported to be more common in GBA1-PD, and also in healthy carriers of 
GBA1 mutations – perhaps reflecting a prodromal phase of PD (Jesús et al. 2016, Beavan 
et al. 2015). Depression scores have also been found to deteriorate more quickly in 
healthy carriers of GBA1 mutations, and GBA1-PD has been associated with an increased 
risk of depression in some studies (Beavan et al. 2015, Swan et al. 2016). Other 
neuropsychiatric features such as hallucinations and psychosis have also been reported to 
occur at increased frequencies in GBA1 variant-carriers (Cilia et al. 2016, Jesús et al. 
2016). These findings are likely to reflect more widespread and rapid neurodegeneration 
in GBA1-PD in comparison to iPD, and add to the overall increased severity of disease.  
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2.2.4 Mortality in GBA1 variant-associated Parkinson’s disease 
 
Few studies have commented on the risk of mortality in GBA1-PD in comparison to iPD, 
possibly due to the relatively short follow-up time in most studies. Brockmann et al 
reported an increased risk of mortality in carriers of GBA1 mutations in comparison to 
non-carriers over three years (Brockmann et al. 2015). However, this study only screened 
for the pathogenic mutations N370S and L444P, so was unable to comment on the risk 
associated with the more common polymorphisms. Additionally, an Italian study in which 
patients were followed up for a mean period of 7.2 years reported an increased risk of 
mortality in carriers of pathogenic GBA1 mutations in comparison to iPD patients, which 
was independent of the development of dementia (Cilia et al. 2016). This study excluded 
any carriers of polymorphisms, and almost all of the GBA1-PD group carried N370S or 
L444P mutations, similar to the Brockmann study. 
 
The risk of mortality in GBA1-PD has not been reported on in an incident cohort, and the 
significance of GBA1 polymorphisms in terms of mortality risk remains unknown. 
 
2.2.5 The role of non-pathogenic GBA1 variants 
 
GBA1 variants not known to cause GD are frequently identified in PD cohorts, and the 
clinical significance of these is often undetermined, as has been discussed above. The 
most commonly encountered of these polymorphisms is the E326K variant, though in a 
large multi-centre study of GBA1 mutations this was not found to be associated with PD 
(Sidransky et al. 2009) – a finding supported by some other studies (Jesús et al. 2016). 
However, most studies have indicated that the E326K variant is found at a significantly 
higher frequency in PD patients (2.4 % to 5 %) compared to healthy controls (0.9 % to 
2.8 %), with an odds ratio for the diagnosis of PD 1.7 to 2.4 (Lesage et al. 2011, Park et 
al. 2002, Mata et al. 2016, Berge-Seidl et al. 2017). In a cohort of PD patients with onset 
below age 50, the frequency of E326K was 7.6 %, in comparison to 2.5 % of age-matched 
controls (Duran et al. 2013). The E326K variant has only been identified in GD patients 
that have concomitant biallelic pathogenic mutations, and it is not thought to be sufficient 
for the development of GD. Though the E326K variant appears to be more common in 
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PD patients compared to healthy individuals, questions remain over the impact that it has 
on clinical course. 
 
Here the natural history of GBA1-PD has been detailed in two community-based incident 
cohorts to test the hypothesis that carrying a GBA1 variant conveys a worse prognosis in 
PD. The time to three important clinical milestones – dementia, postural instability and 
death – has been determined for carriers of any GBA1 variant, as well as for those 
specifically carrying a pathogenic variant or a variant considered to be non-pathogenic.  
 




Clinical data for incident PD patients from the Cambridgeshire Incidence of Parkinson’s 
disease from General Practice to Neurologist (CamPaIGN) and Parkinsonism: Incidence, 
Cognition and Non-motor heterogeneity in Cambridgeshire (PICNICS) cohorts was 
obtained (Table 2.2). The diagnosis of PD was based on the UK Parkinson’s Disease 
Society Brain Bank Criteria. Patients were followed up at 18 month intervals, with 
clinical, cognitive and neuropsychiatric assessments, including UPDRS, MMSE, Beck 
depression inventory, and dyskinesia rating assessments. GBA1 mutation status was 
determined by sequencing in 250 patients, as described previously (Winder-Rhodes et al. 
2013). Briefly, separate PCRs were performed to amplify DNA in three fragments as 
described in Stone et al. 2000. PCR products were visualised on 0.8% agarose gel for 
confirmation of amplification. The PCR product was then cleaned-up using ExoSAP-IT® 
(Affymetrix Inc.) prior to exon-by-exon sequencing (Winder-Rhodes et al. 2013). For a 
further 127 patients GBA1 status was determined using Illumina NeuroX chip array 
(MEGA chip array (Bien et al. 2016)) screening for specific GBA1 mutations (performed 
by Clemens Scherzer’s group, Harvard) (Table 2.1). 
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 PICNICS (n) CamPaIGN (n) Total (n) 
Sequencing 136 114 250 
MEGA Chip Array 111 16 127 
Total 247 130 377 
Table 2.1 - Genetic analysis in the incident PD cohorts. 
 
2.3.2 Genetic analysis of secondary genetic risk factors 
 
Genetic analysis of the MAPT, SNCA, COMT and APOE genes had been performed 
historically on the CamPaIGN and PICNICS cohorts by previous group members. 
Genotyping for the MAPT and SNCA gene is described in Goris et al. 2007. Briefly single 
nucleotide polymorphism genotyping was performed with Taqman Assays‐on‐Demand 
and Assays‐by‐Design on a 7900HT Sequence Detection System (Applied Biosystems). 
Microsatellites were genotyped by amplification with primers from Stefansson et al. 
2005, with separation of fluorescently labelled fragments on a 3700 capillary sequencer 
(Applied Biosystems) (Goris et al. 2007). COMT codon 158 genotyping was performed 
on extracted DNA using a 5′ exonuclease allelic discrimination Taqman assay as 
described in Foltynie et al. 2004. APOE allelic status was determined by typing two non-
synonomous single nucleotide polymorphisms (rs429358 and rs7412) which allows for 
differentiation of ε2, ε3 and ε4 alleles. These polymorphisms were analysed using 
Taqman Assays (Applied Biosystems Assay-On-Demand part numbers C__3084793_20 
and C__904973_10) on a 7900HT Sequence Detection System (Applied Biosystems) 
(Williams-Gray et al. 2009). 
2.3.3 Survival analyses 
 
For survival analyses, patients were grouped into those with wild-type GBA1 (iPD) and 
those with any GBA1 variant (GBA1-PD), with the latter group also being stratified into 
those with pathogenic mutations, and polymorphisms not known to cause GD as indicated 
below. All 250 patients that had undergone full sequencing were included in survival 
analyses, as well as 12 patients that had been found to have a GBA1 abnormality on 
MEGA chip array. Patients that had undergone MEGA chip screening only with no 
Clinical aspects and in vitro modelling of GBA1 variant-associated Parkinson’s disease 
36 Thomas Stoker – September 2019 
detected GBA1 abnormality were excluded, given the possibility that they carried a GBA1 
mutation that had not been screened for, such as the common severe L444P mutation. 
 
Subgroup analysis was also performed in which the GBA1-PD group was divided into 
those with non-pathogenic GBA1 variants (genetic variants not known to cause GD), and 
those with pathogenic GBA1 mutations (those known to cause GD). All patients that had 
had full sequencing were included, as well as six patients that that had pathogenic 
mutations detected in the MEGA chip array. Subjects in which only the MEGA chip array 
was performed with no pathogenic mutation identified were excluded from analysis, to 
ensure that no patients with missed pathogenic mutations were included in the non-carrier 
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0.389 169.38 mg (181.93) 274.12 mg 
(277.0) 
0.309 
Table 2.2 – Patient demographics. Demographics shown for all patients included in 
survival analyses. For subgroup analysis, subjects were excluded if they had only had 
MEGA chip genetic screening and were found to have a GBA1 polymorphism, to ensure 
that no patients with missed pathogenic mutations were included in the other groups. P-
values comparing non-carriers to all GBA1 variant carriers determined by independent 
samples t-tests, and for gender, chi-squared test. P-values for subgroup analysis 
determined by one-way ANOVA. Abbreviations: BDI = Beck depression inventory; F = 
female; M = male; MMSE = Mini-Mental State Examination; SD = standard deviation; 
UPDRS = Unified Parkinson’s Disease Rating Scale. 
 
Comparison of time to death, postural instability and dementia were performed with 
Kaplan-Meier curves, and a Cox Regression model controlling for age at diagnosis and 
sex. Cox regression analysis was also used to investigate the effect of other genetic 
susceptibility factors (MAPT, COMT, SNCA, APOE) on time to the aforementioned 
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outcome measures, controlling for GBA1 mutation status, in addition to age at diagnosis 
and sex. Postural instability was defined as the progression to Hoehn & Yahr stage three, 
whilst dementia was defined as fulfilling Diagnostic and Statistical Manual of Mental 
Disorders (DSM)-IV criteria (functional impairment with cognitive deficits in at least two 
domains) with an MMSE score of 24 or less. In the PICNICS cohort in which follow up 
time was shorter, onset of dementia was defined differently, so only patients from the 
CamPaIGN cohort were included in the analysis for time to dementia. 
 
 CamPaIGN PICNICS Combined 
Number 115 147 262 
Mean follow-up time 
from diagnosis (SD) 
7.95 years (4.44) 5.79 years (3.47) 6.74 years (4.06) 
Range in follow-up 
time from diagnosis 
0 to 18.0 years 0 to 11.42 years 0 to 18.0 years 
Table 2.3 – Follow-up time for survival analysis cohorts. Abbreviations: SD = standard 
deviation. 
 
2.3.4 Statistical analysis 
 
Hazard ratios for each of the outcome measures were determined using a Cox regression 
model. Statistically significant differences in survival times to outcomes were determined 
with log-rank tests. Independent samples T-tests and chi-squared tests were used for 
comparison of patient demographics. One-way ANOVA was used for comparison of 




2.4.1 Incidence and spectrum of GBA1 abnormalities in Parkinson’s 
disease 
 
Of the 377 patients that had had genetic testing of the GBA1 gene, 39 (10.3 %) carried 
abnormalities in the coding regions of the gene. A further eight patients harboured 
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variants in the non-coding regions of the gene, which were included in the wild-type 
group, given that these were felt unlikely to have had any pathological effect. 
 
In total, 17 patients (4.5 %) carried mutations that are known GD-causing mutations 
(hereafter referred to as “pathogenic mutations”). These included N370S (n=7), L444P 
(n=3), R4643C (n=2), G10S (n=2), R257Q (n=1), R48W (n=1) and N426K (n=1). 
Additionally, 22 patients (5.8 %) carried abnormalities in the GBA1 gene which occur at 
low frequencies, but have not been associated with GD (hereafter referred to as 
“polymorphisms”). These included the polymorphisms E326K (n=10; one patient carried 
a concomitant R48W mutation so was considered a pathogenic mutation carrier for 
survival analyses), T369M (n=10), E388K (n=2), and L119L (n=1) (Table 2.4). 
 
It should be noted that 127 patients only had targeted screening for GBA1 mutations 
through the MEGA chip array, rather than full sequencing (Table 2.1). Whilst this 
screened for a number of common mutations, it did not screen for all known GBA1 
mutations, meaning that some GBA1 mutation-carriers may have been missed. The 
incidence of GBA1 abnormality in these cohorts is therefore likely to be slightly higher 
than the 10.3 % reported above. Of these 127 patients, 115 were not found to carry a 
GBA1 variant. The most notable omission from the MEGA chip array was the L444P 
mutation. Based on the observed frequency of L444P in the patients that underwent 
sequencing of the GBA1 gene (1.2 %), it would be expected that an additional one to two 
patients in the study population carried an L444P mutation.  
 












Table 2.4 – Spectrum of GBA1 abnormalities in CamPaIGN and PICNICS cohorts. 
Pathogenic mutations were identified in 17 patients, and polymorphisms identified in 23 
patients. One patient carried the E326K in addition to the pathogenic R48W mutation, so 
was analysed as part of the pathogenic mutation group. 
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2.4.2 Natural history of GBA1 variant-associated Parkinson’s disease 
 
2.4.2.1 Cognitive decline and risk of dementia 
 
There were no differences in MMSE score at baseline between GBA1 variant-carriers and 
non-carriers (Table 2.2). Carrying any GBA1 variant led to a trend towards increased risk 
of progression to dementia compared to PD patients with wild-type GBA1, which was 
short of statistical significance (p=0.074). However, when controlling for age at diagnosis 
and sex, carriers of any GBA1 variant were significantly more likely to develop dementia, 
with a hazard ratio of 3.9 (95 % confidence interval 1.7 to 8.7, p=0.001). Five, ten and 
fifteen year dementia-free survival are shown in Table 2.5. At 10 years, only 25 % of 
carriers of GBA1 abnormalities remained dementia-free, in comparison to 55.5 % of those 
without GBA1 abnormalities. At 15 years, approximately half of wild-type patients 
remained dementia-free, whilst no GBA1-PD patients survived to this time-point. For 
GBA1-PD the estimated median time to dementia was 7.1 years (95 % confidence interval 
5.2 to 9.0), compared to 12.0 years (95 % confidence interval 10.5 to 13.5) for the iPD 
group (Figure 2.1). 
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Number 97 18 11 6 
Estimated mean time 
to dementia (years) 
12.0 (10.5-13.5) 7.1 (5.2-9.0) 7.1 (5.7-8.5) 6.1 (2.8-9.3) 
Estimated median 
time to dementia 
(years) 
13.75 6.5 (5.9-7.1) 6.6 (5.6-7.6) 4.1 (0-8.2) 
5 year survival 
without dementia 
(%) 
81.1 (SE 4.2) 75.0 (SE 10.8) 90.0 (SE 9.5) 50 (SE 20.4) 
10 year survival 
without dementia 
(%) 
55.5 (SE 6.2) 25.0 (SE 14) 22.5 (SE 18.5) 23 (SE 20.4) 
15 year survival 
without dementia 
(%) 
49.1 (SE 7) Nil surviving Nil surviving Nil surviving 
Log-rank p-value - 0.074 0.346 0.049 






Table 2.5 – Long-term follow-up data for progression to dementia in patients with 
iPD, carriers of any GBA1 mutation, carriers of non-pathogenic polymorphisms, 
and carriers of pathogenic mutations. Hazard ratios determined by Cox regression 
analysis controlling for age at diagnosis and sex. 95 % confidence intervals for hazard 
ratio and estimated mean and median shown in brackets. Log-rank p-values shown for 
comparison between the GBA1 groups and the non-carrier group. Abbreviations: SE = 
standard error of the mean. 
 
When sub-classifying the GBA1 abnormalities into carriers of non-pathogenic 
polymorphisms and pathogenic mutations, the increase in dementia risk was only 
statistically significantly in the pathogenic mutation group (p=0.049). There was no 
significant difference between the pathogenic mutation and polymorphism group (Figure 
2.1). However, when controlling for age at diagnosis and sex, both groups had 
significantly increased risk of progression to dementia, with hazard ratios of 3.1 (95 % 
confidence interval 1.2 to 8.5, p=0.024) and 5.6 (95 % confidence interval 1.8 to 17.1, 
p=0.002) for the polymorphism and pathogenic mutation groups respectively. 
 
2.4.2.2 Motor progression 
 
There were no differences in UPDRS motor score, Hoehn and Yahr stage, or levodopa 
equivalent dose between the groups at baseline (Table 2.2). There was an increased risk 
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of progression to postural instability (Hoehn and Yahr stage three), in the GBA1-PD group 
in comparison to the iPD group (p=0.048). At five years from diagnosis, 68 % of GBA1-
PD patients had progressed to Hoehn and Yahr stage three, compared to 44 % of iPD 
patients (Table 2.6). All GBA1-PD patients were censored prior to 10 years, so 10 and 15 
year rates of progression to Hoehn and Yahr stage three could not be calculated. When 
controlling for age at diagnosis and sex, both carriers of non-pathogenic polymorphisms 
and pathogenic mutations had a significantly increased risk of progression to postural 
instability, with hazard ratios of 2.5 (95 % confidence interval 1.3 to 4.8, p=0.005) and 
2.1 (95 % confidence interval 1.2 to 3.8, p=0.013) respectively (Figure 2.1). The increased 
risk of progression to Hoehn and Yahr stage three was independent of the development 
of dementia (hazard ratio 2.2 (95% confidence interval 1.2 to 4.1, p=0.009)). 
 






Number 222 39 16 17 
Estimated mean time 
to HY3 (years) 
6.7 (5.8-7.5) 4.7 (3.3-6.0) 4.8 (2.8-6.8) 4.4 (3.0-5.9) 
Estimated median 
time to HY3 (years) 
5.8 (4.7-7.0) 3.2 (2.7-3.6) 3.0 (2.7-3.3) 4.4 (2.6-6.2) 
5 year survival 
without postural 
instability (%) 
56.0 (SE 3.5) 32.0 (SE 8.2) 30.8 (SE 12.8) 32.4 (SE 11.8) 
10 year survival 
without postural 
instability (%) 
27.3 (SE 4) 8.1 (SE 7.1) 10.3 (SE 9.4) 0 
15 year survival 
without postural 
instability (%) 
7.4 (SE 4) Nil surviving Nil surviving Nil surviving 
Log-rank p-value - 0.048 0.314 0.12 






Table 2.6 – Long-term follow-up data for progression to Hoehn and Yahr stage three 
in patients with iPD, carriers of any GBA1 mutation, carriers of non-pathogenic 
polymorphisms, and carriers of pathogenic mutations. Hazard ratios determined by 
Cox regression analysis controlling for age at diagnosis and sex. 95 % confidence 
intervals for hazard ratio and estimated mean and median shown in brackets. Log-rank p-
values shown for comparison between the GBA1 groups and the non-carrier group. 
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In addition, carrying any GBA1 abnormality was associated with a significantly increased 
risk of death over the follow-up period in comparison to non-carriers (p=0.042). Five, ten 
and fifteen year survival rates are shown in Table 2.7. At 10 years from diagnosis, 66.1 
% of carriers of GBA1 abnormalities had died, in comparison to 50 % of those with iPD. 
At 15 years, 79.8 % of iPD patients had died, whilst all GBA1-PD patients had died. For 
GBA1-PD the estimated median time to death was 8.8 years (95 % confidence interval 
8.2 to 9.4), compared to 10.7 years (95 % confidence interval 10.0 to 11.3) for the iPD 
group. When controlling for age and sex, the hazard ratio for mortality in carriers of any 
GBA1 abnormality was 2.2 (95 % confidence interval 1.4 to 3.5, p=0.001). Both carriers 
of non-pathogenic variants and pathogenic mutations had significantly increased risk of 
mortality, with hazard ratios of 2.0 (95 % confidence interval 1.1 to 3.7, p=0.034) and 2.1 
(95 % confidence interval 1.1 to 4.3, p=0.035) respectively (Figure 2.1). 
 
To explore whether the increase in mortality associated with GBA1 variants was 
attributable to the increased risk of dementia, the dementia outcome was incorporated into 
the Cox regression model, along with age and sex. When controlling for dementia status, 
the increased risk of mortality associated with carrying any GBA1 variant persisted 
(hazard ratio 2.6 (95 % confidence interval 1.5 to 4.6, p=0.001)), suggesting that it is 
independent of the development of dementia. 
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Number 223 39 16 17 
Estimated 
mean time to 
death (years) 
10.7 (10.0-11.3) 9.1 (8.1-10.1) 9.6 (8.5-10.7) 9.5 (7.8-11.3) 
Estimated 
median time to 
death (years) 
10.1 (9.5-10.7) 8.8 (8.2-9.4) 9.6 (8.7-10.5) 8.5 (7.7-9.3) 
5 year survival 
(%) 
89.2 (SE 2.1) 94.3 (SE 3.9 100 100 
10 year 
survival (%) 
50.0 (SE 3.8) 33.9 (SE 9.5) 42.2 (SE 14.7) 29.8 (SE 14.1) 
15 year 
survival (%) 
20.2 (SE 3.8) 0 0 0 
Log-rank p-
value 
- 0.042 0.263 0.261 






Table 2.7 – Long-term follow-up mortality data for patients with iPD, carriers of 
any GBA1 mutation, carriers of non-pathogenic polymorphisms, and carriers of 
pathogenic mutations. Hazard ratios determined by Cox regression analysis controlling 
for age at diagnosis and sex. 95 % confidence intervals for hazard ratio and estimated 
mean and median shown in brackets. Log-rank p-values shown for comparison between 
the GBA1 groups and the non-carrier group. Abbreviations: SE = standard error of the 
mean. 
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Figure 2.1 – Survival analyses for time to dementia, time to Hoehn and Yahr stage 
three, and time to death based on GBA1 status. A), C) and E) show Kaplan-Meier 
curves comparing all GBA1-variant carriers to non-carriers. B), D) and F) show Kaplan-
Meier curves comparing pathogenic mutation carriers, polymorphism carriers and non-
carriers. 
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2.4.3 Interaction between GBA1 abnormalities and other genetic 
susceptibility factors 
 
A number of common genetic variants have been previously associated with PD and its 
clinical expression and progression. It is not known whether the clinical effect of GBA1 
abnormalities in PD are altered by these other genetic risk factors. The natural history of 
GBA1-PD was therefore studied, in the presence or absence of other genetic risk factors 
for which information was available in the CamPaIGN and PICNICS cohorts. These 
included the MAPT haplotype, the SNCA rs356219 polymorphism, the COMT codon 158 
polymorphism, and the apolipoprotein E (APOE) ε4 polymorphism (Table 2.8). 
 
The MAPT gene encodes the neuronal protein tau, which may be hyperphosphorylated or 
form abnormal fibrillary tangles in PD as well as other neurodegenerative diseases 
(Spillantini and Goedert 2013). The MAPT gene can exist in two forms – H1 and H2 
(Baker et al. 1999). Carrying the H2 form in the heterozygous or homozygous state has 
previously been associated with a reduced risk of PD, and reduced risk of cognitive 
decline in PD patients. A meta-analysis demonstrated that the odds ratio for developing 
PD in individuals with the MAPT H1/H1 genotype was 1.4 when compared to H2 carriers 
(Goris et al. 2007). Additionally, the H1/H1 genotype is associated with a greater risk of 
an early dementia (Evans et al. 2011, Goris et al. 2007). This study also demonstrated that 
G/G homozygotes for the SNCA rs356219 polymorphism had a greater susceptibility to 
PD in comparison to those with the G/A or A/A genotypes. Furthermore, the presence of 
both of these risk factors was found to have a synergistic effect with regards to increasing 
the risk of PD. 
 
The role of the COMT codon 158 polymorphism and APOE status in PD are less clear. 
Codon 158 of the COMT gene encodes for the presence of methionine or valine. 
Methionine homozygosity (met/met) reduces the activity of COMT (an enzyme involved 
in dopamine metabolism) by three to four times, in comparison to valine homozygotes 
(val/val). COMT activity in heterozygotes (val/met) is thought to be midway between the 
homozygous states (Lachman et al. 1996).  The met/met genotype has been associated 
with specific cognitive abnormalities in PD, including planning and attentional control 
(Foltynie et al. 2004, Williams-Gray et al. 2008). Carrying the APOE ε4 allele is known 
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to significantly increase the risk of Alzheimer’s disease, and has been suggested to 
increase the risk of dementia in PD (Farrer et al. 1997). Though studies have yielded 
variable results, a recent meta-analysis has suggested that the ε4 allele is associated with 
an increased risk of developing dementia in PD (Sun et al. 2019). 
 
Gene “High-Risk” Variants “Low-Risk” Variants 
MAPT H1/H1 H2/H1 or H2/H2 
SNCA rs356219 G/G A/A or G/A 
COMT codon 158 met/met or met/val val/val 
APOE Heterozygous or homozygous 
for ε4 allele 
No ε4 alleles 
Table 2.8 – Genetic susceptibility factors for PD. GBA1-PD patients in the CamPaIGN 
and PICNICS cohorts were stratified based on the presence or absence of high- or low-
risk variants in secondary genetic risk factors as indicated. Abbreviations: met = 
methionine; val = valine. 
 
In order to assess the clinical impact of these risk factors in the context of GBA1 mutation, 
patients with GBA1-PD were grouped based on the presence or absence of “high-” or 
“low-” risk variants of the relevant susceptibility gene, as shown in Table 2.8 and survival 
analyses performed for time to death, time to dementia, and time to Hoehn and Yahr stage 
three. It should be acknowledged that the effect of the COMT variants in particular are 
thought to differ as a function of disease stage, so their designation as “high-” or “low-” 
risk is somewhat artificial (Williams-Gray et al. 2008). Carriers of any GBA1 variant in 
whom the status of the secondary genetic risk factor was known were included. 
 
Firstly, survival analyses were performed for each of the secondary genetic risk factors 
alone, comparing time to death, development of postural instability and dementia in those 
with “low –risk” genotypes to those with “high-risk” genotypes. None of the four genetic 
risk factors assessed were found to significantly alter mortality, progression to postural 
instability, or dementia. However, when controlling for age, sex and GBA1 status, the 
MAPT H1/H1 haplotype did convey a slight increase in the risk of death (hazard ratio 1.6 
(95 % confidence interval 1.1 to 2.1, p=0.005)) and to a greater extent, the risk of 
dementia (hazard ratio 2.3 (95 % confidence interval 1.2 to 4.4, p=0.016) compared to 
carriers of an H2 allele. There was no increase in the risk of progression to Hoehn and 
Yahr stage 3. Interestingly, when controlling for these confounders, the “high-risk” group 
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for COMT codon 158 were found to have a reduced risk of dementia, with hazard ratio of 
0.4 (95 % confidence interval 0.2 to 0.8, p=0.012). There was no effect on risk of death 
or progression to Hoehn and Yahr stage three. For APOE and the SNCA rs356219 
polymorphism there were no differences in any of the three outcome measures when 
controlling for age, sex and GBA1 mutation status (Figure 2.2 and Table 2.9 to Table 
2.12). 
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Figure 2.2 – Survival analyses for time to dementia, time to Hoehn and Yahr stage 
three, and time to death based on genetic susceptibility factors. Patients from the 
CamPaIGN and PICNICS cohorts were stratified based on the presence of high- or low-
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risk variants in MAPT (A-C), SNCA (D-F), COMT (G-I) and APOE (J-K). Kaplan-Meier 
curves for the three disease milestones are shown. 
 
 Mortality HY3 Dementia 
 H2 carriers H1/H1 H2 carriers H1/H1 H2 carriers H1/H1 
Number 134 252 133 251 49 89 
Estimated 








































76.4 (SE 5) 












47.3 (SE 7.2) 












43.0 (SE 7.7) 
Log-rank p-
value 
- 0.141 - 0.147 - 0.138 






- 2.3 (1.2-4.4; 
p=0.016) 
Table 2.9 – Time to death, progression to Hoehn and Yahr stage three, and dementia 
in PD patients with low-risk (H2 carriers) versus high risk (H1/H1) MAPT 
haplotype. Hazard ratios determined by Cox regression analysis controlling for age at 
diagnosis, sex and GBA1 mutation status. 95 % confidence intervals for hazard ratio and 
estimated mean and median shown in brackets. Log-rank p-values shown for comparison 
between the high- and low-risk MAPT carriers. Abbreviations: HY3 = Hoehn and Yahr 
three; SE = standard error of the mean. 
  
Chapter 2 – Clinical aspects of GBA1 variant-associated Parkinson’s disease 
Thomas Stoker – September 2019     51 
 Mortality HY3 Dementia 
 Val/Val Val/Met or 
Met/Met 
Val/Val Val/Met or 
Met/Met 
Val/Val Val/Met or 
Met/Met 
Number 64 206 64 204 33 95 
Estimated 
































88.8 (SE 4) 83.6 (SE 2.7) 51.2 (SE 7) 52.4 (SE 4) 68.6 (SE 9) 88.3 (4) 
10 year 
survival (%) 







17.8 (3.9) 0 11.7 (SE 4) 40.8 (SE 
13) 
49.8 (SE 8) 
Log-rank p-
value 
- 0.525 - 0.727 - 0.164 





- 0.4 (0.2-0.8; 
p=0.012) 
Table 2.10 – Time to death, progression to Hoehn and Yahr stage three, and 
dementia in PD patients with low-risk (val/val) versus high-risk (met/met or met/val) 
COMT codon 158 genotype. Hazard ratios determined by Cox regression analysis 
controlling for age at diagnosis, sex and GBA1 mutation status. 95 % confidence intervals 
for hazard ratio and estimated mean and median shown in brackets. Log-rank p-values 
shown for comparison between the high- and low-risk COMT groups. Abbreviations: 
HY3 = Hoehn and Yahr three; Met = methionine; SE = standard error of the mean; val = 
valine. 
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 Mortality HY3 Dementia 
 G/A or 
A/A 
G/G G/A or 
A/A 
G/G G/A or 
A/A 
G/G 
Number 27 97 27 96 27 97 
Estimated 




























82.5 (SE 4) 81.5 (SE 8) 42.1 (SE 5) 33.7 (SE 10) 84.0 (SE 
4) 
77.0 (SE 9) 
10 year 
survival (%) 












- 0.422 - 0.533 - 0.921 
Hazard ratio - 1.0 (0.6-1.7; 
p=0.933) 
- 1.0 (0.6-1.7; 
p=0.996) 
- 0.8 (0.4-1.8; 
p=0.633) 
Table 2.11 – Time to death, progression to Hoehn and Yahr stage three, and 
dementia in PD patients with low-risk (G/A or A/A) versus high-risk (G/G) SNCA 
rs356219 genotype. Hazard ratios determined by Cox regression analysis controlling for 
age at diagnosis, sex and GBA1 mutation status. 95 % confidence intervals for hazard 
ratio and estimated mean and median shown in brackets. Log-rank p-values shown for 
comparison between the high- and low-risk SNCA rs356219 carriers. Abbreviations: HY3 
= Hoehn and Yahr three; SE = standard error of the mean. 
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 Mortality HY3 Dementia 












Number 91 33 90 33 91 33 
Estimated 





























81.3 (SE 4) 81.8 (SE 7) 39.2 (SE 6) 43.1 (SE 9) 85.1 (SE 4) 75.8 (SE 8) 
10 year 
survival (%) 








- 0.303 - 0.54 - 0.292 
Hazard ratio - 1.3 (0.8-2.1; 
p=0.251) 





Table 2.12 – Time to death, progression to Hoehn and Yahr stage three, and 
dementia in PD patients with low-risk (No ε4 alleles) versus high-risk (ε4 carriers) 
APOE haplotype. Hazard ratios determined by Cox regression analysis controlling for 
age at diagnosis, sex and GBA1 mutation status. 95 % confidence intervals for hazard 
ratio and estimated mean and median shown in brackets. Log-rank p-values shown for 
comparison between the high- and low-risk APOE carriers. Abbreviations: ApoE = 
apolipoprotein E; SE = standard error of the mean. 
 
In order to study whether the presence of the high-risk variants in the secondary genetic 
risk factors alters the course of GBA1-PD, carriers of all GBA1 abnormalities were 
subdivided into those with the low-risk and high-risk state for the secondary genetic 
factor, and survival analyses for time to death, dementia and Hoehn and Yahr stage three 
were performed (Figure 2.3). None of the secondary factors increased the risk of dementia 
or mortality in GBA1-PD. However, there was a trend towards an increased risk of death, 
which fell slightly short of statistical significance (hazard ratio 2.6 (95 % confidence 
interval 1.0-7.1, p=0.058) in GBA1-PD patients with the H1/H1 MAPT haplotype in 
comparison to H2 carriers, when controlling for age at diagnosis and sex. It may be that 
the small groups resulting from such stratification meant that these analyses were 
insufficiently powered to detect significant differences. The 10 year survival for the 
H1/H1 group was 28.6 % compared to 43.0 % in H2 carriers. There were only two carriers 
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of the APOE ε4 allele within the GBA1-PD cohort precluding any comment on the 
significance of this variant, but both patients had particularly aggressive disease courses, 
with both developing dementia within seven years of diagnosis, and both dying within 
nine years of diagnosis. Projected mean times to these outcomes are shown in Table 2.13. 
 
GBA1-PD patients with the high-risk variant in the SNCA rs356219 locus had an increased 
risk of progression to Hoehn and Yahr stage three when controlling for age at diagnosis 
and sex (hazard ratio 5.3 (95 % confidence interval 1.1-26.2, p=0.041)), with all patients 
reaching Hoehn and Yahr stage three within three years. None of the other genetic risk 
factors tested increased the risk of progression to Hoehn and Yahr stage three. 
 
 Number Estimated Mean 
Time to Dementia 
(Years) 
Estimated Mean 
Time to Postural 
Instability (Years) 
Estimated Mean 
Time to Death 
(Years) 
Low-risk MAPT 20 8.3 (5.5-11.2) 5.1 (2.9-7.3) 9.9 (8.3-11.5) 
High-risk 
MAPT 
18 5.7 (3.9-7.6) 4.2 (2.8-5.6) 8.3 (7.0-9.5) 
Low-risk COMT 5 6.7 (3.0-10.4) 4.0 (1.4-6.6) 9.6 (7.0-12.2) 
High-risk 
COMT 
21 6.5 (4.5-8.6) 4.7 (3.0-6.3) 9.0 (7.5-10.5) 
Low-risk SNCA 11 6.5 (5.8-7.2) 3.2 (2.5-3.8) 8.8 (8.5-9.2) 
High-risk SNCA 5 5.0 (2.1-7.9) 2.6 (0-6.5) 7.1 (4.2-10.9) 
Low-risk APOE 14 7.4 (5.2-9.7) 4.3 (2.0-6.5) 8.7 (6.9-10.6) 
High-risk APOE 2 4.6 (0.7-8.5) 2.8 (2.4-3.2) 7.2 (4.4-9.9) 
Table 2.13 –Time to death, dementia and Hoehn and Yahr stage three based on 
presence of secondary genetic susceptibility factors in GBA1-PD. Patients from the 
CamPaIGN and PICNICS cohorts with GBA1-PD were stratified based on the presence 
of high- or low-risk variants in MAPT, COMT, SNCA or APOE. Estimated mean time to 
death, Hoehn and Yahr stage three, and dementia are shown in the table, with 95 % 
confidence intervals shown in brackets. 
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Figure 2.3. Survival analyses for time to death, postural instability and dementia in 
patients with GBA1-PD with and without secondary genetic risk factors. Patients 
from the CamPaIGN and PICNICS cohorts with GBA1-PD were stratified based on the 
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presence of high- or low-risk variants in MAPT (A-C), SNCA (D-F) COMT (G-I) or APOE 




This study represents the longest follow-up in incident PD patients with GBA1-PD, and 
the inclusion of two community-based cohorts allowed for this to be done in a relatively 
large study population. In contrast, most previous longitudinal studies of GBA1-PD have 
employed prevalent cohorts in which variation in disease duration for example may 
confound the results. Consistent with most previous studies, GBA1 variants were found 
to significantly influence the course of PD in terms of motor and cognitive decline. 
Additionally, the long follow-up time allowed for the study of mortality in GBA1-PD – 
something that has only been commented on in a very limited number of studies – which 
was found to be significantly elevated in variant-carriers. GBA1 polymorphisms, in 
addition to pathogenic mutations, were significantly associated with worse outcomes 
when controlling for confounders. Time to death, diagnosis of dementia, and development 
of postural instability were chosen as outcome measures, given that these represent 
important milestones in the natural history of PD. 
 
2.5.1 Incidence and clinical significance of GBA1 variants in Parkinson’s 
disease 
 
In these cohorts, GBA1-variants were found in approximately 10 % of PD patients, with 
about half of those carrying GD-causing pathogenic mutations. However, there were 115 
patients who were not found to carry a GBA1 variant, but had only targeted screening for 
a limited number of GBA1 abnormalities, meaning that it is likely that some of these 
carried a mutation that was not screened for. The observed frequency of GBA1 mutations 
is therefore likely to be slightly higher in these cohorts. These patients were excluded 
from survival analyses to ensure that there were no potential GBA1-variant carriers in the 
iPD group.  
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GBA1 mutations have previously been associated with an earlier age of onset in PD 
(Brockmann et al. 2015, Clark et al. 2007, Nichols et al. 2009). Here, there were no 
significant differences in the age of onset based on GBA1 status. In both the pathogenic 
mutation group and polymorphism group, the mean age of onset was approximately two 
years earlier than in the iPD group, and it may be that the sample size meant that this 
study was underpowered to detect a difference in the age at onset. 
 
GBA1-PD was found to result in a generally more aggressive disease course. The most 
consistent clinical feature associated with GBA1-PD in comparison to iPD, is an increased 
risk of cognitive decline and dementia. In this study, in carriers of any GBA1 mutation 
the projected mean time to dementia was 7.1 years – approximately five years earlier than 
in the iPD group – which was statistically significant when controlling for confounding 
factors. This was true for pathogenic mutations, of which carriers had a 5.6-fold greater 
risk of dementia than in iPD (p=0.002), and also, to a lesser extent, in carriers of non-
pathological polymorphisms in which the risk of dementia was increased 3.1-fold 
(p=0.024). 
 
The conclusions on motor progression in GBA1-PD have been more variable in previous 
studies, with some studies finding that GBA1 mutations are associated with an adverse 
clinical course (Davis et al. 2016b, Davis et al. 2016a, Winder-Rhodes et al. 2013, 
Brockmann et al. 2015), and others finding no effect (Liu et al. 2016a, Setó-Salvia et al. 
2012, Lunde et al. 2018). Here, carrying any form of GBA1-variant led to an increase in 
motor progression, as judged by the onset of postural instability. Only approximately one 
third of patients carrying any GBA1 variant remained free of postural instability at the 
five year time point, which compared to more than half of the iPD patients. As for the 
risk of dementia, both non-pathogenic and pathogenic GBA1 variants increased the risk 
of progression to postural instability, both by approximately two-fold. 
 
Few studies have commented on mortality in GBA1-PD, but the long duration of 
observation in this study allowed for the effect of GBA1 mutation abnormality on 
mortality in PD to be investigated. Both non-pathogenic polymorphism and pathogenic 
mutation carriers had an approximately two-fold greater risk of death than that in non-
carriers. All carriers of any GBA1 variant had died within 15 years of diagnosis, 
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supporting the fact that carrying a GBA1 abnormality of any kind results in a significantly 
worse prognosis, when compared to patients with wild-type GBA1. The increased risk of 
death associated with GBA1-PD was independent of the development of dementia, 
suggesting that other mechanisms may contribute to the increased risk of death in this 
group. For example, the increased risk of motor progression may result in an earlier risk 
of falls and immobility in GBA1-PD which may contribute to death. Other factors that 
have not been investigated in this study, including the incidence of autonomic features 
for example, may also contribute to the increased risk of mortality in GBA1-PD. 
Similarly, the development of postural instability was also independent of dementia 
status, suggesting that GBA1 variants have widespread detrimental effects, accelerating 
degeneration in motor and cognitive pathways. 
 
2.5.2 Effect of concomitant genetic susceptibility factors in GBA1 variant-
associated Parkinson’s disease 
 
A growing number of genetic susceptibility loci have now been reported in PD, and it is 
thought that an individual’s risk of developing PD may be in part due to a polygenic risk 
profile (Nalls et al. 2011, Nalls et al. 2014, Polito, Greco and Seripa 2016). As such, it 
was hypothesised that the clinical course of GBA1-PD would be adversely affected by the 
presence of concomitant genetic risk factors. For the CamPaIGN cohort, data on MAPT 
haplotype, COMT codon 158 status, SNCA rs356219 polymorphism and APOE haplotype 
were available, with the former two also being available for patients in the PICNICS 
cohort. 
 
Carrying a MAPT H2 allele led to a slight but statistically significantly better prognosis, 
with a reduced risk of mortality and dementia, in comparison to those with the H1/H1 
haplotype, independent of GBA1 status. None of the other genetic risk factors (COMT, 
SNCA, APOE) alone were found to adversely affect clinical course, which may be 
attributed to the small sample size and a relatively small biological effect in comparison 
to carrying a GBA1 abnormality. In fact, methionine-carriers at COMT codon 158 actually 
had a significantly reduced risk of dementia in these cohorts. The previous literature 
regarding the impact of COMT codon 158 in PD is limited, and the clinical significance 
of this result is questionable in this small sample. 
Chapter 2 – Clinical aspects of GBA1 variant-associated Parkinson’s disease 
Thomas Stoker – September 2019     59 
 
When investigating the effect of carrying a secondary genetic risk factor within the GBA1-
PD population, none of the four genetic risk factors significantly altered the risk of 
dementia or mortality. Though not significant, there was a trend that carrying the H1/H1 
MAPT haplotype in addition to a GBA1 variant led to a reduced time to mortality, with 
mean time to death being more than a year earlier in GBA1-PD patients carrying the 
H1/H1 MAPT haplotype in comparison to those carrying an H2 allele. The small sample 
size meant though that our study was probably under-powered to detect a significant 
difference. In addition, because of the small sample size, patients with all GBA1 
abnormalities were included in this analysis including those with non-pathogenic 
polymorphisms, which are probably associated with a more benign clinical picture than 
those with pathogenic mutations. In a larger cohort, it would be useful to stratify patients 
based on whether they carry pathogenic or non-pathogenic GBA1 variants, in addition to 
the high-risk MAPT haplotype. Nevertheless, this observation lends some support to the 
hypothesis that carrying both a GBA1 mutation and the high-risk MAPT haplotype leads 
to a particularly aggressive clinical course, and it would be useful to investigate this with 
a larger clinical cohort. 
 
The presence of the SNCA rs356219 high risk genotype in GBA1-PD led to a significantly 
increased risk of progressing to Hoehn and Yahr stage three, with all patients reaching 
this outcome within three years, when controlling for age at onset and sex. There was no 
effect on mortality or development of dementia, suggesting that any synergistic 
interaction between these two genetic risk factors has a predominant effect on pathology 
contributing to motor features. However, it should be acknowledged that only five 
patients across the cohorts carried both a GBA1 abnormality and the high-risk SNCA 
genotype, making it difficult to ascertain the true clinical significance of this observation. 
Previous studies have suggested that GCase directly interacts with α-synuclein, though 
the significance of this in vivo remains unknown (Yap et al. 2011, Yap et al. 2013). 
Additionally, GCase has been identified in Lewy bodies, with mutant forms more likely 
to be found in these structures (Goker-Alpan et al. 2010). The clinical observation of 
accelerated motor course raises the interesting possibility that, just as GBA1 mutations 
alter the propensity of GCase to interact with α-synuclein, polymorphisms in α-synuclein 
may also alter the dynamics between the two proteins, with clinical consequences. 
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The stratification of risk of adverse outcomes in PD is potentially important when 
determining inclusion criteria for future clinical trials, particularly as regenerative and 
more targeted disease modifying therapies begin to enter the clinic. For example, it would 
be preferable to trial treatments targeting the motor aspects of PD in patients with 
predominantly motor symptoms and low risk of dementia, in whom the potential benefits 
are greatest. A greater understanding of how the genetic risk factors for PD interact will 
potentially allow us to categorise patients more accurately into those with low- and high-
risk for development of dementia and/or early death, based on the presence of only a small 
number of genetic susceptibility factors. This latter group may be ideal for the trial of 
putative disease modifying therapies. 
 
2.5.3 Clinical significance of non-pathogenic GBA1 polymorphisms 
 
As has been discussed, as well as the GD-causative pathogenic GBA1 mutations, a 
number of GBA1 variant polymorphisms have been found at increased frequency in PD. 
These include the E326K, T369M and E388K polymorphisms for example, all of which 
were represented in this study. Of these, the E326K variant has been most extensively 
reported on, with the majority of studies finding that there is an increased risk of PD, as 
well as a more severe clinical course than in non-carriers. The role of the other common 
variant, T369M, is less clearly defined (Davis et al. 2016b, Mallett et al. 2016). 
 
In this study, the E326K and T369M polymorphisms were each found in 10 of the 377 
patients (2.7 %) in which they were screened for, making them the most commonly 
identified variants. This frequency is consistent with what has been reported in previous 
studies. The large meta-analysis of GBA1 mutations and variants in PD by Sidransky et 
al. did not identify the E326K variant to be associated with PD (Sidransky et al. 2009). 
This may be due to the fact that the study population was enriched for individuals from 
Jewish, Portuguese, and Asian populations, in which the E326K allele is absent or 
relatively infrequent (Bras et al. 2009, Ruskey et al. 2019). 
 
Chapter 2 – Clinical aspects of GBA1 variant-associated Parkinson’s disease 
Thomas Stoker – September 2019     61 
Here, carrying a non-pathogenic GBA1 polymorphism significantly increased the risk of 
dementia and motor progression, indicating that they should be considered significant 
adverse genetic factors in PD. Additionally, this is the first study to have found that these 
polymorphisms are associated with a significantly increased risk of mortality in 
comparison to non-carriers. The long follow-up period in this study meant that all patients 
carrying GBA1 abnormalities, including those with non-pathogenic polymorphisms, died 
during the follow-up period. This association may not have been seen in previous studies 




The major limitations of this epidemiological study are related to sample size. 
Combination of two incident cohorts allowed for an initial relatively large study 
population. However, for survival analyses, 115 patients were excluded from the analysis 
due to the fact that they had only had limited genetic analysis of the GBA1 gene, such that 
they could potentially have carried unidentified GBA1 mutations. Additionally, for 
dementia outcome, only the CamPaIGN patients were included, because of differences in 
the definition of dementia onset between the two cohorts. 
 
The limited sample size was a particular problem when investigating potential synergistic 
effects of GBA1 variants and concomitant secondary genetic risk factors. Though some 
interesting results were observed, such as the trend towards increased risk of mortality in 
GBA1-PD patients carrying the H1 MAPT haplotype, and the significantly increased rate 
of motor progression in those carrying the high-risk SNCA allele, the small groups meant 
that the significance of these findings is uncertain. Nevertheless, these observations are 
worth exploring further in larger cohorts. 
 
2.5.5 Concluding remarks 
 
Consistent with most previous studies, analysis of the CamPaIGN and PICNICS cohorts 
suggested that GBA1 mutations adversely affect clinical course. The effect of non-
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pathogenic polymorphisms on clinical course in prior studies has been less clear. The 
E326K and T369M polymorphisms in particular are common in PD, though studies have 
yielded conflicting results in terms of their impact on prognosis. Here, carriers of these 
variants did indeed have a significantly worse prognosis, and the presence of these 
therefore seems likely to be of clinical significance. Additionally, no other studies have 
reported on the effect of concomitant genetic susceptibility factors in GBA1-PD, and 
although it is difficult to draw robust conclusions here due to the limited sample size, 
there are interesting observations that indicate that the presence of certain genetic variants 
may further worsen prognosis when associated with GBA1 mutations. This is hypothesis 
would be interesting to address in larger cohorts. 
 
Despite the disadvantages relating to small group sizes, this study also had some 
advantages over some previous reports. Most notably, the follow-up time in these cohorts 
of up to 18 years from diagnosis is longer than has previously been published, offering a 
fuller picture of the natural history of GBA1-PD. The two cohorts included patients with 
incident PD only, meaning that patients were observed from diagnosis to death (or loss 
to follow-up) so there was a high incidence of patients meeting the clinical outcomes 
studied. Furthermore, in contrast to previous epidemiological studies of GBA1-PD which 
have often involved hospital-based cohorts, which may over-represent those with atypical 
or more aggressive disease, this study included patients recruited from the community. 
The findings in relation to the frequency of GBA1 abnormalities and in relation to their 
impact on clinical course, are therefore probably more representative of the overall PD 
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Generation of iNs offers a source of aged adult neurons which can be used for the study 
of age-related neurodegenerative diseases. Direct conversion of somatic cells may be 
driven through the expression of proneural transcription factors, the expression of 
neuronal microRNAs or inhibition of the REST complex. The major potential advantage 
of iNs over similar iPSC-derived neurons, is that they maintain the age signature of the 
host, potentially retaining important aspects that determine the propensity for pathology 
to develop. In this study, iNs have been generated from healthy controls and PD patients 
through the expression of Ascl1 and Brn2, combined with REST suppression. The iNs 
produced expressed neuronal markers including α-synuclein, and neuronal purities and 
conversion efficiencies of up to around 35 % and 50 % respectively were achieved. iNs 
took on a typical simple neuronal morphology, with the extension of neurites. Limitations 
of the iN system included an impure population of cells that are relatively immature. 
 
3.2 Introduction to chapter 
 
Identification of disease-modifying drugs for neurodegenerative conditions such as PD is 
hindered by the limitations of existing disease models. The propensity for development 
of PD pathology clearly has cell-type specific properties, as evidenced by the fact that 
neurodegeneration occurs in well-defined anatomical structures, such as the substantia 
nigra pars compacta (Dickson 2012, Kalia and Lang 2015, Braak et al. 2003). 
Additionally, other than in rare genetic forms of the disease, PD is a disease of aged cells, 
with incidence of disease rising with age (Pringsheim et al. 2014). Furthermore, it is 
thought that an individual’s risk of PD is, at least in part, dependent on a profile of poorly 
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defined genetic susceptibility factors (Ferreira and Massano 2017, Lill et al. 2012). As 
such, it is desirable for a disease model to retain the following aspects in order to faithfully 
represent the propensity for intracellular PD pathology to develop: 
 
 i) A relevant cell type (i.e. human neurons) 
 ii) Cellular properties related to age 
 iii) The genetic profile associated with PD risk 
 
These factors will not only determine the pathology that is observed in a disease model, 
but will also potentially influence the behaviour of an experimental drug in the system, 
so the more closely that they reflect patient neurons, the more reliably the model would 
be expected to predict the ability of a drug to have a beneficial effect. In addition to these 
factors, there are also practical aspects important in a disease model, such as being derived 
from accessible tissue, reproducibility, and ability to scale up. 
 
Many systems have been used to study the pathogenesis of PD, and to screen drugs for 
the condition. These include standard cell lines, such as neuroblastoma cells, in which an 
insult is applied such as α-synuclein overexpression, introduction of a pathogenic 
mutation or application of a toxin, but these fail to capture any of the three factors 
mentioned above (Wang et al. 2012, El-Agnaf et al. 1998). Additionally, introducing 
these experimental insults greatly exaggerates properties such as the propensity for α-
synuclein aggregation (e.g. through supra-physiological levels of the protein, or 
introduction of aggregate-prone mutant forms of the protein), such that they are a further 
step removed from what happens in patients. Similarly, animal (rodent, primate and 
drosophila) models rely on the introduction of significant insults (such as the use of 
dopaminergic neuron toxins or transgene expression) for any relevant pathology to be 
seen (Masliah et al. 2000, Giasson et al. 2002, Kikuchi et al. 2017), as these animals do 
not develop PD spontaneously. Findings in these systems therefore will also not fully 
represent those occurring in patients. It is possible to generate patient neurons from 
patient-derived iPSCs, fulfilling the first and third criteria listed above. Highly pure 
populations of subtype-specific (e.g. dopaminergic) neurons can be generated (Kikuchi 
et al. 2017), meaning that it is possible to study disease mechanisms in relevant cell-types 
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(Fernandes et al. 2016, Sánchez-Danés et al. 2012). However, these cells fail to 
recapitulate age meaning that they may miss out on important aspects of pathogenesis 
(Lapasset et al. 2011, Horvath 2013, Victor et al. 2018). Furthermore, the way in which 
a drug behaves in these cells may be fundamentally different to the way it acts in an aged 
intracellular environment. Another potential disadvantage of iPSCs for disease-
modelling, is the clonal nature of the derived differentiated cells. They therefore fail to 
represent genetic variations between individual cells which may contribute to the cell’s 
susceptibility to pathology (Grskovic et al. 2011). Furthermore, it is known that long-term 
culture of stem cells results in the acquisition of genetic aberrations, with those that confer 
a growth advantage coming to dominate the cell population, potentially altering disease 
phenotypes (Hussein et al. 2011, Gore et al. 2011). 
 
Direct lineage conversion of fibroblasts to iNs offers a source of aged adult neurons, 
which retain relevant host genetic risk factors. The retention of the aged cellular 
phenotype potentially means that iNs can provide a more faithful disease model than 
similar iPSC-derived neurons, in which DNA methylation patterns, transcriptomes and 
extent of DNA damage for example, revert to those of young cells (Mertens et al. 2015, 
Huh et al. 2016). In this project therefore, iNs were generated to form the basis of a novel 
drug-screening tool for PD. 
 
Generation of iNs through direct reprogramming is a relatively novel technique, first 
reported in 2010. The application of iNs has been limited to date, largely due to inefficient 
conversion protocols. However, an understanding of microRNA-mediated differentiation 
pathways has allowed for the development of reprogramming protocols in which these 
microRNAs are utilised or bypassed, leading to a dramatic improvement in direct lineage 
conversion efficiencies. 
 
In this project, iNs were generated through constitutive expression of two proneural 
transcription factors (Ascl1 and Brn2), as well as two short-hairpin ribonucleic acid 
(shRNA) sequences which suppress the REST complex – a neuronal inhibitory target of 
miRNA-9/9* and miRNA-124. In this chapter the reprogramming methods and iN 
product are described. 
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3.2.1 Rationale for use of induced neurons 
 
As is discussed above, accurate representation of PD pathology in experimental models 
is challenging. Given that the clinically relevant pathology that occurs in PD is largely 
confined to neurons, and that the disease does not occur spontaneously in animals, it is 
preferable for an in vitro disease model to be based on human neurons. Furthermore, 
neurodegenerative diseases such as PD, Alzheimer’s disease, motor neuron disease, and 
Huntington’s disease for example, are strongly associated with aging, thus it is also 
desirable to retain elements of age in models of these conditions. Of course, aged human 
neurons are not easily accessible, and post-mortem tissue does not allow for the study of 
dynamic events involved in PD pathogenesis, or the study of drug effects. The conversion 
of adult somatic cells to iPSCs through forced expression of defined pluripotency factors, 
with subsequent differentiation to neurons has offered a new avenue for studying 
pathogenesis and for in vitro therapeutic screening in PD. However, the use of iPSC-
derived neurons fails to capture an important aspect of PD – age. 
 
It has been shown that iPSC-reprogramming essentially results in rejuvenation of the cell 
to an embryonic state, in terms of the epigenetic landscape, telomere length, and gene 
expression profile as well as a number of other parameters (Huh et al. 2016, Mertens et 
al. 2015, Horvath 2013, Maherali et al. 2007). Additionally, observation of pathology in 
iPSC-derived neurons employed for disease-modelling often requires the use of 
significant insults such as oxidative stressors, autophagy inhibition, prolonged culture 
time or chemically-mediated proteasome inhibition, making the system less reflective of 
the processes that lead to disease in patients (Jeon et al. 2012, Nekrasov et al. 2016, 
HD_iPSC_Consortium 2012). Direct lineage conversion to generate iNs in contrast, has 
been shown to lead to retention of age-dependent signatures in a number of domains, 
suggesting that these cells better retain an important aspect of PD pathogenesis.  This has 
been demonstrated in a number of studies through direct comparison of age-related 
phenotypes in iNs and iPSC-derived neurons from the same individuals, and iNs may 
therefore offer a more faithful disease model (Mertens et al. 2015, Yang et al. 2015, Tang 
et al. 2017, Kim et al. 2018, Huh et al. 2016). iNs are a relatively novel technology, with 
only a small number of studies utilising them for disease-modelling to date, but it is 
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beginning to emerge that they are able to capture elements of pathology that are not seen 
in iPSC-derived neurons (Victor et al. 2018). 
 
3.2.2 Markers of cellular aging 
 
Aging is associated with a number of changes in a variety of intracellular structures and 
processes (Table 3.1). These changes reflect the age of the individual from which they 
were derived, rather than simply the age of the individual cell. Whilst these age-related 
changes may not be directly related to the pathogenesis of diseases such as PD, they 
suggest that the intracellular environment of an aged cell is different to that of a young 
cell, which may have implications for the development of disease and response to 
treatments. 
 
Perhaps the best characterised of these age-related changes, are in the epigenetic 
landscape of the cell (Fraga and Esteller 2007, Rodríguez-Rodero et al. 2010). The 
methylation status at CpG dinucleotide sites in the DNA has been clearly shown to change 
with age, with a number of genomic regions becoming either hyper- or hypomethylated 
(Horvath et al. 2012, Christensen et al. 2009, Bollati et al. 2009, Bell et al. 2012). 
Determination of the pattern of DNA methylation in a cell allows for prediction of the 
chronological age of the host organism, with high accuracy – an observation that is 
preserved across a wide range of tissue and cell types, including neurons (Horvath 2013). 
The pattern of methylation at 353 CpG sites has been termed the “epigenetic clock,” and 
it has been suggested that the hyper- or hypomethylation at these sites reflects the 
cumulative work performed by a cell’s epigenetic maintenance system, and thus reflects 
age. Assessment of the DNA methylation status in different types of blood cells, some of 
which have very short lifespans (e.g. CD14-positive monocytes) while others have 
prolonged lifespans (e.g. CD4-positive T lymphocytes), revealed similar methylation age 
(Horvath 2013). Importantly therefore, the epigenetic clock appears to reflect the 
chronological age of an organism, rather than of the individual cell. 
 
Additionally, age-dependent differences exist in terms of the gene expression profile in a 
number of cell types (Lu et al. 2004, Berchtold et al. 2008, Mertens et al. 2015, Fraser et 
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al. 2005, Glass et al. 2013). In dermal fibroblasts from young individuals, 78 genes were 
differentially expressed in comparison to in dermal fibroblasts from individuals over 40 
years old (Mertens et al. 2015). In the human frontal cortex, age is associated with down-
regulation of genes involved in mitochondrial function, synaptic plasticity and vesicular 
transport (Lu et al. 2004). In contrast, stress response and DNA repair genes were 
upregulated with aging. Those genes that were downregulated were under the control of 
promoters that were particularly susceptible to DNA damage associated with aging, 
which may account for some of the age-related transcriptomic changes that are seen (Lu 
et al. 2004). The profile of gene expression in aging has been shown to differ between 
different anatomical regions within the brain, suggesting that there are inherent 
differences in how certain brain regions are affected by age, which may potentially 
underlie the vulnerability of specific anatomical regions in certain neurodegenerative 
diseases (Berchtold et al. 2008, Fraser et al. 2005). 
 
A number of other biochemical properties are also altered with aging, which also supports 
the concept that the intracellular environment in an aged cell is inherently different to that 
in cells from young individuals. For example, nuclear membrane integrity is disrupted 
with ageing, as evidenced by loss of nuclear-cytoplasmic compartmentalisation, reduced 
expression of the nuclear pore-associated transport receptor RAN binding protein 17 
(RANBP17), and abnormalities in nuclear morphology (Mertens et al. 2015, Miller et al. 
2013, Tang et al. 2017). Accumulation of double-stranded DNA breaks also occurs with 
age, as demonstrated by the increased presence of serine 139-phosphorylated H2A 
histone family member X (γH2AX) foci in fibroblasts from older individuals (Tang et al. 
2017, Miller et al. 2013). Mitochondrial aberrations also appear to accumulate in cells 
from aged individuals. For example, increased levels of reactive oxygen species (Yang et 
al. 2015, Miller et al. 2013), oxidised proteins (Kim et al. 2018) and oxidative DNA 
damage (Prigione et al. 2011, Lu et al. 2004), and reduced mitochondrial membrane 
potential and adenosine triphosphate (ATP) synthesis (Kim et al. 2018) are all observed 
in cells from aged individuals. 
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Epigenetic - Methylation status at defined CpG sites 
- Loss of trimethylated H3K9m23 
- Loss of HP1γ 
Transcriptome - Altered gene expression profiles with aging 
Nuclear membrane integrity - Reduced RANBP17 
- Loss of nucleocytoplasmic compartmentalisation 
- Nuclear blebbing 
- Loss of LAP2α 
Senescence - Increased SA-β-galactosidase activity 
- Reduced telomere length 
Mitochondrial - Fragmentation 
- Oxidative damage 
- Reduced membrane potential 
- Reduced ATP synthesis 
DNA / Chromosome integrity - Double-stranded DNA breaks 
- Oxidative DNA damage 
Table 3.1 – Age-related intracellular changes. Ageing is associated with a number of 
alterations to epigenetic parameters, gene expression, DNA integrity and mitochondrial 
function for example. Abbreviations: ATP = adenosine triphosphate; DNA = 
deoxyribonucleic acid; HP1γ = heterochromatin protein one γ; LAP2α = lamina-
associated peptide two α; RANBP17 = RAN binding protein 17; SA-β-galactosidase = 
senescence-associated-β-galactosidase. 
 
3.2.3 Rejuvenation of induced pluripotent stem cells 
 
Reprogramming to iPSCs using pluripotency factors results in loss of the cellular markers 
of aging discussed in the previous section. This is perhaps desirable when aiming to 
develop iPSC-based regenerative therapies, but limits the utility of iPSC-derived cells for 
disease-modelling, particularly with regard to neurodegenerative diseases which are 
strongly associated with aging. Telomere length and telomerase activity is increased in 
iPSCs (Lapasset et al. 2011, Marion et al. 2009, Agarwal et al. 2010, Prigione et al. 2011, 
Suhr et al. 2010), whilst senescence-associated markers such as P16INK4A and P21CIP1 
expression, and senescence-associated-β-galactosidase (SA-β-galactosidase) activity are 
reduced in comparison to their parent cells (Lapasset et al. 2011). iPSC reprogramming 
also results in epigenetic changes, such that the DNA methylation age is reset to that of 
an embryonic stem cell (Horvath 2013, Marion et al. 2009, Maherali et al. 2007). 
Additionally, iPSCs resemble human ESCs in terms of gene expression profile (Lapasset 
et al. 2011, Patterson et al. 2012, Prigione et al. 2011) and mitochondrial health (Lapasset 
et al. 2011, Prigione et al. 2011). Mitochondria in iPSCs from both young and old 
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individuals take on a morphology that resembles those of embryonic stem cells, switching 
from a tubular shape with dense cristae to a rounded shape with poorly developed cristae. 
Additionally, iPSC-reprogramming results in reduced reactive oxygen species 
production, and increased mitochondrial membrane potential, with levels of oxidative 
DNA damage also being reset to the minimal levels seen in embryonic stem cells 
(Prigione et al. 2011). Differentiated progeny derived from iPSCs also resemble their 
embryonic stem cell-derived counterparts in terms of proliferative potential and 
transcriptome (Lapasset et al. 2011, Patterson et al. 2012). It has also been suggested that 
neural precursor cells derived from human iPSCs resembled fetal neural cells from a very 
early developmental stage (Patterson et al. 2012). 
 
Comparison of iPSCs derived from young and old individuals showed that these are 
indistinguishable in terms of markers of aging including expression of RANBP17, lamin 
A, lamina-associated protein two α (LAP2α), heterochromatin protein one γ (HP1γ), and 
trimethylated H3K9me (Miller et al. 2013, Mertens et al. 2015). Additionally, double-
stranded DNA damage and accumulation of mitochondrial reactive oxygen species was 
also eradicated during iPSC-reprogramming (Miller et al. 2013). The gene expression 
signature in iPSCs derived from young and old individuals is also similar, which contrasts 
with the age-dependent changes that are observed in differentiated cells (Prigione et al. 
2011, Mertens et al. 2015). Furthermore, the loss of age-associated signature persists on 
differentiation of iPSCs into fibroblasts or dopaminergic neurons, with iPSC-derived 
products from old individuals closely resembling those from young individuals (Miller et 
al. 2013, Mertens et al. 2015). 
 
However, age-related phenotypes have been restored in iPSC-derived fibroblasts through 
the expression of progerin – an abnormal protein which results in the premature aging 
syndrome Hutchinson-Gilford Progeria syndrome (Hennekam 2006). The expression of 
progerin induced several of the aforementioned markers of cellular aging, including 
nuclear morphology abnormalities, reduced LAP2α expression, accumulation of double 
strand DNA breaks, increased mitochondrial reactive oxygen species, shortened telomere 
length and increased SA-β-galactosidase levels (Miller et al. 2013). The age profile of 
progerin-expressing iPSC-derived fibroblasts resembled that of primary fibroblasts from 
aged individuals. However, induction of age in iPSC-derived dopaminergic neurons was 
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less effective. Whilst age-related changes in nuclear morphology, DNA damage and 
reactive oxygen species levels were observed in iPSC-derived neurons, there were no 
changes in LAP2α or SA-β-galactosidase levels for example (Miller et al 2013). Further 
studies are necessary to characterise the effect of progerin-expression in iPSC-derived 
neurons, but this potentially represents an avenue to iPSC-based models that capture 
elements of the aging profile. 
 
3.2.4 Retention of age in direct conversion 
 
Whilst iPSCs lose these age-related effects, iNs have been shown to retain the changes 
associated with the age of the individual from which they are generated. iNs derived from 
human adult fibroblasts display age-dependent differences in the transcriptome (Mertens 
et al. 2015, Huh et al. 2016). Interestingly, whilst the transcriptome is different when 
comparing young and old fibroblasts and iNs, only a small number of the differentially 
expressed genes are shared by both of these cell types (Mertens et al. 2015). This suggests 
that there may be transcriptomic aging profiles that are different in different cell types, 
and that this is reflected during direct reprogramming. Similarly, the microRNA profile 
in iNs derived from young and old individuals differs (Huh et al. 2016). 
 
iNs have also been shown to retain age-related changes in mitochondrial function. An 
analysis of the expression of 1118 mitochondrial genes in iNs, found that 70% of the 
analysed genes were downregulated in cells derived from individuals over 40 years old, 
compared to in those derived from individuals under 40 years old (Kim et al. 2018). 
Within the downregulated genes, 93% of the genes related to electron transport chain 
complexes I to IV were downregulated, along with genes involved in the tricarboxylic 
acid cycle and pentose phosphate pathway (Kim et al. 2018). iNs derived from older 
individuals also had a reduced density of axonal mitochondria, with increased 
mitochondrial fragmentation in comparison to those from younger individuals (Kim et al. 
2018). iNs have also been shown to demonstrate age-dependent reductions in 
mitochondrial membrane potential and ATP synthesis, and accumulation of reactive 
oxygen species and oxidative protein damage (Kim et al. 2018, Huh et al. 2016). 
Interestingly, whilst these changes are observed in fibroblasts from aged individuals, they 
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are not as pronounced as in iNs (Kim et al. 2018). This observation could be a result of 
the direct conversion process itself, but alternatively may be a demonstration that iNs 
recapitulate neuron-specific aging profiles. 
 
Other age-related changes that have been shown to be preserved in iNs include disruption 
of nuclear membrane permeability (Mertens et al. 2015), methylation age (Huh et al. 
2016), DNA damage (Huh et al. 2016, Tang et al. 2017) and telomere shortening (Huh et 
al. 2016). 
 
3.2.5 The use of induced neurons in disease-modelling studies 
 
The number of published studies involving iNs has grown considerably over the past few 
years. However, only a small number of studies have employed iNs for disease-modelling 
or in vitro treatment testing. 
 
Jovicic et al generated iNs from two adult humans with, and three without mutations in 
c9orf72, through lentiviral expression of Ascl1 and Ngn2, and culture with small 
molecules and neurotrophic factors for three weeks. These iNs were then co-cultured with 
mouse astrocytes for a further week (Jovičić et al. 2015). Characterisation of the neuronal 
product was limited in this study to determining expression of β3-tubulin. The 
morphology of the iNs generated was not discussed, but they appeared to have multiple 
short neurite processes emerging from the cell body. The iNs were utilised to assess the 
integrity of nuclear-cytoplasmic transport, with differences observed in the localisation 
of regulator of chromosome condensation one (RCC1 – a Ran guanine nucleoside 
exchange factor), in iNs derived from healthy controls compared to those derived from 
mutation carriers. 
 
A recent study in which medium spiny neurons were generated from Huntington’s disease 
patients and healthy controls via direct conversion identified relevant pathological 
changes in the Huntington’s disease iNs in comparison to the control iNs (Victor et al. 
2018). These included the presence of mutant huntingtin aggregates in about 10 % of the 
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iNs (reflecting human post-mortem findings), oxidative DNA damage and double-
stranded DNA breaks, and reduced viability. Mitochondrial dysfunction was also evident 
in the Huntington’s disease iNs, as evidenced by increased mitochondrial superoxide 
production and a reduction in mitochondrial membrane potential. These changes were not 
observed in unconverted fibroblasts, demonstrating the importance of using a relevant 
cell type. Additionally, this group compared the pathology seen in these iNs, to that seen 
in iNs derived from embryonic fibroblasts that had been generated from iPSCs from the 
same patient lines. This allowed for comparison of the same neuronal product, with the 
only differences being related to passage through the stem cell stage and the associated 
cellular rejuvenation. Interestingly, no huntingtin aggregates were observed in the iPSC-
derived, “embryonic” iNs, demonstrating the importance of retention of age, and the 
potential for iPSC-derived reprogramming to miss important aspects of pathology (Victor 
et al. 2018). 
 
iNs have also been used for drug screening in a study of motor neuron disease (Liu, Zang 
and Zhang 2016b). In this study, cholinergic motor neurons were generated from three 
patients with FUS mutations. The localisation of FUS was found to be cytoplasmic (in 
contrast to the usual nuclear localisation) in mutation-carrying iNs, and this 
mislocalisation was not seen in fibroblasts from the same individuals, adding further 
support to the idea that using a relevant cell type is necessary for the modelling of 
neurodegenerative disease in vitro. The iNs from FUS-mutation carriers also had altered 
morphology, abnormal electrophysiological activity, and reduced viability, in comparison 
to iNs derived from healthy donors. They used this pathology as a platform for screening 
potential therapeutic agents, and found that one drug, the cyclin-dependent kinase 
inhibitor kenpaullone, improved neuronal morphology and viability in the mutation-
carrying iNs. 
 
Son et al have also generated a protocol for developing spinal motor neurons from mouse 
and human fibroblasts (Son et al. 2011). When co-cultured with glial cells containing the 
G93A mutations in the SOD1 gene (the basis for a mouse model of amyotrophic lateral 
sclerosis), there was a reduction in the number of surviving iNs compared to when co-
cultured with wild-type glial cells. Introduction of the G93A SOD1 mutation into iNs also 
resulted in reduced neuronal viability (Son et al. 2011). Induced motor neurons have also 
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been generated directly from spinal muscular atrophy patients, which had a reduced 
neurite growth rate, and accelerated neurite degeneration in comparison to controls 
(Zhang et al. 2017).  
 
iNs have also been used in a study of the pre-synaptic effects of polymorphisms in the 
microRNA, miR137 – a gene that has been linked to the risk of schizophrenia (Siegert et 
al. 2015). This group generated iNs through expression of Ascl1, Brn2, and Myt1-L. After 
four weeks they transduced the iNs with a virus containing a construct to induce mCherry 
expression under the control of the glutamatergic neuron-specific CAMK2A promotor, 
to allow for isolation of neurons from the fibroblast population. They identified elevated 
levels of miR-137 in iNs derived from individuals carrying polymorphisms in the minor 
alleles of miR-137. Importantly, these changes were not seen in fibroblasts from the same 
individuals. 
 
iNs have also been employed in preliminary studies of familial Alzheimer’s disease. iNs 
were generated from controls, as well as patients with mutations in the APP (which 
encodes amyloid precursor protein) and PSEN1 (which encodes presenilin one) genes 
using a combination of chemical factors. Increased levels of Aβ40 and Aβ42 were 
observed in comparison to controls, along with increased levels of tau and phosphorylated 
tau (Hu et al. 2015). 
 
Recently, iNs have been used to characterise cellular aspects in patients with the 
mitochondrial disease, myoclonic epilepsy with ragged red fibres (MERRF), in 
comparison to iNs derived from healthy controls (Villanueva-Paz et al. 2019). iNs derived 
from the two MERFF patients in this study had reduced complexity of neuronal 
morphology, abnormal mitochondrial morphology, reduced mitochondrial membrane 
potential, higher reactive oxygen species levels, reduced ATP production, and evidence 
of a block in the autophagy pathway. 
 
In this chapter the details of the direct generation of iNs from patient-derived fibroblasts 
are discussed, including the acquisition of neuronal markers and morphology. In addition, 
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technical approaches aiming to optimise the direct conversion process for disease-
modelling are considered.  
 
3.3 Materials and methods 
 
3.3.1 Derivation and expansion of primary fibroblast cultures 
 
Skin biopsies were obtained from the medial forearm of patients with PD and healthy 
controls, in the John van Geest Centre for Brain Repair PD research clinic, with approval 
from the Cambridge Central Research Ethics Committee (REC09/H0311/88). PD patients 
and healthy controls were recruited through the PD research clinic. GD patients and their 
relatives had previously been recruited by Dr Lucy Collins, through the Cambridge 
University Hospitals NHS Foundation Trust lysosomal storage disorder clinic, with the 
support of Professor Tim Cox. Genetic analysis of the GBA1 gene had been previously 
carried out on these individuals by Dr Sophie Winder-Rhodes as described in Winder-
Rhodes et al. 2013. 
 
The biopsy site was cleaned with ChloraPrep applicators, and 1 to 2 ml of 1 % lidocaine 
was instilled subcutaneously. A 4 mm punch biopsy was performed, and the skin sample 
was dissected from the subcutaneous tissue with a blade, and placed immediately into 25 
ml of pre-warmed fibroblast medium (Dulbecco’s Modified Eagle Medium (DMEM) + 
glutamax (Gibco) + 10% fetal bovine serum (FBS – Biosera) + 1 % penicillin / 
streptomycin / fungomycin (PSF – Sigma)). 
 
Skin samples were washed twice in fresh medium and sectioned into six to eight pieces. 
These were added to a six-well plate coated in 0.1 % gelatin (Sigma), and cultured in 
fibroblast medium at 37OC with 5 % carbon dioxide. The medium was topped up on days 
two and four, and then full medium changes were performed every two to three days 
thereafter until fibroblasts had reached full confluency. They were then passaged as 
described below. Biopsy specimens were transferred to a new six-well plate and the 
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process repeated to obtain more fibroblasts. This was repeated until the biopsy specimen 
stopped yielding fibroblasts. 
 
3.3.2 Fibroblast and HEK-293T cell culture 
 
Cells were cultured in fibroblast medium at 37OC in 5 % carbon dioxide. The medium 
was changed every two to three days, and cells were passaged once they were at 80 to 90 
% confluency. Fibroblasts were dissociated in 0.05 % trypsin for five minutes, and 
remaining cells flushed with medium. They were centrifuged at 400 x G for five minutes 
at room temperature and the supernatant discarded. The cell pellet was re-suspended and 
re-plated in T75 flasks (Thermo Scientific Nunc) for ongoing culture or frozen in 45 % 
DMEM + glutamax, 45 % FBS and 10 % dimethyl sulfoxide (DMSO – Sigma). 
 
HEK-293T cells (Clontech) were dissociated in 0.05% trypsin for five minutes and 
remaining cells were flushed with medium. The cell solution was inverted three times to 
distribute cells evenly, and cells were re-plated in T175 flasks or frozen as above. 
 
Cells were thawed by placing the cryovial in a 37OC water bath until only a small amount 
remained frozen, and then added to 5 ml of pre-warmed fibroblast medium. The cell 
solution was then centrifuged at 400 x G for five minutes at room temperature (for 
fibroblasts) or 100 x G for five minutes at room temperature (for HEK-293T cells). The 
supernatant was aspirated and discarded and the cell pellet re-suspended in medium. 
 
3.3.3 Plasmid amplification and purification 
 
Vector plasmids were kindly provided by Janelle Drouin-Ouellet (University of 
Montreal). These included the third generation lentivirus packaging vectors pRSV-REV, 
pMD2.G, and pMDL, and the transfer vector 3410 (containing open reading frames for 
ASCL1, BRN2 and the shRNA sequences targeting the REST complex, under control of  
non-regulated phosphoglycerate kinase (pGK) and U6 promotors and the Woodchuck 
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hepatitis virus post-transcriptional regulator element (WPRE)) (Drouin-Ouellet et al. 
2017). 
 
Plasmids were amplified using chemically competent One ShotTM Top 10 Escherichia 
coli (Invitrogen), and purified using the Nucleobond® Xtra endotoxin-free Midiprep or 
Maxiprep kits (Machery-Nagel). Bacterial transformation was performed by adding 2 to 
5 μl of plasmid solution to a vial of E. coli which was then kept on ice for 30 minutes. 
The E. coli were then heat-shocked at 42OC for 30 seconds before 250 μl of super optimal 
broth (SOC) medium was added. The vial was then incubated for one hour at 37OC with 
shaking at 225 rpm before being spread onto Lysogeny broth (LB) agar (Sigma) plates 
containing 100 μg/ml ampicillin (Sigma) and incubated at 37OC overnight. A single 
colony was picked and added to 3 ml of LB broth (Sigma) containing ampicillin 50 μg/ml 
as a starter culture. This was incubated for eight hours at 37OC with shaking at 225 rpm. 
LB broth from the starter culture was then diluted 1:1000 in 100 ml (Midiprep) or 300ml 
(Maxiprep) of fresh LB broth, which was then incubated overnight at 37OC with 
continuous shaking at 225 rpm. The plasmids were then extracted and purified as per the 
instructions from the Nucleobond® Xtra Midiprep or Maxiprep kit. Verification of 
plasmid amplification was performed with agarose gel electrophoresis after 
fragmentation using restriction endonucleases (Supplementary Table 7.1). 
 
3.3.4 Lentivirus production and titration 
 
HEK-293T cells were seeded at a density of 12.5 million cells per T175 flask (Thermo 
Scientific Nunc), with two flasks per batch of virus. Packaging and transfer vector 
plasmids were mixed for each batch of virus in the following proportions: pMDL 7.5 μg, 
pMD2.G 5.5 μg, pRSV-Rev 3.9 μg, and 3410 25 μg, with 3.5 ml of DMEM + 1 % PSF 
(with no serum). Polyethylenimine (Polysciences) 1 mg/ml (126 μl) was then added and 
the mixture vortexed for 10 seconds and kept at room temperature for 15 minutes. The 
medium in the T175 flasks was changed, and 1.8 ml of the transfection mix was added to 
each flask. These were then incubated for 45 hours at 37OC. The medium from the T175 
flasks was harvested and centrifuged at 800 x G for 10 minutes at 4OC. The resulting 
supernatant was filtered through a 0.45 μm sterile filter, and then centrifuged at 25000 
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rpm for 90 minutes at 4OC. The supernatant was discarded and the pellet covered in 100 
μl of phosphate-buffered saline (PBS) and kept at 4OC for two hours, before it was 
resuspended by vortexing for five seconds, and then frozen. Alternatively, 12 ml Lenti-
XTM concentrator (Clontech) was added to 36 ml of the filtered supernatant, before 
incubation at 4OC for two to four hours. The Lenti-XTM supernatant solution was then 
centrifuged at 1500 x G at 4OC for 45 minutes. The supernatant was discarded and the 
cell pellet was gently resuspended in PBS before being snap frozen and stored at -80OC. 
 
Lentivirus titre was calculated by a comparative quantitative PCR (qPCR) performed on 
the 3410 virus and a reference virus containing a green fluorescent protein (GFP)-transfer 
vector that had previously been quantified through fluorescence-activated cell sorting 
(FACS). HEK-293T cells were transfected with 0.1 μl, 1 μl or 3 μl of the test virus or the 
reference virus, and the DNA was extracted using the DNeasy Blood and Tissue Kit 
(Qiagen) as per the manufacturer instructions. The albumin gene was used as an 
endogenous control, with WPRE as the reporter gene. The qPCR reaction consisted of 1 
μl DNA sample, 5 μl primer/probe mastermix (Eurofins Genomics), and 4 μl TaqmanTM 
mastermix (Applied Biosystems), and qPCR was performed in technical triplicate. The 
primer/probe mastermix consisted of 0.95 M forward and reverse primers, and 0.7 M 
probe for the relevant gene Supplementary Table 7.2. Viral titre was calculated using the 
delta delta Ct method (Rao et al. 2013). 
 
3.3.5 Direct neural reprogramming 
 
Culture vessels were coated with 0.1 % gelatin and incubated at 37OC for 30 minutes to 
one hour. Other culture matrices used included poly-L-ornithine, fibronectin and laminin 
(PFL), poly-L-ornithine alone, poly-L-ornithine combined with laminin (PL), and 
GeltrexTM. For PFL- and PL-coated plates, poly-L-ornithine (Sigma) 15 µg/ml in PBS 
with Ca2+ and Mg2+ was added, before incubation at 37OC overnight. The poly-L-
ornithine was removed, and laminin (Thermo Fisher) 5 µg/ml in PBS with Ca2+ and Mg2+ 
was added to the wells which were incubated for two hours 45 minutes. After three 
washes with PBS, for the PFL-coated plates fibronectin (Thermo Fisher) 5 µg/µl was then 
added and the plates incubated overnight at 37OC. PBS was then added to PL- or PFL-
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coated plates, which were then kept at 4OC. To prepare GeltrexTM plates, GeltrexTM was 
diluted 1:100 in DMEM/F12 medium and added to wells. The plate was then incubated 
at 37OC for 30 minutes to one hour. All plates were pre-warmed in the incubator prior to 
use.  
 
Fibroblasts in culture were passaged as described in section 3.3.2. and the desired number 
of cells were plated in fibroblast medium, at densities of 13393 cells/cm2 to 27777 
cell/cm2 as detailed below. Conversions were performed in 96-, 24- or 6-well plates 
(Thermo Scientific Nunc), 48-well plates (Greiner CELLSTAR®), or Ibidi 96-well 
square plates. Viral transduction was performed the following day at a multiplicity of 
infection (MOI) of 20 (day zero). A full change of fibroblast medium was performed the 
following day. On day three the medium was changed to neural conversion medium 
(Ndiff227 – Clontech) with added small molecules and growth factors as per Table 3.2. 
Half medium changes were performed every two to three days throughout the conversion 
process. At day 17 post-transduction, the medium was changed to late conversion medium 
(Ndiff 227 containing only growth factors, without small molecules), with ongoing half-
medium changes every two to three days until the day of analysis. 
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CHIR99021 Axon 2 μM Activation of canonical Wnt signalling pathway 
through inhibition of GSK3 
 
SB431542 R & D Systems 10 μM Inhibition of  TGFβ superfamily SMAD 
signalling via ALKs 5,4 and 7 
 
Valproic acid Merck Millipore 1 μM Remodelling of chromatin via inhibition of 
histone deacetylase, facilitating binding of 
ectopic transcription factors 
 
Noggin R & D Systems 50 ng/ml Binds BMPs (members of TGFβ superfamily) 
preventing activation of their receptors 
 
LDN-193189 Axon 0.5 μM Inhibition of  TGFβ superfamily SMAD 
signalling via ALKs 2 and 3 
 
 
Growth factors and signalling molecules 
 
GDNF R & D Systems 2 ng/ml Neurotrophic factor 
 
NT-3 R & D Systems 10 ng/μl Neurotrophic factor 
 
LM-22A4 R & D Systems 2 μM Synthetic partial agonist of trkB receptor (BDNF 
receptor)  
 
Db-cAMP Sigma 0.5 mM Activation of cAMP signalling transduction 
cascade and neurotrophic factor-mediated 
neuronal survival 
Table 3.2. Small molecules and growth factors used during neural reprogramming. 
Abbreviations: ALK = activin receptor-like kinase receptor; BDNF = brain-derived 
neurotrophic factor; BMP = bone morphogenic protein; Db-cAMP = dibutyryl cyclic 
adenosine monophosphate; GDNF = glial cell line-derived neurotrophic factor; GSK3 = 
glycogen synthase kinase 3; NT-3 = neurotrophin-3; TGFβ = transforming growth factor 




Cells were fixed in 4 % paraformaldehyde at room temperature for 20 minutes, or in ice 
cold methanol for 10 minutes. After fixation with paraformaldehyde, cells were 
permeabilised in 0.1 % triton-X-100 for 10 minutes at room temperature (there was no 
additional permeabilisation after fixing with methanol). Blocking was performed for 60 
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minutes at room temperature with 5 % serum in PBS. Primary antibody diluted in 5 % 
serum was then added to the cells and they were kept at 4OC overnight. They were washed 
twice with PBS before Alexa Fluor fluorophore-conjugated secondary antibodies 
(Thermo Fisher) diluted to 1:500 in 5 % serum were applied, and they were kept at room 
temperature for two hours. They were then washed in PBS before nuclear counterstaining 
with 4′,6-diamidino-2-phenylindole (DAPI) 1 µg/ml or Hoescht 333412 2 µg/ml for 10 
minutes at room temperature was performed. Cells were washed in PBS before analysis. 
The antibodies used are listed in Supplementary Table 7.3. 
 
3.3.7 Calculation of conversion efficiency and neuronal purity 
 
Imaging was performed using the CellomicsTM Array Scan XTI (Thermo Fisher). The 
average fluorescence intensity for each cell, and the number of cells in the well was 
quantified using a “target activation” program at 10x or 20x magnification. Conversion 
efficiency was defined as the number of cells expressing neuronal markers over the total 
number of fibroblasts originally plated, and neuronal purity was defined as the number of 





𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑐𝑒𝑙𝑙𝑠 𝑒𝑥𝑝𝑟𝑒𝑠𝑠𝑖𝑛𝑔 𝑛𝑒𝑢𝑟𝑜𝑛𝑎𝑙 𝑚𝑎𝑟𝑘𝑒𝑟𝑠





𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑡𝑎𝑢 𝑜𝑟 𝑀𝐴𝑃2 𝑝𝑜𝑠𝑖𝑡𝑖𝑣𝑒 𝑐𝑒𝑙𝑙𝑠
𝑇𝑜𝑡𝑎𝑙 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑐𝑒𝑙𝑙𝑠 𝑖𝑛 𝑤𝑒𝑙𝑙
 × 100 
 
3.3.8 Magnetic cell sorting 
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Fibroblasts were initially plated in six-well plates coated with GeltrexTM, at a density of 
200000 cells per well, and converted to iNs as described above. Prior to sorting, the 
converting cells were dissociated with trypsin 0.05 % and centrifuged for five minutes at 
400 x G. The cell pellet was resuspended in NDiff227 medium before a cell count was 
performed to determine the total number of cells prior to sorting. The cells were 
centrifuged again for five minutes at 300 x G and the pellet resuspended in 80 µl 
magnetic-activated cell sorting (MACS) running buffer (pH 7.2 PBS with 0.5 % bovine 
serum albumin (BSA) and 2 mM ethylenediaminetetraacetic acid (EDTA)). Human 
neural cell adhesion molecule (NCAM) CD56 microbeads (20 µl – Miltenyi) were added 
and the solutions incubated for 30 minutes at room temperature. One ml of MACS buffer 
was then added and the solutions centrifuged at 300 x G for 10 minutes. Cell pellets were 
resuspended in 500 µl MACS buffer and solutions were passed through pre-soaked LS 
columns (Miltenyi). 
 
NCAM-negative cells were collected in a tube and centrifuged at 400 x G for five 
minutes, before the cell pellet was resuspended in neuronal medium and counted. NCAM-
positive cells were flushed from the MACS cylinder with 5 ml MACS buffer, before being 
centrifuged for five minutes at 400 x G. The cell pellet was resuspended in neuronal 
medium. The NCAM-positive cell count was estimated by subtracting the NCAM-
negative cell count from the total count prior to sorting. Cells were plated at a density of 
7500 cells per well in a 96-well plate (Ibidi), coated with GeltrexTM. NCAM-positive cells 
were plated in neuronal medium. NCAM-negative cells were plated in fibroblast medium, 
and then either kept in fibroblast medium or switched to neuronal medium the following 
day. Cells were fixed at day 24 post-transduction for analysis. Magnetic cell sorting was 
performed with the assistance of Dr Shaline Fazal. 
 
3.3.9 Details of adult dermal fibroblast cell lines 
 
A total of 15 cell lines were used in this study, as shown in Table 3.3. These included a 
number that had been previously acquired as described above, as well as those from some 
newly recruited patients. The cell lines included four healthy control individuals, though 
only two of these were confirmed not to carry GBA1 mutations. Six iPD lines, three 
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GBA1-PD lines, and two lines with concomitant GD and PD (GD+PD) were used. 
Experiments were carried out using two to five cell lines per phenotype, as detailed in the 
relevant sections. 
 
The mean age was 58.5 years (standard deviation 4.7) for the healthy control group, 65.5 
years (standard deviation 4.4) for the iPD group, 63.3 years (standard deviation 6.0) for 
the GBA1-PD group, and 54.7 years (standard deviation 1.4) for the GD+PD group. There 
were no statistically significant age differences between any of the groups, as determined 
by one-way ANOVA with post-hoc Tukey analysis (p=0.093). 
 
Cell Line Sex Age at Biopsy Phenotype GBA1 Genotype 
C1 F 54 Healthy control WT/WT 
C2 M 57 Healthy control WT/WT 
CT1 F 65 Healthy control Unknown 
CTS2 F 58 Healthy control Unknown 
PD5 F 68 iPD WT/WT 
PD6 F 66 iPD WT/WT 
PD7 M 65 iPD WT/WT 
PDTS262 M 69 iPD WT/WT 
PDTS41 F 68 iPD WT/WT 
PDTS1192 M 57 iPD WT/WT 
PD2 F 64 GBA1-PD N370S/WT 
PD4 M 57 GBA1-PD E326K/WT 
PD3 M 69 GBA1-PD E326K/WT 
GD5 M 56 GD+PD L444P/R463C 
PD1 F 58 GD+PD R463C/R463C 
Table 3.3. – Details of primary adult fibroblast cell lines. Abbreviations: F = female; 
GBA1-PD = GBA1-mutation-associated PD; GD = Gaucher disease; GD+PD = 
concomitant GD and PD; iPD = idiopathic PD; M = male; WT = wild-type. 
 
3.3.10 Statistical analysis 
 
All statistical tests were performed using IBM SPSS software. For comparison between 
two independent groups Levene’s test of equal variance was performed to determine if 
equal variance could be assumed, and p-values were determined with independent 
samples T tests. Multiple group comparisons were performed with one-way ANOVA 
with post-hoc Tukey analysis. Statistical significance is indicated by asterixes as follows: 
* = p ≤ 0.05; ** = p ≤ 0.01; *** = p ≤ 0.001. 
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3.4.1 Conversion efficiency and neuronal purity 
 
iNs were initially generated from fibroblasts derived from healthy control (n=2), iPD 
(n=2), GBA1-PD (n=3) and GD+PD (n=2) individuals, as described in section 3.3.5, and 
cultured to day 17 post-transduction. Immunocytochemistry for β3-tubulin was 
performed, and high-throughput microscopy was used to measure the mean fluorescence 
intensity for each cell. Each cell line was analysed in technical triplicate, with the mean 
of these replicates taken to provide a single value for neuronal purity and conversion 
efficiency for each individual line. 
 
Conversion efficiency for the nine cell lines ranged from 4.6 % to 19.8 %, with an overall 
mean conversion efficiency of 11.5 % (95 % confidence interval 7.6 % to 15.3 %). The 
conversion efficiency of the GBA1-PD group was lower than in the healthy control group 
(p=0.027), with no other significant differences between the groups. Neuronal purity 
ranged from 6.7 % to 18.4 % with an overall mean neuronal purity of 12.6 % (95 % 
confidence interval 9.2 % to 16.0 %). There were no significant differences in neuronal 
purity between any of the groups (see Figure 3.1). 
  
Chapter 3 – Generation of Induced Neurons 
Thomas Stoker – September 2019     85 
 
Figure 3.1 – Conversion efficiency and neuronal purity. iNs were generated from 
healthy control (n=2), iPD (n=2), GBA1-PD (n=3) and GD+PD (n=2) fibroblast cell lines. 
At day 17, immunocytochemistry was performed for the neuronal marker β3-tubulin. 
Each cell line was analysed in triplicate, with 12 fields (20x) per well imaged. The total 
number of cells analysed for each cell line ranged from 3059 to 11653. Error bars 
represent the standard error of the mean. Statistical significance based on one-way 
ANOVA with post-hoc Tukey analysis indicated by asterixes. 
 
It was noted that with subsequent conversions, conversion efficiencies and neuronal 
purities were generally higher than in these initial experiments, and a retrospective 
analysis of 56 conversions taken to different time points ranging between day 10 and day 
29 post-transduction, involving 13 cell lines was performed (Figure 3.2) . No statistically 
significant differences in neuronal purity or conversion efficiency were found between 
the different phenotypic groups at day 17, 20, or 29 (statistical significance could not be 
calculated at the other time points when only single values were available for some of the 
groups). Overall, neuronal purities were generally in the region of 15 % to 35 %, with 
conversion efficiencies of approximately 15 % to 50 %. The overall mean values for 
neuronal purity and conversion efficiency in each group are shown in Table 3.4. Overall, 
the highest mean neuronal purities and conversion efficiencies were noted in the GBA1-
PD cell lines at day 24 and day 27. However, this is most likely to be due to the fact that 
these were the cell lines most used, and were over-represented in experiments performed 
at a later date when technical experience was higher, rather than any biological 
phenomenon. 
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 Number of 
conversions 
Mean neuronal purity 
(%) 
Mean conversion efficiency 
(%) 
Healthy control 10 23.3 % (11.2 % to 35.5 %) 28.6 % (15.0 % to 42.3 %) 
iPD 12 19.0 % (11.1 % to 26.9 %) 23.5% (10.7 % to 36.3 %) 
GBA1-PD 28 26.2% (21.4 % to 31.1 %) 44.5% (32.2 % to 56.9 %) 
GD+PD 6 16.4% (9.2 % to 23.5 %) 14.8% (5.5 % to 24.2 %) 
Table 3.4 – Retrospective analysis of conversion efficiency and neuronal purity data. 
A total of 56 conversions were retrospectively analysed with the mean values for neuronal 
purity and conversion efficiency determined for each patient group (95% confidence 
intervals shown in brackets). 
 
 
Figure 3.2 – Cumulative conversion efficiency and neuronal purity data. Mean 
conversion efficiency (A and C) and neuronal purity (B and D) was determined 
retrospectively for healthy controls (n=4), iPD (n=4), GBA1-PD (n=3), and GD+PD (n=2) 
cell lines, across 56 conversions. The numbers of cells counted in each conversion ranged 
from 485 to 31236 for individual cell lines. There were no significant differences between 
the phenotypes at any of the time points assessed, or between the cell lines. Statistics 
performed with one-way ANOVA for multiple comparisons, and independent sample T-
tests for time points in which there were only two groups represented. 
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3.4.2 Acquisition of neuronal markers and morphology 
 
In order to characterise neuronal marker acquisition over the conversion period, iNs were 
generated from three PD lines, including one that carried a GBA1 mutation. These were 
fixed in ice-cold methanol at day zero (i.e. unconverted fibroblasts), day 10 post-
transduction, and day 17 post-transduction, before immunocytochemistry for neuronal 
markers (see Figure 3.4 and Figure 3.5). Expression of β3-tubulin, tau, MAP2 and α-
synuclein was induced over the course of the conversion. β3-tubulin and tau expression 
was seen by day ten, with further increases in the proportion of cells expressing these 
markers at day 17, when 23.4% were positive for β3-tubulin, and 38.6% were positive for 
tau. MAP2 and α-synuclein were not expressed at day ten, but there were significant 
increases in the expression of these markers at day 17, suggesting that these are induced 
later than β3-tubulin and tau. Demonstration of α-synuclein expression was then 
performed in seven cell lines (two healthy control, three GBA1-PD and two GD+PD) at 
day 17 post-transduction, with significant increases in mean α-synuclein intensity in iNs 
when compared to fibroblasts, in all cell lines (Figure 3.3). 
 
 
Figure 3.3 – Induction of α-synuclein expression in patient-derived iNs. A) Mean α-
synuclein intensity increased significantly in all iN lines tested when compared to the 
unconverted parent fibroblasts. B) Representative image demonstrating α-synuclein 
expression in iNs at day 17 post-transduction. Scale bar represents 50µm. 
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Figure 3.4 – Neuronal marker acquisition during conversion process. Images taken 
at 20x magnification showing expression of β3-tubulin, tau, MAPT and α-synuclein in 
untransduced fibroblasts, and at day 10 and 17 post-transduction. Scale bar represents 
100µm. 
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Figure 3.5 – Time-course analysis of neuronal purity and conversion efficiency. 
Fibroblasts from three PD patients were converted to iNs and fixed at day 0, 10 or 17 
post-transduction and stained for neuronal markers (β3-tubulin (A, B), tau (C, D), MAP2 
(E, F), α-synuclein (G, H). Cells were considered to express each neuronal marker when 
the mean intensity was greater than two standard deviations above the mean value for the 
unconverted fibroblasts. Statistical significance based on independent samples t-tests 
indicated by asterixes. 
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The conversion process results in the acquisition of neuronal morphology, with converted 
cells extending neurite outgrowths. At day 17, 9.8 % of cells had neurites greater than 
120 µm in length, with 15.0 % of cells having neurites between 60 µm and 120 µm in 
length. It should be noted that even in the unconverted fibroblasts 7.9 % of cells were 
adjudged to have neurites between 60 µm and 120 µm, which was due to a limitation in 
the neurite analysis protocol, which could not completely discriminate between elongated 
cell processes seen in fibroblasts, and authentic neurites. Cells judged to have no, or very 
short (less than 60µm in length) neurites, made up 91.7 % of cells in the unconverted 
fibroblasts, dropping to 75.2 % of the cells at day 17 post-transduction (see Figure 3.6).  
 
Figure 3.6 – Neurite Length Analysis. iNs from two iPD and a GBA1-PD line were 
generated and fixed prior to transduction (day zero), and at day 10 and day 17 post-
transduction. Maximum neurite length was calculated using a CellomicsTM XTI neuronal 
profiling assay. Bars represent the mean values of all three cell lines. The proportion of 
cells with short neurites (0 to 60 µm) decreased through the conversion, whilst the 
proportions with medium (60 to 120 µm) and long (greater than 120 µm) neurites 
increased. 
 
3.4.3 Impact of Culture Matrix 
 
At the start of the conversion process, fibroblasts were plated onto wells coated with 0.1 
% gelatin. This is a substrate to which fibroblasts adhere strongly, and therefore may 
result in reduced neuronal purities, due to the persistence of unconverted fibroblasts in 
the culture vessel. Furthermore, it is known that neuronal culture and neurite growth can 
be enhanced by the use of charged culture matrices with substrates such as poly-L-
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ornithine (Richner et al. 2015, Ge et al. 2015). When cultured on gelatin, iNs frequently 
degenerated beyond day 35, and it was considered that culture on an alternative matrix 
would be necessary for long-term studies. 
 
Generation of iNs on a number of different culture matrices and surfaces was performed 
to investigate whether one allowed for prolonged culture and increased purity. First, 
fibroblasts from a healthy control and an iPD line were plated onto a 0.1% gelatin matrix 
before being converted to iNs. At day 12 post-transduction, cells were dissociated with 
accutase and re-plated in new wells coated with PFL. This resulted in an increase in 
neuronal purity, which was statistically significant in the iPD line based on the mean 
values of the technical replicates (p=0.002, Figure 3.7). However, though this approach 
resulted in higher purities than culture on gelatin alone, further conversion attempts in 
which the cells were passaged at day 12 yielded highly variable outcomes, resulting from 
detachment of the cells after a few days following re-plating, limiting the utility of this 
approach. 
 
Figure 3.7 –Neuronal purity after passaging iNs and plating onto PFL matrix. 
Fibroblasts from an iPD and a healthy control cell line were passaged at day 12 post-
transduction and re-plated onto wells coated with PFL. These were compared to cells 
cultured on gelatin throughout. Statistical significance, indicated by asterixes, was 
determined with independent samples T tests based on the mean values of the technical 
replicates for gelatin- and PFL-coated wells, for each cell line.  
 
Because of the variability seen with the day 12 passaging approach, combined with the 
technical difficulty of scaling this up to the high numbers of wells that would be required 
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for disease-modelling and drug-screening, other culture conditions were trialled. These 
included the use of the PFL matrix, poly-L-ornithine alone, PL, and GeltrexTM from the 
start of conversion. This was performed directly on plastic, and also on glass cover slips, 
given that it had previously been reported that neuronal extensions developed better on 
glass (Richner et al. 2015). Whilst cells took on typical neuronal morphologies on all of 
these surfaces none allowed for the preservation of neuronal morphology for prolonged 
culture times. Culture on the PFL matrix, and its constituents often resulted in cells 
peeling away from the surface after approximately one to two weeks post-transduction 
(Figure 3.8). GeltrexTM allowed for the development of neuronal morphology, but when 
prolonged culture was attempted the cells degenerated as with the gelatin condition.  
Given the problems with reliability and lack of efficacy in the use of these matrices with 
regards to increasing the longevity of the cultures, subsequent experiments were 
performed using 0.1% gelatin as the culture matrix, which yielded consistent results with 
acceptable neuronal purities for analysis at day 20 to day 30. 
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Figure 3.8 – Impact of culture matrix on neuronal morphology. A) iNs cultured to 
days 22, 31 and 41 on gelatin or GeltrexTM matrices. B) iNs cultured on PFL matrix. 
Image shows cells peeling from surface at day ten. Scale bars represent 200 µm. 
 
3.4.4 Magnetic-activated cell sorting 
 
One of the main limitations of the iN approach, is that the resulting cell population is not 
pure. In addition to iNs, there remain some unconverted fibroblasts, and probably a 
population of cells which have taken on some neuronal characteristics whilst retaining 
some fibroblast characteristics. Given that the efficacy of reprogramming varies between 
different cell lines, the neuronal population of one cell line will be contaminated by these 
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other cell types to a greater or lesser extent when compared to other cell lines, posing 
limitations on analyses. 
 
The use of MACS was investigated as a potential means of increasing neuronal purity. 
NCAM, a neuronal cell surface adhesion molecule, expression was induced during the 
neuronal reprogramming process, and was not present on unconverted fibroblasts. Cells 
from a healthy control, a PD and a Huntington’s disease line were converted to iNs, with 
magnetic sorting at day 3, 10 and 17. In addition, untransduced fibroblasts from the cell 
lines were also sorted to determine whether a significant number of false positives 
occurred.  
 
Untransduced fibroblasts did not express NCAM. Even so, a mean of 10.5 % of sorted 
cells were retained in the “NCAM-positive” fraction. However, in this “NCAM-positive” 
fraction, β3-tubulin and NCAM fluorescence intensity was negligible, suggesting that 
there were some false-positives and that sorting on NCAM is not completely specific 
(Figure 3.9). 
  
Sorting at day 3, 10 or 17 post-transduction led to relatively high neuronal purities of 
approximately 50 % as judged by the proportion of cells expressing β3-tubulin. Mean 
fluorescence intensity for β3-tubulin and NCAM were significantly higher in the NCAM-
positive population of transduced cells, when compared to NCAM-negative cells at all 
time points after day minus one (Figure 3.9). 
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Figure 3.9 – MACS sorting for NCAM expression of iNs at multiple time points. 
White bars at all time points represent the NCAM-positive portion of cells. Light grey 
bars at all time points indicate the NCAM-negative portion of cells, cultured in fibroblast 
medium. Dark grey bars for the day 10 and day 17 time point indicate an additional 
population of NCAM-negative cells that were subsequently cultured in neuronal medium. 
When compared to the NCAM-negative portion cultured in fibroblast medium, the mean 
β3-tubulin intensity (A) and NCAM intensity (B) was significantly higher in the NCAM-
positive portion at all time points post-transduction, but not in untransduced fibroblasts. 
Similarly, neuronal purity (C) was increased in the NCAM-positive portion. Conversion 
efficiency (D) was greatest in the day 17 sorted cells. Error bars represent standard error 
of the mean. 
 
In contrast, conversion efficiencies were low, particularly when sorted at early time 
points. The highest mean conversion efficiency was achieved at day 17, which was 9.6 
%. It is likely that loss of cells during the multiple centrifugation steps and sorting process, 
as well as some cell death during the sorting process limited conversion efficiency. So 
whilst sorting allowed for the generation of higher purity yields than had previously been 
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achieved, it is a resource expensive process, requiring large numbers of starting cells. As 
a result, this approach was not taken further in this work. 
 
 
Figure 3.10 – β3-tubulin and NCAM expression in untransduced fibroblasts from a 
PD cell line sorted with MACS. Scale bar represents 100 µm. 
 
 
Figure 3.11 – β3-tubulin and NCAM expression in PD cells sorted with MACS at 
day three post-transduction. Scale bar represents 100 µm. 
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Figure 3.12 – β3-tubulin and NCAM expression in PD cells sorted with MACS at 
day 10 post-transduction. Scale bar represents 100 µm. 
 
 
Figure 3.13 – β3-tubulin and NCAM expression in PD cells sorted with MACS at 
day 17 post-transduction. Scale bar represents 100 µm. 
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NCAM-negative cells were cultured in fibroblast medium till day 24. At all time points 
neuronal purity remained under 3 % in this portion. In addition, for the day 10 and 17 
sorted cells, NCAM-negative cells were also cultured in neuronal medium until day 24, 
to see if any of they still had the potential to convert post-sorting. Indeed, at day 10 further 
culture of the NCAM negative cells in neuronal medium allowed for neuronal purity of 
34.6 %, suggesting that there were a population of cells that were capable of converting 
to iNs, but had not done so by day ten. At day 17, there was also some further conversion 
of the NCAM-negative cells when cultured in neuronal medium. However, this was much 
lower than in the day 10 sorted cells, with a neuronal purity of only 5.2 % (Figure 3.9). 
This suggests that if a cell has not successfully converted to an iN by day 17, then it is 
unlikely to do so. 
 
These results suggest that the population of cells in a conversion can broadly be divided 
into three subgroups: 
 
i. Cells that convert to iNs efficiently and quickly – These cells had started 
expressing NCAM prior to sorting. 
ii. Cells that convert slowly, but have the potential to convert to iNs over time – 
These cells had not acquired neuronal identity at the time of sorting, but acquired 
it thereafter. 
iii. A population of cells that fail to convert – This may include cells that were not 
successfully transduced with the virus, cells in which the transfer vector failed to 
integrate, and cells with an inherent resistance to conversion. 
 
Although sorting led to an increase in neuronal purity, it required very high numbers of 
cells, due to cell loss during the process. As such it was not felt practical for disease-
modelling studies, which were carried out on unsorted cells. For immunocytochemistry-
based studies this was not a limitation, as iNs could be isolated from unconverted cells 
through visualisation of neuronal markers, but for other assays this constituted a 
limitation of this model. 
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3.5 Discussion 
 
Since the first description of iNs in 2010, several other protocols have been published 
(Vierbuchen et al. 2010, Pang et al. 2011, Ambasudhan et al. 2011, Caiazzo et al. 2011, 
Son et al. 2011, Drouin-Ouellet et al. 2017, Yoo et al. 2011, Ladewig et al. 2012). Despite 
the growing number of reports documenting iN protocols, their application in terms of 
disease-modelling, and particularly drug screening has been limited to only a small 
number of studies, discussed in section 3.2.5. In this project, a combination of the two 
main reprogramming approaches (forced expression of proneural transcription factors, 
and of specific microRNAs) has been used to generate iNs, with a view to their 
application as a drug-screening tool. 
 
The conversion efficiencies (approximately 20 % to 50 %) and neuronal purities 
(approximately 15 % to 35 %) achieved here, far exceed that seen in the early iN 
protocols, and is similar to other groups that have used this method (Drouin-Ouellet et al. 
2017). 
 
3.5.1 Limitations and challenges of iN reprogramming 
 
The use of iNs means that it is possible to generate patient-derived adult human neurons, 
relatively quickly. As has been discussed, the major theoretical advantage of iNs over 
iPSC-derived neurons is that they have consistently been shown to retain the effects of 
aging (Mertens et al. 2015, Kim et al. 2018, Huh et al. 2016), which has been 
demonstrated to be important in recapitulating pathology in neurodegenerative diseases 
(Victor et al. 2018). Of course, as with all disease models, there are limitations to this 
approach, which will now be discussed. 
 
Firstly, while relatively consistent conversion efficiencies were achieved, there was 
variability between different cell lines, with some cell lines reprogramming well 
consistently, and others failing to reprogram effectively. There was also a degree of 
variability in the efficacy of reprogramming within the same cell line, across different 
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conversions. In this study, the main determinant of this factor was probably related to 
technical experience, with conversions performed at later dates proving more effective 
compared to the first conversions attempted. However, it is also possible that there are 
biological determinants, such as epigenetic and transcriptomic factors that determine the 
reprogramming capacity of a cell line (Biddy et al. 2018, Rais et al. 2013, Guo et al. 
2014). In initial conversions, the conversion efficiency in the GBA1-PD group was lower 
than in healthy controls, with neuronal purities being similar across all groups. This may 
be explained by differences in the growth rate between cell lines, as an increased growth 
rate in the first 24 hours of the conversion would result in a lower MOI at the time of 
transfection. It would therefore be important to determine the growth rate of each cell line 
in future studies. Additionally, factors relating to cell line storage and maintenance, such 
as the duration and method of freezing, number of passages, and the skin biopsy 
processing may also contribute to the variability seen between conversions. It is therefore 
important that these elements are controlled for as far as is possible. The effect of these 
factors has not been studied in great depth (though it has been reported that passage 
number does not dramatically alter conversion efficiency (Drouin-Ouellet et al. 2017)), 
and optimisation of these factors for iN reprogramming is important for this technique to 
generate truly reproducible disease models, using similar approaches to those being 
performed with stem cell products being generated for clinical trials. 
 
Secondly, although neuronal purities were relatively high in this study (in comparison to 
many previous studies), a high number of unconverted cells remained in the culture, 
which poses some limitations on the applicability of the iN system. The population of 
unconverted cells has not been characterised, and it probably consists of a mixture of 
fibroblasts which failed to convert, cells which began to switch fate and reverted to the 
fibroblast state, cells that possess traits of both fibroblasts and iNs, and cells that are 
converting but are doing so at a slower rate than other cells in the well. The impure 
population means that assays may be restricted to fluorescence-based assays in which the 
absence of neuronal markers can be used to exclude unconverted cells from the analysis. 
Assays that require cell lysis will be affected by contaminating unconverted fibroblasts, 
limiting the utility of this system. For example, protein detection via Western blot on a 
mixed population of unconverted fibroblasts, partly converted cells, and iNs will yield 
results that are a product of these different cell types, making their interpretation 
challenging. The variability in conversion efficiency for any particular cell line between 
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different conversions further compounds this, as individual experiments will be 
influenced to differing degrees by impure populations, increasing variance between 
experimental replicates. In contrast, iPSC-based models allow for the generation of 
neuronal purities approaching 100 %, which constitutes a significant advantage over 
current iN protocols (Kikuchi et al. 2017). However, if consistent neuronal purities can 
be achieved across all cell lines, this problem is somewhat circumvented, as all lines 
would be affected similarly. Additionally, for assays focussing on neuron-specific 
pathology (for example that induced by α-synuclein PFFs which is discussed at depth in 
the next chapter), the presence of unconverted cells should not dramatically alter the read-
out. Optimising neuronal purity was attempted here through the use of alternative culture 
matrices, with no benefit found, and through magnetic cell sorting. The latter was 
attempted as a relatively atraumatic means of sorting (in contrast to FACS) after which 
cells could be re-plated, and though this did boost neuronal purity, it was still only at 50 
%, with significant cell loss leading to low efficiencies. One potential use of the MACS 
technique would be to interrogate the biological factors that prevent reprogramming. If 
the NCAM-negative portion were to be harvested and cultured, they would represent a 
population of cells that is enriched with cells that were resistant to conversion. It would 
be interesting to compare the epigenetic and transcriptomic profiles of these cells, to an 
unsorted fibroblast population, as this may provide insight into why some cells are 
resistant to reprogramming. 
 
Another potential limitation is that the iNs generated through this approach are not of any 
specific subtype, though they express some cortical neuron markers such as TBR and 
consist of predominantly glutamatergic and GABAergic neurons (Drouin-Ouellet – 
unpublished results and Drouin-Ouellet et al. 2017). Though there are iN protocols that 
have yielded specific neuronal types (Son et al. 2011, Victor et al. 2014), the generation 
of dopaminergic neurons, which would be useful for the modelling of PD, has been 
difficult to achieve (Caiazzo et al. 2011, Pfisterer et al. 2011a). In contrast, differentiation 
of iPSCs offers the potential for the derivation of dopaminergic neurons expressing 
midbrain dopaminergic neuron (e.g. En1 and nurr1) and floor-plate (e.g. FoxA2) markers 
(Hartfield et al. 2014, Kikuchi et al. 2017), allowing for the study of disease mechanisms 
on a population of cells that appear to be specifically susceptible to PD pathology. Having 
said this, the most consistent factor that differentiates GBA1-PD from iPD clinically, is 
the increased incidence of dementia, reflecting more widespread cortical disease. 
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Therefore, cortical neurons are perhaps the best neuronal type to interrogate the specific 
pathogenic mechanisms associated with GBA1 mutations in PD. Though the iN system 
employed here does not generate authentic cortical neurons, the presence of cortical 
markers and the neurotransmitter expression resembling that in most cortical neurons, 
means that this system yields a population of cells that could provide insight into the 
pathogenic mechanisms of GBA1-PD. 
 
Perhaps the most important limitation of the iN system described is the inability to 
cultivate the cells in large numbers for longer than a month. Though it is an advantage of 
iN reprogramming that neurons can be generated from adult somatic cells in a short space 
of time, the limited culture longevity brings about some significant drawbacks. First, it is 
known that the iNs generated from this and other protocols are functionally immature at 
about a month post-transduction, in that they do not generate spontaneous action 
potentials at this stage (Liu et al. 2013). It has been possible for iNs derived using this 
protocol to be cultured on glass coverslips for several months, and they have been 
demonstrated to be electrophysiologically active after 60 to 90 days (Drouin-Ouellet et 
al. 2017). However, only a small proportion of cells survive to these time points, such 
that the numbers of cells required for disease-modelling and drug-screening cannot be 
taken to this late stage. So, although the iNs retain the age profile of the cell with regard 
to genetic, epigenetic, mitochondrial, and protein-clearance system parameters for 
example, they are functionally young cells. So while iNs offer a useful platform for 
investigating intracellular pathogenic processes, or the behaviour of drugs, in aged cells, 
they are not practical for studying the effects of these things on functionality of the cell, 
with current protocols at least. 
 
Another problem associated with the restricted time in cell culture is that there is only a 
limited time in which pathology can develop. Ideally, when studying neurodegenerative 
conditions such as PD in vitro, one would see the characteristic intracellular protein 
aggregates which are central to the pathogenic process. Of course, such pathology takes 
time to develop in vitro, and in this iN system, little in the way of intracellular protein 
aggregation was seen (this is discussed in detail in chapter 4). Some previous studies 
involving other model systems have applied other insults to the cells to induce the 
formation of α-synuclein aggregates or accumulation of α-synuclein, including 
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expression of aggregate-prone forms of α-synuclein, overexpression of α-synuclein to 
supraphysiological levels, or inhibition of the proteasome (Rideout et al. 2001, Hasegawa 
et al. 2004, Xu et al. 2002). However, the use of these insults takes the model further 
away from the processes that occur in patients, meaning that they may be less able to 
predict whether a drug will effectively attenuate pathology in patients. 
 
3.5.2 Future Work 
 
It is now possible for iNs to be generated relatively reliably using a variety of techniques, 
and the iN field has now reached the point at which questions should primarily focus on 
the applicability of these cells for disease-modelling and drug testing. As cell-based 
treatments for PD move towards the clinic, there will continue to be interest in the 
potential of iNs to form the basis of a regenerative therapy, but due to the limitations 
discussed above, it is unlikely that they will offer a superior cell product to stem cell-
derived neural progenitors, and it is likely that the retention of the age signature would 
have a detrimental effect on survival times of iNs grafted into patients. The role of iNs is 
therefore likely to be in answering questions about disease mechanisms and drug effects 
in patient cells. 
 
To facilitate the progression of iN reprogramming techniques to a widely used in vitro 
tool, there are some general areas that future work should focus on. As has been 
mentioned, there is variability in the efficacy of reprogramming between different cell 
lines, and also between different conversions in the same cell line. This may be in part 
due to inherent properties of the cell lines, such as the epigenetic landscape which will 
determine the propensity for proneural transcription factors to bind to target sites, but 
there may also be variability introduced by the way cell lines have been handled. A 
systematic investigation of the optimal culture methods for the parent fibroblasts 
(including cell density, cryopreservation process, thawing process) would therefore 
potentially be useful in reducing the variability seen. 
 
Next, the inability to generate completely pure populations of neurons also hinders the 
use of iNs as is discussed above. This is particularly important when studying autonomous 
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intracellular pathways such as autophagy, in which there may be cell type-specific 
differences in activity. If there are differing proportions of unconverted fibroblasts in 
different cell lines at the time of analysis, it is difficult to draw firm conclusions when 
comparing between them. It is desirable, but not necessary, for neuronal purities of 100% 
to be achieved, with the most important thing being consistency of neuronal purity 
between cell lines. This could theoretically be achieved through several approaches. 
Firstly, improving conversion efficiency should drive up neuronal purity. This may be 
possible with improved vectors, but there is a probably a biological limit as to what can 
be achieved here, as there are likely to be some cells that are incapable of converting 
effectively for reasons that remain unknown. Some studies have co-transfected cells with 
vectors encoding anti-apoptotic genes (such as Bcl-xL) which has boosted conversion 
efficiency (Victor et al. 2018). However, apoptosis is the mechanism of neuronal death 
in PD and other neurodegenerative diseases, so interfering with this process will distance 
the model from the processes occurring in patients. Another possibility would be 
selectively killing unconverted cells. This however, is difficult to achieve given that the 
cell population is not dichotomous, and the majority of cells in the culture are probably 
in an intermediate state, with some fibroblast and some neuronal properties. This means 
that it is therefore a significant challenge to identify a property that will reliably and 
efficiently segregate unconverted from converted cells. 
 
A number of toxins can be used in vitro to kill replicating cells. However, if there were 
residual dividing cells within the culture, the well would become overcrowded during the 
reprogramming process, which does not happen. It therefore seems unlikely that these 
toxins will be able to selectively kill the unconverted or partly converted cells. Some 
groups have used sorting methods, using the neuronal surface marker NCAM-1 to 
segregate unconverted cells from iNs (Mertens et al. 2015), though in this project it was 
not possible to generate great improvements in neuronal purity with this approach. 
Furthermore, the sorting process (either FACS or MACS) is traumatic for the cells, and 
may reduce cell survival. Nevertheless, if a marker which is suitably specific for 
successfully converted iNs can be identified, then this will be a useful tool. 
 
An alternative method would be to incorporate a gene for an autofluorescent protein into 
the transfer vector, which would then allow for transduced cells to be accurately detected 
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with FACS. However incorporating the required genetic material for this, in addition to 
all reprogramming factors, may result in genetic cargos that exceed the capacity of 
lentivirus vectors. Additionally, the presence of the fluorescent marker would identify 
cells that had successfully been transfected, but these would not necessarily all have 
reprogrammed to iNs. 
 
A third important target for future iN work is maximisation of culture longevity and 
neuronal maturity. As has been discussed, in most reported iN papers prolonged culture 
is required for iNs to become electrophysiological active, and as such, experiments are 
often carried out on cells that retain the age-signature of the individual, but that do not 
function as a mature neuron. In this study, it was not possible to culture cells to the time 
points at which they would be expected to be electrophysiologically active, and it would 
therefore be desirable to undertake a systematic assessment of the optimal culture 
conditions for prolonged culture, and also to investigate the potential of other 
reprogramming factors to speed up the maturation of iNs (Ruetz et al. 2017). In the 
protocol employed in this project, five small molecules, and four growth factors are 
employed. It is known that exposure to some of these small molecules for prolonged 
periods is detrimental to neuronal growth (Ladewig et al. 2012) (hence they are 
withdrawn from day 17), and it may be that as iNs mature further the optimal culture 
conditions change. 
 
3.5.3 Concluding remarks 
 
Here, iNs have been generated from healthy control individuals, as well as PD patients 
with no GBA1 abnormalities, or heterozygous or homozygous GBA1 variants. Whilst 
there are a number of limitations to the use of iNs, and there are several areas for future 
work, conversion efficiencies in this study were approximately 15 % to 50 % and neuronal 
purities were approximately 15 % to 35 %. In contrast to early iN protocols, the efficacy 
of conversion was therefore sufficient to allow for disease-modelling studies to be 
performed, and this platform was taken forward to serve as the basis for the drug-
screening model discussed in the next chapter.
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4 INTRACELLULAR 





The mechanisms by which heterozygous GBA1 mutations predispose to PD are not 
known. Some studies have suggested that the pathogenesis is predominantly dependent 
on loss of enzyme activity, whilst other observations suggest that a gain of toxic function 
is more likely. Dysfunction of the lysosome-autophagy system has been strongly linked 
to GBA1-PD, with a smaller number of studies identifying mitochondrial dysfunction in 
models of GBA1 mutation-associated disease. In this study, differences were identified in 
the lysosome-autophagy system of GBA1-PD patients in comparison to healthy controls 
and patients with iPD, though there was no evidence of mitochondrial dysfunction under 
baseline conditions. iNs were treated with α-synuclein PFFs, to induce the formation of 
α-synuclein aggregates and subsequent pathology, which occurred to a greater extent in 
GBA1-PD iNs compared to the other groups. This iN model of PFF-induced pathology 
yielded a number of reproducible outcome measures to be taken forward for drug-
screening studies. 
 
4.2 Introduction to chapter 
 
GBA1 mutation-associated disease has been studied in a number of model systems, 
including those in which GCase enzyme activity is suppressed chemically (e.g. through 
the inhibitor, conduritol-β-epoxide) or through genetic knock-down, transgenic cell lines 
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and animals carrying GBA1 mutations, as well as cell lines and post-mortem tissue from 
patients. Of course, each model has its own limitations and may miss out on certain 
aspects of disease. For example, enzyme-suppression models may provide insight into 
any pathogenic loss-of-function mechanisms, but cannot tell us about the effects of the 
misfolded protein itself. Knock-in of pathogenic mutations in cell lines results in high 
non-physiological levels of mutant protein expression, such that they exceed the levels 
occurring in patients, which may lead to pathological effects that do not occur in vivo. 
Neurons derived from iPSCs from patients fail to capture any contribution of age to the 
pathogenic process as is discussed in the previous chapter.  
 
The first section of the chapter focuses on studies involving patient-derived dermal 
fibroblasts, in which basic pathogenic pathways (the lysosome-autophagy system and 
mitochondrial function) have been studied, which has provided the basis for the initial 
drug selection, for testing in this novel model. The second half of the chapter focuses on 
the use of iNs to establish a drug-screening model. iNs were chosen for this study for 
several reasons that have been discussed. Importantly, iNs allow for the study of α-
synuclein pathology without artificially overexpressing the protein, which cannot be 
performed in the native fibroblasts which do not express α-synuclein. As has been 
discussed in detail in chapter 3, iNs also retain cellular age, so that they potentially capture 
age-related elements of pathogenesis, and so can be used to more accurately predict the 
behaviour of a drug in patients, in comparison to similar iPSC-derived neurons. Because 
α-synuclein aggregates were not observed spontaneously in iNs, aggregate-formation was 
induced by treating the cells with PFFs of α-synuclein. The induction of aggregates in iNs 
and associated pathology offers a number of outcome measures that could be taken 
forward to drug-screening studies. 
 
The mechanisms by which GBA1 mutations predispose to PD are incompletely 
understood, but a number of intracellular pathways have consistently been implicated. 
These pathways would therefore be reasonable initial targets for putative disease-
modifying treatments. The current understanding of these mechanisms are discussed in 
the following sections. 
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4.2.1 The lysosome-autophagy system 
 
Dysfunction of the lysosome-autophagy system appears to be central to GBA1-PD, with 
abnormalities in these pathways being identified in a growing number of studies. 
However, the exact mechanism of dysfunction in this system is not clear. Autophagy 
refers to a number of processes through which a cell is able to clear protein and 
dysfunctional organelles, allowing the products of degradation to be recycled. The major 
autophagy pathways involved in clearance of α-synuclein are chaperone-mediated 
autophagy and macroautophagy (Figure 4.1) (Cuervo et al. 2004, Webb et al. 2003). 
 
4.2.1.1 Overview of autophagy pathways 
 
In chaperone-mediated autophagy, chaperone molecules allow for soluble proteins to be 
targeted to lysosomes and broken down by lysosomal enzymes (Cuervo and Dice 1998, 
Dunn 1994). Proteins carrying the KFERQ peptide motif are targeted to lysosome-
associated membrane protein two A (LAMP2A), situated in the lysosomal wall (Cuervo 
and Wong 2014, Chiang et al. 1989). In contrast, macroautophagy involves the formation 
of double membrane-bound vacuolar organelles (autophagosomes) through the 
elongation of cytosolic phagophore membrane fragments. This process involves a number 
of autophagy-related (ATG) proteins, with phagophore expansion dependent on a 
complex consisting of ATG5, ATG12 and ATG16L1. These autophagosomes engulf 
proteins and organelles targeted for degradation, before they fuse with lysosomes to form 
autolysosomes. The contents are then degraded through lysosomal hydrolysis 
(Rubinsztein, Bento and Deretic 2015). 
 
Initiation of macroautophagy may occur due to a variety of stimuli, including starvation 
and nutrient depletion (Chen et al. 2014), ATP depletion (Hardie, Ross and Hawley 2012), 
and pharmacological agents such as rapamycin (Noda and Ohsumi 1998). The most well-
known pathway by which macroautophagy is initiated is mediated by the mammalian 
target of rapamycin complex one (mTORC1) – a pathway that is highly conserved across 
species. This protein complex prevents the initiation of macroautophagy through 
phosphorylation of a number of ATG proteins, restricting autophagosome formation 
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(Hosokawa et al. 2009).  Other, mTORC1-independent, regulatory pathways for the 
initiation of macroautophagy also exist. Adenosine monophosphate-activated protein 
kinase (AMPK) inhibits the activity of mTORC1 but is also able to increase the formation 
of autophagosomes independently. AMPK is activated by reduced ATP levels, so is 
important in initiation of macroautophagy in the context of energy depletion (Cárdenas et 
al. 2010). In a third pathway, stimulation of phosphatidylinositol 3-kinase (PI3K or 
VPS34), for example by beclin-1, results in recruitment of ATG16L to sites of 
autophagosome formation, through increased levels of phosphatidylinositol 3-phosphate 
(PI3P) (Dooley et al. 2014, Furuya et al. 2005). 
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Figure 4.1 – Major mammalian autophagy pathways. In macroautophagy, phagophore 
membrane forms in response to multiple triggers, heralding the formation of 
autophagosomes. Targets of degradation are taken into autophagosomes, facilitated by 
proteins such as P62/SQSTM1. The contents are degraded after fusion of 
autophagosomes with lysosomes. In chaperone-mediated autophagy, proteins are targeted 
directly to lysosomes, mediated by chaperone-molecules. Abbreviations: AMPK = 
Adenosine monophosphate activated protein kinase; ATP = adenosine triphosphate; 
mTORC = Mammalian target of rapamycin complex; PI3K = Phosphatidylinositol 3-
kinase. 
 
4.2.1.2 Measurement of autophagy 
 
During the formation of autophagosomes, LC3b (ATG8) is cleaved by ATG4 to form 
LC3b-I. LC3b-I is then conjugated with phosphatidylethanolamine to form LC3b-II, 
which is associated with the autophagosome membrane (Figure 4.1). This process can be 
exploited in analysing the initiation of autophagy, as an increase in LC3b-II levels relative 
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to LC3b-I or total protein levels indicates an increased number of autophagosomes. 
Additionally, identification of fluorescent LC3b puncta can allow for the visualisation of, 
and quantification of autophagosomes. It is important to note that a rise in autophagosome 
numbers may occur due to increased activation of autophagy, but may also arise due to 
an impairment in the later stages of autophagy (preventing clearance of autophagosomes). 
It is therefore necessary to interpret changes in LC3b-II levels or puncta in context, and 
to utilise modulators of various steps in the macroautophagy pathway (for example, 
inhibitors of lysosome-autophagosome fusion (e.g. bafilomycin A1) or inducers of 
autophagosome formation (e.g. starvation conditions, rapamycin)), to understand their 
meaning (Klionsky et al. 2016). 
 
P62/SQSTM1 is another widely used marker of activity of the macroautophagy pathway. 
This protein has been identified in Lewy bodies, as well as neurofibrillary tangles of 
Alzheimer’s disease, and the huntingtin aggregates seen in Huntington’s disease, and it 
has been suggested that P62/SQSTM1 binds to ubiquitinated protein aggregates, 
potentially being involved in the targeting of them for degradation (Pankiv et al. 2007). 
It is also involved as an autophagy receptor in the process of mitochondrial priming, when 
dysfunctional mitochondria are removed through the autophagy pathway (mitophagy) 
(Geisler et al. 2010). P62/SQSTM1 facilitates the uptake of degradation targets into 
autophagosomes, and is itself degraded during the macroautophagy process following the 
formation of the autolysosome (Pankiv et al. 2007, Klionsky et al. 2016). Therefore, there 
is generally accepted to be an inverse correlation between levels of P62/SQSTM1 and 
macroautophagy activity – as macroautophagy activity increases, so does the rate of 
P62/SQSTM1 degradation, resulting in lower levels (Klionsky et al. 2016). However, 
there are some circumstances in which P62/SQSTM1 levels increase in association with 
increased autophagy, as its expression may be upregulated, meaning that, as with LC3b-
II, interpretation of changes in the P62/SQSTM1 level must be taken in context (Colosetti 
et al. 2009, Toepfer et al. 2011). For example, increased transcription of P62/SQSTM1 
may occur in response to oxygen radical stress (Ishii et al. 1997), inhibition of proteasome 
activity (Kuusisto, Suuronen and Salminen 2001), or expression of mutant huntingtin 
(Nagaoka et al. 2004). 
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As well as determining P62/SQSTM1 levels, it is also possible to quantify fluorescent 
P62/SQSTM1-positive cytoplasmic puncta. Whilst some of these puncta mark non-
membrane bound aggregates representing targets for autophagic degradation 
(sequestosomes, or P62/SQSTM1 bodies) (Pankiv et al. 2007), the majority have been 
shown to represent autophagosomes or autolysosomes (Bjørkøy et al. 2005). Again, this 
poses challenges to interpretation of data, as an increase in puncta may represent an 
increase in the number of autophagosomes, but may also represent an increase in the 
number of sequestosomes implying a defect in autophagic protein clearance. Establishing 
the size of the puncta may allow for differentiation of these, with autophagosomes being 
0.1 µm to 0.2 µm in diameter, and sequestosomes being 0.5 µm to 1 µm in diameter 
(Bjørkøy et al. 2005). 
 
4.2.1.3 Autophagy dysfunction in GBA1 mutation associated-Parkinson’s disease 
 
Several studies have demonstrated perturbations in the lysosome-autophagy system in 
GBA1-PD, but the exact nature of this is yet to be elicited. Dysfunction of this system 
could occur at any of the steps involved in this pathway, including: 
 
i. Biosynthesis of autophagosomes and lysosomes 
ii. Uptake of targets of degradation into autophagosomes 
iii. Formation of autolysosomes through fusion of lysosomes and autophagosomes 
iv. Enzymatic degradation of cargo by lysosomal enzymes (Stoker et al. 2018a). 
 
Knock-down of GBA1 in mouse cortical neurons using an shRNA results in reduced 
levels of lysosomal proteolysis (Mazzulli et al. 2011). Increased numbers of 
autophagosomes and lysosomes have been identified in neuroblastoma cells and in iPSC-
derived dopaminergic neurons carrying GBA1 mutations (Fernandes et al. 2016, 
Schöndorf et al. 2014, Bae et al. 2015). Similar observations have been made in mouse 
cortical neurons, in the setting of inhibition of GCase activity using conduritol-β-epoxide 
(Rocha et al. 2015b) and shRNA-mediated GBA1 knockdown (Mazzulli et al. 2011), 
suggesting that a reduction in enzyme activity is sufficient to induce these changes. These 
findings suggest that the synthesis of these structures is not the underlying problem in 
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GBA1-PD, but that instead any problem is due to the later stages in the pathway, which 
may result in accumulation of lysosomes and autophagosomes.  
 
Reduced co-localisation of autophagosomes and lysosomes has been noted in iPSC-
derived neurons derived from carriers of GBA1 mutations, in comparison to isogenic 
controls, which may imply that the mutation is associated with a reduction in formation 
of autolysosomes (Schöndorf et al. 2014). There is also evidence that lysosomal function 
is abnormal in the context of GBA1 mutation or reduced GCase activity. For example, 
iPSC-derived neurons derived from GBA1 mutation carriers have enlarged lysosomes, 
containing increased amounts of electron dense material, in comparison to those from 
isogenic controls (Fernandes et al. 2016). Knock-down of GBA1 in primary mouse 
cortical neurons also results in enlargement of lysosomes (Mazzulli et al. 2011). 
 
The results discussed here are consistent with there being a defect in the lysosome-
autophagosome fusion stage of autophagy. However, it is important to note that most of 
these observations have been made in models of GCase enzyme activity suppression, 
meaning that any effects of the mutant protein are not captured. In a study involving 
hippocampal neurons and hippocampal allocortex from transgenic mice carrying a single 
GBA1 allele with the L444P mutation (L444P/wt), deficits in both lysosome-
autophagosome fusion and also in the initiation of autophagy were observed (Li et al. 
2018). To further interrogate this, LC3b levels were assessed in SH-SY5Y cells with 
GBA1 knocked-out (-/-), and in those expressing L444P in addition to normal GBA1 
(L444P-wt/wt), with preserved enzyme activity. GBA1 knock-out resulted in increased 
LC3b-II levels compared to wild-type cells consistent with a block in the late-stages of 
autophagy, whilst expression of L444P resulted in reduced autophagosome numbers. 
Autophagic flux was assessed through the use of leupeptin and pepstatin to inhibit the 
fusion stage, which was found to be reduced in knock-out cells, but preserved in L444P-
wt/wt cells. Together this data suggests that there may be dual mechanisms involved, with 
loss of enzyme activity resulting in an impairment in lysosome-autophagosome fusion, 
and the presence of mutant enzyme having a gain-of-function effect resulting in an 
impairment in autophagosome formation (Li et al. 2018). 
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Lysosomal dysfunction and inhibition of GCase activity are known to increase the amount 
of α-synuclein released by the cell through exocytosis (Bae et al. 2014, Alvarez-Erviti et 
al. 2011, Papadopoulos et al. 2018). It may therefore be, that rather than simply increasing 
the propensity of an individual cell to develop α-synuclein pathology, GBA1-mediated 
dysfunction of the lysosome-autophagy system facilitates the propagation of pathology, 
as extracellular α-synuclein may be taken up by adjacent neurons. This could theoretically 
explain the more widespread pathology and more aggressive clinical course seen in 
GBA1-PD than those in iPD. 
 
4.2.2 Mitochondrial dysfunction in GBA1 mutation-associated-Parkinson’s 
disease 
 
Whilst the role of mitochondrial dysfunction in PD is incompletely understood, it is clear 
that it contributes, at least in some cases. It’s importance is illustrated by the observation 
that mitochondrial toxins such as MPTP and rotenone induce death of nigral 
dopaminergic neurons (Langston et al. 1983, Testa et al. 2005, Schapira 2008), and the 
fact that some familial forms of PD arise due to mutations of genes involved in 
mitochondrial function and health (e.g. PARK7 and PINK1) (Kalia and Lang 2015). The 
importance of mitochondrial dysfunction in GBA1-PD is not clear, and only a small 
number of studies have commented on mitochondrial dysfunction in this setting (Cleeter 
et al. 2013, Osellame et al. 2013, Xu et al. 2014, de la Mata et al. 2015, Li et al. 2018). 
Importantly with regard to GBA1-PD, dysfunctional mitochondria may be cleared by the 
lysosome-autophagy system through mitophagy, and problems with this system as occur 
in GBA1-PD may therefore exaggerate any mitochondrial-mediated pathogenic 
mechanisms. 
 
Most of the studies of mitochondrial dysfunction in GBA1-PD  have been performed in 
enzyme suppression models (which fail to represent any potential effects from mutant 
GCase protein), or in models involving biallelic GBA1 abnormalities, more closely 
reflecting GD rather than GBA1-PD. Suppression of GCase activity through treatment 
with conduritol-β-epoxide in neuroblastoma cells (Cleeter et al. 2013) and wild-type 
neurons (Xu et al. 2014) reduces oxygen consumption and ATP production suggesting 
that a loss-of-function effect can precipitate mitochondrial dysfunction. Additionally, a 
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progressive decline in mitochondrial membrane potential in vitro has also been reported 
with prolonged GCase suppression in SH-SY5Y cells, lending further support to this idea 
(Cleeter et al. 2013). Mitochondrial morphology and function is also disrupted in GBA1 
knockout mice, with abnormalities being of greater significance in those in which both 
alleles were knocked-out compared to those with one preserved allele (Osellame et al. 
2013). 
 
Transgenic mice carrying heterozygous GBA1 mutations (L444P/wt), as occurs in GBA1-
PD, have also been found to have abnormal mitochondrial morphology, reduced 
mitochondrial membrane potential, and increased superoxide production, with similar 
findings in fibroblasts from patients with GBA1-PD (Li et al. 2018, McNeill et al. 2014). 
Increased levels of the antioxidant NQ01 have also been seen in patient fibroblasts 
(McNeill et al. 2014). All of these findings support a potential role for mitochondrial 
dysfunction in GBA1-PD. 
 
Mitophagy, a specific form of macroautophagy, is important in the clearance of 
dysfunctional mitochondria. In transgenic mice with the L444P/wt GBA1 genotype also 
expressing mt-Keima (a protein targeted to mitochondria, with bimodal fluorescence 
properties, such that under neutral conditions it fluoresces green and under acidic (i.e. 
lysosomal) conditions it fluoresces red), reduced delivery of mitochondria to the 
lysosomes has been detected (Li et al. 2018). Treatment with CCCP or antimycin, which 
normally induce mitophagy, failed to increase mitochondrial co-localisation to 
lysosomes, suggesting that induction of mitophagy is impaired in the context of GBA1 
mutation. Mitochondrial priming is the process through which dysfunctional 
mitochondria are targeted for degradation through mitophagy, which involves the 
recruitment of autophagy receptors to the mitochondria (Geisler et al. 2010). Levels of 
these autophagy receptors were reduced in mitochondrial fractions from L444P/wt mice 
hippocampi, suggesting that there is a failure in mitochondrial priming, leading to a 
reduction in mitophagy (Li et al. 2018). 
 
The discussion so far suggests that perturbations in mitochondrial function arise 
downstream of GBA1-mediated autophagy dysfunction. However, it has recently been 
suggested that oxidative stress is an earlier component of the pathogenic process in PD 
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(Burbulla et al. 2017). Mitochondrial oxidant stress is associated with PARK7 (DJ-1) 
knockout or dysfunction in dopaminergic neurons generated from patient-derived iPSCs, 
and after prolonged culture, this is accompanied by a reduction in GCase enzyme activity 
and impaired lysosomal proteolysis (Burbulla et al. 2017). While this process occurs in 
cells from patients with sporadic PD, it was accelerated in neurons derived from patients 
with homozygous PARK7 mutations, supporting the idea that mitochondrial dysfunction 
is an important aspect of PD pathogenesis, and that it potentially induces lysosomal 
dysfunction. Furthermore, mitochondrial antioxidants reduce the levels of soluble α-
synuclein, suggesting that oxidant stress contributes to α-synuclein accumulation 
(Burbulla et al. 2017). This study suggests that a sequential pathogenic pathway exists in 
PD, with mitochondrial oxidant stress leading to a reduction in GCase enzyme activity 
and lysosomal function, with consequent α-synuclein accumulation (Stoker et al. 2018a). 
GBA1 mutation may feed into this by lowering the threshold for, or altogether bypassing 
the need for, mitochondrial oxidant stress. 
 
4.2.3 Endoplasmic reticulum stress in GBA1 mutation associated-
Parkinson’s disease 
 
As has been mentioned, loss of GCase enzyme activity does not fully explain the 
pathogenic basis of GBA1-PD, and there is therefore probably a contribution from the 
gain of a toxic function of the misfolded protein. Normal processing of GCase involves 
folding within the ER, prior to delivery to the lysosomes via the Golgi apparatus (Jović 
et al. 2012, Reczek et al. 2007). Mutations that result in misfolding of GCase potentially 
lead to retention of the protein in the ER, where ER-chaperone molecules attempt 
refolding to restore the correct protein structure (Brodsky and McCracken 1999, Sitia and 
Braakman 2003). Failure to correctly re-fold the protein results in its removal through 
ER-associated protein-degradation (ERAD) and the ubiquitin-proteasome system 
(Brodsky and McCracken 1999, Sitia and Braakman 2003, Yoshida 2007, Kopito 1997). 
Once the capacity of this mechanism is surpassed, and there is failure to clear the 
misfolded protein, the unfolded protein response (UPR) is activated (Høyer-Hansen and 
Jäättelä 2007). If ER stress is prolonged, the UPR may fail to restore normal homeostasis, 
and the cell may be directed to an apoptotic fate. 
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Endoglycosidase-H can be used to determine the transit of GCase to lysosomes, as the 
lysosomal form of the enzyme is resistant to endoglycosidase-H-mediated degradation, 
whilst the pre-Golgi form is not (Ron and Horowitz 2005, Bendikov-Bar et al. 2013). The 
proportion of endoglycosidase-H-resistant GCase is significantly lower in association 
with GBA1 mutations when compared to the wild-type protein, indicating that there is 
failure of the proper processing of mutant GCase.  Additionally, mutant GCase is seen to 
co-localise with calnexin (an ER marker), suggesting that it is retained in the ER, and the 
propensity for ER retention seems to contribute to the severity of GD (Ron and Horowitz 
2005). The levels of ER-resident chaperones Bip/GRP78 and calreticulin have been 
shown to be increased in iPSC-derived neurons derived from GBA1-PD patients carrying 
N370S mutations, with mediators of the UPR also being upregulated (Fernandes et al. 
2016). UPR-mediators are also increased in post-mortem brain tissue from patients with 
GBA1-PD in comparison to those with iPD (Gegg et al. 2012). Markers of ER stress are 
also increased in transgenic drosophila expressing mutant human GBA1 compared to 
those expressing wild-type human GBA1 (Suzuki et al. 2013, Sanchez-Martinez et al. 
2016). The use of molecular chaperones (ambroxol and isofagamine) which facilitate the 
correct folding of GCase reduce ER stress markers in human fibroblasts and in drosophila 
overexpressing mutant GBA1. Indeed, such chaperones are considered a potential 
therapeutic approach in GBA1-PD, having entered clinical trials (Sanchez-Martinez et al. 
2016, Bendikov-Bar et al. 2013). 
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Figure 4.2 – Pathogenic mechanisms of GBA1-PD. Reduced GCase enzyme activity 
results in a block in the autophagy pathway and accumulation of glycosphingolipid 
substrates which stabilise pathogenic oligomeric species of α-synuclein. The mutant 
protein also impairs autophagosome formation. Autophagy dysfunction results in 
accumulation of α-synuclein and impaired clearance of dysfunctional mitochondria. A bi-
directional loop occurs in which α-synuclein further impairs normal processing of GCase, 
and reduces its delivery to lysosomes. Additionally, the misfolded enzyme is retained in 
the ER, resulting in activation of the unfolded protein response. Abbreviations: α-syn = 
α-synuclein; ER = Endoplasmic reticulum; GCase = Glucocerebrosidase; HMW = High-
molecular weight. 
 
4.2.4 α-synuclein accumulation and aggregation in GBA1 mutation-
associated Parkinson’s disease 
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Abnormalities of GBA1 and GCase have been shown to increase α-synuclein levels in a 
number of in vitro and in vivo studies (Table 4.1). Most of these studies have correlated 
the accumulation of α-synuclein to reduced GCase activity, though others have suggested 
that it is more likely to occur due to the presence of misfolded enzyme. For example, 
conduritol-β-epoxide treatment in mice (Rocha et al. 2015b, Manning-Boğ et al. 2009) 
and in neuroblastoma cells (Manning-Boğ et al. 2009, Cleeter et al. 2013) was associated 
with increased levels of α-synuclein. The aforementioned study in which GBA1 
expression was suppressed with an shRNA molecule also identified increased levels of 
high-molecular weight α-synuclein in association with reduced lysosomal proteolysis, 
supporting the idea that reduced GCase activity may lead to accumulation of α-synuclein 
(Mazzulli et al. 2011). Introduction of GBA1 mutations that result in loss of enzyme 
function in neuroblastoma cells also has been shown to lead to accumulation of 
oligomeric α-synuclein levels – an effect that was not seen when GBA1 mutations that 
did not affect GCase activity were introduced (Bae et al. 2015). 
 
However, although increased levels of α-synuclein were seen in MES23.5 and PC12 cells 
with knock-in pathogenic GBA1 mutations, this did not correlate with a reduction in 
GCase enzyme activity, and could not be recapitulated through chemical GCase 
inhibition, raising the possibility that the elevated levels of α-synuclein were mediated by 
an alternative, gain-of-function mechanism (Cullen et al. 2011). Knocking in a single 
GBA1 L444P mutation in mouse cortical neurons also impaired clearance of α-synuclein, 
and resulted in increased steady-state levels (Fishbein et al. 2014). The inconsistent 
results regarding the importance of enzyme activity further suggests that the mechanisms 
of risk conveyed by GBA1 mutations are complex, and that there may be more than one 
mode of pathology (Li et al. 2018). 
 
Age-associated α-synuclein accumulation has been seen in vivo, in mouse models 
incorporating GBA1 mutations. In the first of these studies, α-synuclein levels increased 
over time, in mice homozygous for D409V mutations in the GBA1 gene (Cullen et al. 
2011). Aggregates of α-synuclein also accumulate in mice with homozygous GBA1 
mutations combined with a hypomorphic prosaposin transgene (Xu et al. 2011, Xu et al. 
2014). These studies suggest that a reduction in GCase enzyme activity and/or the 
presence of mutant GCase protein could facilitate the development of α-synuclein 
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aggregates in vivo, but it should be noted that the biallelic insults in these systems mimic 
the pathogenic state of GD, and the relevance to GBA1-PD is unclear. 
 
Reduction in GCase enzyme activity leads to the accumulation of sphingolipid substrates 
in lysosomes. This process is known to be important in the pathogenesis of GD, but the 
role of substrate accumulation in GBA1-PD is not clear. It has been shown that the GCase 
substrate glucosylceramide leads to stabilisation of pathogenic high molecular weight 
recombinant α-synuclein oligomers in vitro, which is followed by an increased propensity 
for aggregates to form, and it may be that sphingolipids contribute to the increased risk 
of PD associated with GBA1 mutations (Mazzulli et al. 2011, Zunke et al. 2017).  
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Study Model Result 
 
In vitro studies 
 
Mazzulli et al. 
2011 
shRNA-mediated knockdown of GBA1 
in primary mouse cortical neurons 
Increased soluble monomeric and 
oligomeric α-synuclein levels, and 
increased insoluble high molecular 
weight α-synuclein assemblies 
Manning-Boğ 
et al. 2009 
Cleeter et al. 
2013 
Chemical suppression (CβE) of GCase in 
neuroblastoma cells 
Increased levels of monomeric α-
synuclein 
Cullen et al. 
2011 
Overexpression of mutated GCase 
(L444P, D409V or N370S) in MES23.5 
and PC12 cells expressing wild-type or 
A53T α-synuclein 
Increased levels of α-synuclein 
(reversible with induction of autophagy) 
Fishbein et al. 
2014 
Primary cortical neuron cultures from 
mice carrying heterozygous L444P 
GBA1 mutations 
Reduced clearance of α-synuclein 
Increased steady-state levels of α-
synuclein 
Bae et al. 2015 Neuroblastoma cells with GBA1 
mutations that reduce enzyme activity, 
or GBA1 mutations with no effect on 
enzyme activity 
Increased oligomeric α-synuclein levels 
and exosomal release of α-synuclein  
aggregates, associated with mutations 
that reduce enzyme activity (not those 
where enzyme activity is preserved) 
 
In vivo studies 
 
Rocha et al. 
2015b 
Chemical suppression (CβE) of GCase in 
wild-type mice 
Accumulation of insoluble α-synuclein 
aggregates 
Manning-Boğ 
et al. 2009 
Chemical suppression (CβE) of GCase in 
wild-type mice 
Increased levels of monomeric α-
synuclein 
Xu et al. 2011 
Xu et al. 2014 
Transgenic mice with homozygous 
D409V or V394L GBA1 mutations 
combined with hypomorphic prosaposin 
transgene 
Age-dependent accumulation of α-
synuclein aggregates 
Cullen et al. 
2011 
Mice with homozygous D409V GBA1 
mutations 
Age-dependent increase in α-synuclein 
levels 
Table 4.1 – Studies demonstrating accumulation of α-synuclein in the context of 
GBA1 mutation or GCase activity suppression. Abbreviations: CβE = conduritol-β-
epoxide; GCase = glucocerebrosidase; shRNA = short-hairpin ribonucleic acid. 
 
It is clear that the relationship between α-synuclein, the GCase protein and GCase enzyme 
activity is complex (Figure 4.2). Several studies associate reduced enzyme activity with 
increased α-synuclein levels or aggregates, as discussed above. A bidirectional loop has 
been proposed in which reduced GCase activity, perturbed lysosomal function and 
accumulation of glycosphingolipid substrates leads to the accumulation of α-synuclein, 
including pathogenic oligomeric species. The loop is completed by the fact that α-
synuclein impedes transit and normal processing of the GCase protein across the Golgi 
apparatus, resulting in reduced delivery of GCase to the lysosomal compartment, and a 
further reduction in lysosomal activity. Overexpression of α-synuclein results in an 
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increase in the ER-associated form of GCase, with a reduction of the glycosylated, post-
ER form (Mazzulli et al. 2011). GCase activity has been reported to be reduced in PD 
patients without GBA1 mutations, which may be in part explained by this process 
(Alcalay et al. 2015, Gegg et al. 2012). Further support for this idea comes from the fact 
that knocking out α-synuclein in mice results in an increase in GCase enzyme activity 
(Fishbein et al. 2014). 
 
The favoured explanation for accumulation of α-synuclein in the context of GBA1-PD is 
the reduced protein-clearance associated with dysfunction of the lysosome-autophagy 
system. It has also been shown in vitro that recombinant GCase and α-synuclein directly 
interact with one another, with α-synuclein reducing GCase enzyme activity (Yap et al. 
2011, Yap et al. 2013). This interaction may account for the reduction in GCase enzyme 
activity that has been observed in patients without GBA1 mutations (Alcalay et al. 2015, 
Gegg et al. 2012). GCase is known to occur in Lewy bodies, and this is seen to a greater 
extent in carriers of GBA1 mutations, leading some to postulate that the mutant enzyme 
serves as a platform for aggregate formation (Goker-Alpan et al. 2010). However, α-
synuclein has a lower propensity to interact with N370S GCase than with wild-type 
GCase, suggesting that this interaction does not account for the increased tendency for α-
synuclein aggregation in GBA1-PD (Yap et al. 2011). It is possible instead, that this 
interaction constitutes an element of the bidirectional feedback loop, whereby increased 
levels of α-synuclein exacerbate the pre-existing defect in GCase enzyme activity in 
GBA1-PD.  
 
Here, it was hypothesised that GBA1 variants in patient-derived fibroblasts and iNs would 
harbour aberrations in the lysosome-autophagy system and of mitochondrial function. 
The following sections detail the characterisation of these deficits in patient cells. 
Additionally, iNs were treated with PFFs of α-synuclein in order to induce PD relevant 
α-synuclein pathology, with a view to taking this forward to drug testing trials. 
 
4.3 Materials and methods 
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4.3.1 Immunocytochemistry for autophagy markers 
 
Fibroblasts were cultured to 80 to 90 % confluency before being passaged and plated on 
96-well plates (Thermo Scientific Nunc) at a density of 5000 cells per well. The cells 
were incubated at 37OC for 24 hours. Medium was removed, and the cells washed once 
in PBS, before  HBSS with Ca2+ and Mg2+ (starvation conditions), bafilomycin 100 nM 
in fibroblast medium, wortmannin 100 nM in fibroblast medium, or DMSO vehicle 
control were then added to the cells, each in technical triplicate. The cells were then 
incubated for four hours at 37OC. The treatments were then removed, and the cells were 
washed in PBS before being fixed in ice cold methanol for 10 minutes. 
 
For immunocytochemistry, blocking was performed by incubating the cells in 5 % goat 
serum in PBS, for one hour at room temperature. Primary antibodies against 
P62/SQSTM1 (Genetex GTX629890) and LC3b (sigma L7543) diluted to 1:500 in 5 % 
goat serum was added to the cells, which were then incubated overnight at 4OC. The cells 
were washed twice in PBS before secondary antibodies (Thermo Fisher Scientific Alexa 
Fluor) 1:500 in 5 % goat serum were added for two hours at room temperature. The cells 
were washed once in PBS without electrolytes and then nuclear counterstaining was 
performed with DAPI 1 µg/ml in PBS for 20 minutes at room temperature. High-
throughput analyses using CellomicsTM XTI spot count and cell health profiling protocols 
were performed to quantify the number of fluorescent puncta and mean intensity. 
 
Reagents were prepared as follows: Bafilomycin A1 (Sigma SML1661 or Sigma B1793) 
and wortmannin (Tocris 1232) were dissolved in DMSO to give a stock concentration of 
10 µM and 200 µM respectively. Stock solutions were diluted in fibroblast medium to 
give working concentrations of 100 nM. Vehicle control consisted of fibroblast medium 
with 1:100 DMSO. 
 
4.3.2 LysotrackerTM red DND-99 assay 
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Fibroblasts from two healthy controls, two patients with iPD and three patients with 
GBA1-PD were passaged and plated on a 24-well plate (Thermo Scientific Nunc) at a 
density of 5000 cells per well, in technical triplicate. The cells were incubated at 37OC 
for five days, with a medium change being performed on day three. 
 
The medium was removed from the wells, and LysotrackerTM DND-99 (Thermo Fisher 
Scientific) diluted to 50 nM in HBSS with Ca2+ and Mg2+ was added to each well, and 
the plate was incubated at 37OC for 30 minutes. The cells were then washed in HBSS and 
fixed in 4 % paraformaldehyde (PFA) for 20 minutes. Nuclear counter-staining with 
DAPI 1 µg/ml was then performed for 20 minutes at room temperature. 
 
High-throughput imaging analysis were performed using CellomicsTM XTI. A total of 20 
fields per well were imaged at 20 times magnification. Spot count and spot area per well 
were calculated using the spot detector protocol, and the mean values for all cells in each 
cell line was used to give a single value for each individual cell line which was used for 
statistical analysis. 
 
4.3.3 MitoSOXTM red assay 
 
Fibroblasts from healthy controls (n=2), and patients with iPD (n=1) and GBA1-PD (n=2) 
were passaged and plated at a density of 20000 cells per well in a 96-well plate (Ibidi), in 
technical triplicate. They were incubated for 48 hours at 37oC before the medium was 
removed and the cells were washed in HBSS. MitoSOXTM 5 µM and DAPI 1 µg/ml in 
HBSS with Ca2+ and Mg2+ without phenol red was then added, and the plate incubated at 
37OC, protected from light, for 30 minutes. The plate was transferred to the plate reader 
and fluorescence intensity was read at 544 nm / 590 nm for MitoSOXTM red and at 355 
nm / 460 nm for DAPI. The MitoSOXTM fluorescence intensity for each well was 
corrected based on the corresponding value for DAPI fluorescence intensity, to ensure 
that differences seen were not due to variations in the number of cells. A mean value of 
the technical replicates was obtained to provide a single value for each cell line which 
was used for analysis. 
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4.3.4 TMRE assay for mitochondrial membrane potential and 
MitoTrackerTM green assay for mitochondrial content 
 
Fibroblasts from healthy controls (n=2), or patients with iPD (n=2) and GBA1-PD (n=3)  
were passaged and plated at a density of 12000 cells per well in a 96-well plate (Ibidi) in 
technical triplicate. This plate was then incubated at 37OC for 72 hours. The medium was 
removed and replaced with 1 µM tetramethylrhodamine, ethyl ester (TMRE) in HBSS 
with Ca2+ and Mg2+, and the plate was then incubated for 30 minutes at 37OC, protected 
from light. The TMRE was then removed and the cells were washed twice in 0.2 % BSA 
in PBS, before being transferred to the cell plate reader for fluorescence intensity 
measurement at excitation / emission frequencies 544 nm / 590 nm. The mean value for 
the technical replicates was used to generate a single value for each cell line which was 
used for analysis. 
 
When analysis was performed in iNs, medium was removed and the cells were washed 
once with PBS, before TMRE 200 nM or MitoTrackerTM Green 200 nM in Ndiff227 was 
added. The plate was incubated for 20 minutes at 37oC before the TMRE or 
MitoTrackerTM solution was removed and replaced with Hoescht 33342 2 µg/ml in HBSS 
with Ca2+ and Mg2+ with further incubation at 37oC for 10 minutes. The cells were washed 
twice in PBS before fluorescence intensity was measured at excitation / emission 355 nm 
/ 460 nm (Hoescht) and 544 nm / 584 nm (TMRE) or 485 nm / 520 nm (MitoTrackerTM 
Green) using the cell plate reader. 
 
4.3.5 Adenosine triphosphate production assay 
 
Fibroblasts from healthy controls (n=3), and patients with iPD (n=2) and GBA1-PD (n=3) 
were passaged and plated at a density of 10000 cells per well in a 96-well plate (Ibidi), 
with four wells per line. After 48 hours incubation, carbonyl cyanide 4-(trifluoromethoxy) 
phenylhydrazone (FCCP) was added to one well for each line, to give a final 
concentration of 10 µM, and the cells were incubated for a further 12 hours. The ATP 
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luminescence assay (Abcam) was then performed as per the manufacturer’s instructions. 
Medium was replaced with HBSS with Ca2+ and Mg2+, before 50 µl detergent was added, 
followed by a five minute incubation at room temperature, shaking at 300 rpm. Substrate 
(50 µl) was added to each well before a further five minutes of shaking. The plate was 
then incubated, at room temperature protected from light, for 10 minutes, before 
luminescence was read on the microplate reader. 
 
4.3.6 Transfection of fibroblasts and treatment with α-synuclein pre-formed 
fibrils 
 
Fibroblasts were plated at a density of 5000 cells per well in a 24-well plate (Thermo 
Scientific Nunc) coated with 0.1 % gelatin. After three days of culture, 50 ng of plasmid 
DNA encoding eGFP-tagged wild-type α-synuclein was added to each well, kindly 
supplied by Professor David Rubinsztein (University of Cambridge). Lipofectamine 3000 
(Thermo Fisher Scientific) was diluted in Opti-MEM medium, and combined with P3000 
reagent and plasmid mixture as per the manufacturer’s protocol. The mixture was 
incubated for 15 minutes at room temperature before being added drop-wise into the cell 
medium. 
 
α-synuclein PFFs or PBS vehicle control were added to the cells the following day, and 
the cells were incubated for a further three days before being fixed. Immunocytochemistry 
for GFP and α-synuclein was performed. Images were acquired on the CellomicsTM XTI 
microscope, and spot detector analysis was performed to determine total spot count and 
total spot area per cell for both GFP and α-synuclein. For each condition, 20 microscopy 
fields were acquired at 20 times magnification, and the mean value from the 20 fields was 
used for statistical analysis. 
 
4.3.7 Treatment with α-Synuclein pre-formed fibrils 
 
PFFs were generated by Dr Wei-Li Kuan by dissolving recombinant wild-type human α-
synuclein monomers in pH 7.6 10 mM Tris-HCl and 50 mM sodium chloride at a 
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concentration of 5 mg/mL. This solution underwent shaking at 1000 rpm for seven days 
at 37OC. The resultant PFF product was then verified using transmission electron 
microscopy, an ultracentrifigation-sedimentation assay, and through seeding onto 
primary human fetal neurons. PFFs were stored at a concentration of 5 µg/µl. Prior to use 
stock PFF was diluted 1:52 in Ndiff227 medium. This working solution of PFFs was then 
sonicated for 60 minutes in a sonicator water bath, before the desired volume was added 
to wells. A half medium change was performed three days later, with further half medium 
changes every two to three days until the time of analysis. Final concentrations of PFFs 
were 0.3 to 2.7 ng/µl as detailed below. 
 
To assess the effect of PFFs in fibroblasts, 50000 fibroblasts were plated in a six well 
plate coated with 0.1 % gelatin in 2 ml medium. The following day 40 µl of sonicated 
PFFs were added. Half medium changes were performed every two to three days and the 
cells were fixed in methanol after 10 days of PFF exposure. Immunocytochemistry for α-
synuclein was performed prior to imaging using the confocal microscope. 
 
4.3.8 Caspase activity assay 
 
Fibroblasts from iPD lines (n=4) and GBA1-PD lines (n=2) were converted to iNs. At day 
17 post-transduction, they were treated with a single dose of sonicated α-synuclein PFFs 
at a dose of 0.4 µg/ml or 1.5 µg/ml, or vehicle control, in technical triplicate. They were 
then cultured for a further 10 days, with medium changes every two to three days. 
 
On day 27 post-transduction, a total caspase activity assay was performed (Thermo Fisher 
Scientific I35104). The polycaspase reagent FAM-VAD-FMK was diluted as per 
manufacturer’s instructions, in Ndiff227, before being added to the cells which were then 
incubated for one hour at 37OC. The medium was then removed and replaced with 
Hoescht 33342 2 µg/ml diluted in HBSS with Ca2+ and Mg2+, with incubation for five 
minutes at 37OC. The cells were then washed twice in wash buffer, before being fixed in 
apoptosis fixative solution for 20 minutes at room temperature. Fluorescence intensity 
was measured using a cell plate reader at 355 nm / 460 nm for Hoescht and at 480 nm / 
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520 nm for the polycaspase reagent. The polycaspase signal was divided by the Hoescht 
signal to correct for differences in cell numbers. 
 
4.3.9 Western blot analysis 
 
Fibroblasts were plated at 100000 cells per well in six-well plates and converted to iNs. 
iNs were dissociated with trypsin 0.05 % and flushed from the well with Ndiff227 
medium, and centrifuged at 400 x G for five minutes. Cell pellets were resuspended in 40 
µl lysis buffer (5 M urea, 2.5 % sodium dodecyl sulphate (SDS), 50 mM Tris pH 6.8 and 
30 mM sodium chloride) and incubated on ice for five minutes. Lysates were centrifuged 
at 10000 rpm for 2 minutes at 4oC and the supernatants transferred to new tubes. Protein 
was quantified using a BCA assay kit (Thermo Scientific), and 20 µg protein was loaded 
onto acrylamide gels and run alongside standard molecular weight markers. Gels were 
transferred onto polyvinylidene difluoride membranes (30 V for ninety minutes at 4oC), 
followed by blocking in 5 % fat-free milk powder in Tris-buffered saline with 0.1 % 
Tween (TBS-T) for one hour, and incubation overnight at 4°C in 5 % milk with the LC3b 
primary antibody (Sigma L7543) 1:500. Horseradish peroxidase (HRP)-conjugated 
secondary antibodies were then added and membranes were developed with ECLTM 
detection reagent (GE Healthcare). Membranes were stripped with two 15 minute washes 
in pH 2.2 stripping buffer containing 15 g glycine, 1 g SDS, and 10 ml Tween 20 in 1 l 
ultrapure water, before being washed three times in TBS-T. Protein detection using 
P62/SQSTM1 antibody (abcam 91526) 1:500 was then performed as described above. 
Densitometric quantification of Western blots was performed using ImageJ analysis 
software. The measurements were normalized to β-Actin as the loading control. Western 
blotting was performed with the assistance of Dr Shaline Fazal. 
 
4.3.10 Statistical analysis 
 
All statistical tests were performed using IBM SPSS software. When comparing two 
independent groups, p-values were determined with independent samples T tests, after 
determining the equality of variance with Levene’s test for equal variance. Multiple group 
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comparison was performed with one-way ANOVA and post-hoc Tukey analysis. 
Statistical significance is indicated by asterixes as follows: * = p ≤ 0.05; ** = p ≤ 0.01; 




4.4.1 Lysosome-autophagy dysfunction 
 
GCase protein levels and activity had previously been assessed in the fibroblasts from the 
cell lines used in this study, with GBA1-PD lines showing a non-significant reduction in 
GCase protein levels, and a significant reduction in GCase enzyme activity to 36.5% of 
the mean activity of that in healthy controls (Collins et al. 2017). 
 
To first investigate whether GBA1 mutation was associated with differences in activity of 
the lysosome-autophagy system, immunocytochemistry for the macroautophagy markers 
P62/SQSTM1 and LC3b was performed in patient derived fibroblasts from healthy 
controls (n=3), and patients with iPD (n=4) and GBA1-PD (n=3) (Figure 4.3). Fibroblasts 
were cultured under starvation conditions for four hours to induce macroautophagy. Mean 
P62/SQSTM1 intensity was significantly higher in the GBA1-PD group than the healthy 
control (p=0.003) and iPD (p=0.007) groups, suggesting that GBA1-PD is associated with 
reduced ability to induce macroautophagy. There were no differences between any of the 
other groups. LC3b intensity was also greater in the GBA1-PD group in comparison to 
healthy controls and iPD patients but this did not reach significance (p=0.068 and p=0.08 
respectively).  It was not possible to obtain images of sufficient resolution to quantify 
LC3b-positive puncta to determine the number of autophagosomes. 
 
P62/SQSTM1 levels were then quantified following treatment with bafilomycin A1 (an 
inhibitor of autophagosome-lysosome fusion) or wortmannin (an inhibitor of PI3K), 
which is important in autophagosome formation. Bafilomycin treatment led to a 
significant increase in P62/SQSTM1 levels in healthy controls (p=0.003), signalling 
reduced autophagic flux, as expected. There was a similar rise in the iPD group though 
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this did not reach statistical significance. The rise in P62/SQSTM1 intensity with 
bafilomycin in the GBA1-PD group was lower than in the other groups.. All groups did 
however have a statistically significant increase in the P62/SQSTM1 spot count following 
bafilomycin A1 treatment (Figure 4.3 and Figure 4.4). The difference between the 
P62/SQSTM1 spot count after bafilomycin A1 treatment and the spot count in baseline 
conditions was used as an estimate of autophagic flux. There was no difference in 
autophagic flux between any of the groups (p=0.77). 
 
Wortmannin treatment did not alter P62/SQSTM1 levels in the healthy control or iPD 
groups, suggesting that they had sufficient reserve in their capacity to initiate autophagy 
through PI3K-mediated or alternative pathways. In contrast, there was a non-significant 
increase in P62/SQSTM1 levels in the GBA1-PD group, with a significant increase in the 
number of P62/SQSTM1 positive puncta (p=0.002). These structures were large in size, 
suggesting that they represented sequestosomes (rather than autophagosomes), indicating 
that wortmannin significantly impaired autophagic degradative capacity in the GBA1-PD 
group (Figure 4.3 and Figure 4.4). 
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Figure 4.3 – Autophagy markers in patient-derived fibroblasts. P62/SQSTM1 (A) 
and LC3b (B) intensity were increased in GBA1-PD fibroblasts after starvation in 
comparison to other groups. C) P62/SQSTM1 intensity increased following bafilomycin 
A1 treatment in healthy control fibroblasts. D) The number of P62/SQSTM1 puncta 
increased following bafilomycin A1 100nM treatment in fibroblasts. There were no 
differences in autophagic flux (the difference in P62/SQSTM1 spot count after 
bafilomycin A1 treatment and under baseline conditions) between groups. Wortmannin 
increased P62/SQSTM1 intensity (E) and spot count (F) only in GBA1-PD fibroblasts. 
For comparison between the three phenotypic groups, statistical significance was 
determined with one-way ANOVA and post-hoc Tukey analysis. Independent samples T 
tests were used to compare baseline to treatment conditions within each group. Statistical 
significance indicated by asterixes. 
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Figure 4.4 – P62/SQSTM1 immunocytochemistry in patient fibroblasts with 
bafilomycin A1 and wortmannin treatment. Bafilomycin A1 increased the number of 
small P62/SQSTM1-positive puncta in healthy control, iPD, and GBA1-PD fibroblasts. 
Wortmannin did not significantly alter P62/SQSTM1 immunocytochemistry in healthy 
controls or iPD cells, but led to accumulation of large P62/SQSTM1-positive puncta in 
GBA1-PD fibroblasts. Scale bar represents 50 µm. 
 
Lysosomal mass in the fibroblasts was quantified using LysotrackerTM red DND-99 
(Figure 4.5). The lysosome count (p=0.035) and total lysosome area (p-0.031) were 
statistically higher in the GBA1-PD group when compared to healthy controls – a finding 
consistent with previous reports (Bae et al. 2015). There were no significant differences 
between the iPD group and the control or GBA1-PD groups. 
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Figure 4.5 – Lysosomal mass in patient fibroblasts. LysotrackerTM red DND-99 was 
used to quantify lysosomal mass. Lysosomal count (A) and area (B) were higher in GBA1 
variant-carrying fibroblasts, compared to healthy controls. C) Representative images of 
LysotrackerTM DND-99 staining. Cell lines were analysed in triplicate. Independent 
samples T tests were used to compare mean values between groups. Statistical 
significance indicated by asterixes. Scale bar represents 50 µm. 
 
P62/SQSTM1 intensity was also assessed at baseline in iNs, where no difference was 
observed between the groups (Supplementary Figure 7.1). This may be explained by the 
fact that only baseline staining was performed in iNs, without the use of starvation to 
induce autophagy, or chemical inhibitors of the various stages of autophagy. LC3b-II 
levels were determined in iNs from healthy controls (n=2), and patients with iPD (n=4) 
and GBA1-PD (n=3) with Western blot analysis (Supplementary Figure 7.3). Under 
starvation conditions, LC3b-II levels were non-significantly reduced in the GBA1-PD 
group compared to healthy controls, by approximately 50% (p=0.074) (Figure 4.6). There 
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Figure 4.6 – LC3b quantification in iNs. iNs were generated from healthy controls 
(n=2), and patients with iPD (n=4) and GBA1-PD (n=3). At day 22 post-transduction iNs 
were kept in neuronal medium or starved in HBSS with calcium and magnesium for six 
hours, before protein was harvested in 5 M urea lysis buffer. A) Western blot for LC3b 
in iN cell lysates. B) Autophagosome numbers after starvation were reduced in iNs from 
GBA1-PD patients compared to those from healthy controls and iPD patients, as judged 
by LC3b-II levels. Abbreviations: S=starvation. 
 
4.4.2 Mitochondrial dysfunction 
 
Because autophagy is important for the clearance of dysfunctional mitochondria, and 
because mitochondrial abnormalities have been reported in a small number of studies of 
GBA1-PD, mitochondrial superoxide production, and mitochondrial membrane potential 
were determined in fibroblasts using MitoSOXTM red and TMRE-based assays 
respectively. There were no significant differences in mitochondrial superoxide 
production (p=0.053) or mitochondrial membrane potential (p=0.362) between any of the 
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groups. There was a trend towards lower mitochondrial membrane potential in the GBA1 
mutation-carrying cell lines, and it may be that the small sample size prevented detecting 
a true difference in mitochondrial membrane potential (Figure 4.7 and Figure 4.8). 
 
Figure 4.7 – Assessment of mitochondrial health in patient fibroblasts. A) 
MitoSOXTM red fluorescence intensity in fibroblasts from healthy controls (white bars, 
n=2), and patients with iPD (light grey bar, n=1) and GBA1-PD (dark grey bars, n=2).Bars 
represent the mean value of triplicates for each line. B) Mitochondrial membrane potential 
in fibroblasts from healthy controls (n=2), and patients with iPD (n=2) and GBA1-PD 
(n=3). There were no significant differences in mitochondrial superoxide production or 
mitochondrial membrane potential. Statistical significance determined by one-way 
ANOVA. Statistically significant difference indicated by asterix. 
 
Figure 4.8 – TMRE assay of mitochondrial membrane potential in patient 
fibroblasts. Scale bar represents 200 µm. 
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To determine if there were any functional differences in mitochondrial capacity 
associated with GBA1 mutations, a luminescence-based ATP production assay was 
performed. In-keeping with the above observations, ATP production was similar between 
healthy controls, and patients with iPD or GBA1-PD with no significant difference 
detected (p=0.361) (Figure 4.9). These data suggest that at baseline, there is no major 
deficit in mitochondrial function, in association with GBA1 mutation. 
 
 
Figure 4.9 – ATP production in patient fibroblasts. ATP production was estimated 
using a luminescence assay in healthy controls (n=3), and patients with iPD (n=2), GBA1-
PD (n=3). FCCP 10 µM treated fibroblasts were used as a negative control. There were 
no significant differences in ATP production between any of the disease groups at 
baseline (p=0.361). 
 
Mitochondrial parameters were also investigated in iNs derived from healthy controls 
(n=2), and patients with iPD (n=3) or GBA1-PD (n=2). Mitochondrial content was first 
estimated using MitoTrackerTM green dye, with no significant differences between the 
groups (p=0.177). There were no differences in mitochondrial membrane potential, as 
judged by TMRE assay (p=0.77), or in the estimate of functional polarised mitochondria 
(p=0.128), determined as the ratio of TMRE to MitoTrackerTM signal. Similarly, there 
were no significant differences in mitochondrial superoxide production (p=0.766). As 
expected, treatment with the mitochondrial uncoupler FCCP resulted in a reduction in 
mitochondrial membrane potential and estimated functional polarised mitochondria, and 
an increase in superoxide production in all groups. 
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Figure 4.10 – Mitochondrial assays in iNs. There were no significant differences in total 
mitochondrial content (A), mitochondrial membrane potential (B), estimated total 
functional polarised mitochondria (C) or mitochondrial superoxide production (D) 
between healthy controls (n=2), and patients with iPD (n=3) or GBA1-PD (n=2). E) 
Representative images of above. Scale bar represents 200 µm. 
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4.4.3 Treatment of induced neurons with α-synuclein pre-formed fibrils 
 
In order to use iNs as a novel disease model and in vitro drug-screening tool for PD, PFFs 
of pathogenic α-synuclein were used to induce PD-relevant pathology. Treatment with 
PFFs has previously been shown to induce α-synuclein aggregates and neurodegeneration 
in cultured neurons and animals (Luk et al. 2009, Volpicelli-Daley et al. 2011, Luk et al. 
2012a). Initially, iNs from four cell lines  (two healthy controls, one patient with iPD and 
one with GBA1-PD) were generated, and treated with a single dose of PFFs (0.3 ng/µl) at 
day 17 post-transduction. They were cultured for a further 10 days, with ongoing medium 
changes every two to three days until day 27 post-transduction. All lines demonstrated 
pFTAA (pentameric formyl theophene acetic acid)-positive aggregates, which were more 
numerous in the PD cell lines than in the healthy controls. These aggregates were 
subsequently shown to consist of α-synuclein with immunocytochemistry (Figure 4.11). 
Immunocytochemistry for β-amyloid (another aggregate-prone protein) was also 
performed as a negative control, which was not identified in the pFTAA-positive 
aggregates (Figure 4.12). 
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Figure 4.11 – PFF-induced α-synuclein aggregates in patient-derived iNs. The 
majority of observed aggregates were extracellular, situated adjacent to cells (see 
magnified boxes). A smaller number of intracellular aggregates could be seen (white 
arrows). Scale bars represent 50 µm. 
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Figure 4.12 – Confocal microscopy images of pFTAA-positive aggregates in iNs.  iNs 
from a GBA1-PD cell line were treated with α-synuclein PFFs before staining with 
pFTAA and immunocytochemistry for α-synuclein and β-amyloid. Aggregates were 
found to consist of α-synuclein (A) but not to contain β-amyloid (B). Abbreviations: 
pFTAA = pentameric formyl theophene acetic acid. Scale bar represents 100 µm. 
 
This was subsequently repeated with iNs generated from healthy control lines (n=3), iPD 
lines (n=2) and GBA1-PD lines (n=3), to see if the burden of PFF-induced aggregates 
differed between the different phenotypes. The healthy controls had a lower number and 
area of PFF-induced aggregate per iN than all of the other groups, though this did not 
reach statistical significance, probably due to the low sample size, and the large standard 
deviation in the PD groups (Figure 4.13). The aggregates were not observed to contain 
phosphorylated α-synuclein on immunocytochemistry (Supplementary Figure 7.2). 
 
Clinical aspects and in vitro modelling of GBA1 variant-associated Parkinson’s disease 
142 Thomas Stoker – September 2019 
 
Figure 4.13 – Quantification of PFF-induced aggregates in patient-derived iNs. 
Number (A) and area (B) of PFF-induced α-synuclein aggregates in iNs derived from 
healthy controls (n=3), and patients with iPD (n=2) and GBA1-PD (n=3). Each cell line 
was analysed in triplicate and a mean value for each cell line used for statistical analysis. 
The burden of PFF-induced aggregates was low in healthy controls compared to disease 
groups. Abbreviations: iN = induced neuron; PFF = pre-formed fibril. 
 
The PFF-induced aggregates were then quantified following exposure to three different 
doses of PFFs (0.4 ng/µl, 1.9 ng/µl and 2.7 ng/µl) in iNs derived from healthy controls 
(n=4), iPD patients (n=5), and GBA1-PD patients (n=3). In the healthy control, iPD and 
GBA1-PD groups, there were increases in the number of α-synuclein-positive spots at the 
0.4 ng/µl PFF dose but this only reached significance for the iPD (p=0.01) and GBA1-PD 
(p=0.024) groups when compared to treatment with vehicle control. There were further 
increases in the number of α-synuclein-positive aggregates with the two higher PFF doses 
(Figure 4.14 and Figure 4.15). At the lower PFF dose, the healthy control group had a 
reduced propensity for aggregate accumulation in comparison to the iPD group (p=0.009) 
and the GBA1-PD group (p=0.002). The total area of aggregates was also greater in the 
GBA1-PD group compared to healthy controls at the highest PFF dose (p=0.05). There 
were no significant differences in the number of aggregates per cell between the groups 
at the two higher PFF doses, though at each dose the number of PFF-induced aggregates 
was lowest in the healthy control group, and highest in the GBA1-PD group.  
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Figure 4.14 – Number of PFF-induced α-synuclein aggregates with different PFF 
doses. iNs from healthy controls (n=3), and patients with iPD (n=5) and GBA1-PD (n=3) 
were treated with 0.4 ng/µl, 1.9 ng/µl or 2.7 ng/µl of PFFs, or vehicle control. At the 
lowest dose, the number of aggregates observed was statistically greater in the iPD group 
(p=0.009) and the GBA1-PD group (p=0.002) compared to controls. There were no 
significant differences between the three groups at the other doses. Statistically significant 
differences between the phenotypic groups determined by one-way ANOVA with post-
hoc Tukey analysis at each PFF dose indicated by asterixes. Abbreviations: PFF = pre-
formed fibrils. 
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Figure 4.15 – PFF-induced aggregates at different PFF doses. There were dose-
dependent increases in the number of PFF-induced aggregates in all disease groups. At 
the lowest dose, the number of PFF-induced aggregates in healthy controls was low. Scale 
bar represents 50µm. Abbreviations: PFF = pre-formed fibril. 
 
The majority of the aggregates appeared to be on the perimeter of the cells, and to further 
determine the location of them, confocal microscopy was performed. This demonstrated 
that the majority of the aggregates were extracellular, adjacent to cells (Figure 4.16), 
though a small number of intracellular aggregates were present (Figure 4.11). 
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Figure 4.16 – Extracellular PFF-induced aggregates. Confocal microscopy image 
showing extracellular PFF-induced aggregates in iNs derived from an iPD patient. Scale 
bars represent 50 µm. 
 
To verify that the pFTAA-positive α-synuclein aggregates were not residual PFFs that 
had adhered to the culture matrix, PFFs generated from fluorescent-tagged α-synuclein 
monomers were generated. These were applied to fibroblasts from a healthy control and 
a GBA1-PD cell line. Cells were then fixed and imaged at day one, three, six and eight 
(Figure 4.17). Fluorescent-tagged PFFs could clearly be observed intracellularly in both 
cell lines in a proportion of the cells at day one, but their presence declined over the 
subsequent time-points, being undetectable by day six (Figure 4.18). Fibroblasts from a 
GBA1-PD line were also treated with untagged PFFs, before immunocytochemistry for 
α-synuclein was performed after 10 days. A small number of α-synuclein-positive spots 
of small size were observed, though this was significantly fewer than that seen with iNs 
derived from the same cell line, indicating that the observed aggregates were specific to 
neuronal cells (Figure 4.19).  
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Figure 4.17 – Treatment of patient fibroblasts with fluorophore-tagged PFFs. 
Fluorescent PFFs could be seen within cells at day one post-treatment, but were 
undetectable from day six onwards. Scale bar represents 200 µm. 
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Figure 4.18 – Clearance of fluorophore-tagged PFFs over time. Fibroblasts from a 
healthy control line and iPD line were treated with fluorophore-tagged PFFs, and 
fluorescent spot-count determined at 24 hours, three days, six days, and eight days post-
treatment. The number of fluorescent puncta decreased to low levels in both lines within 
six days. 
 
To further demonstrate that PFFs themselves do not persist in the culture vessel, PFFs 
were added to a six-well plate in the absence of cells. Half-medium changes were 
performed to mimic the conversion protocol, and after 10 days the wells were washed and 
stained for α-synuclein – there were no persisting PFFs, confirming that PFFs do not 
adhere to the culture matrix, and that the observed α-synuclein aggregates in iNs did not 
consist of residual PFFs (Figure 4.19). Taken together, these observations suggest that 
the PFFs themselves are cleared by cells within a short time-frame, that they do not adhere 
to the culture matrix directly, and that the observed PFF-induced aggregates do not occur 
in fibroblasts, but are specific to the iNs. 
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Figure 4.19 – α-synuclein aggregates in fibroblasts and iNs treated with PFFs for 10 
days. No aggregates were observed when PFFs were incubated in the absence of cells, 
and only small numbers were seen in fibroblasts when compared to those seen in iNs from 
the same GBA1-PD cell line. 
 
To confirm that α-synuclein PFFs were able to induce aggregation of α-synuclein 
expressed within the recipient cell, fibroblasts from an iPD line were transfected with a 
plasmid encoding GFP-tagged wild-type α-synuclein, and subsequently treated with PFFs 
or PBS vehicle control. In transfected cells, PFF treatment resulted in the accumulation 
of GFP and α-synuclein-positive puncta, detected on immunofluorescence (Figure 4.20). 
The total area of α-synuclein aggregate per cell in the transfected cells treated with PFF 
was significantly greater than in transfected cells treated with PBS (p<0.0001), or 
untransfected cells treated with PFF (p<0.0001) or PBS (p<0.0001) (Figure 4.21).  A 
small number of α-synuclein-positive puncta were present in untransfected cells treated 
with PFFs, thought to represent residual PFFs that were yet to be cleared at this early 
stage. α-synuclein-positive puncta were only observed in very small numbers in 
transfected or untransfected cells that were not treated with PFFs.  
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Figure 4.20 – α-synuclein PFF-induced aggregates in fibroblasts expressing GFP-
tagged α-synuclein. α-synuclein aggregates were observed in transfected cells treated 
with PFFs, which were co-localised to GFP signal, indicating that they consisted of α-
synuclein from within the cell. These aggregates were not observed in the absence of PFF 
treatment or in untransfected cells. Abbreviations: αSyn = α-synuclein; GFP = Green 
fluorescent protein; PFF = Pre-formed fibrils. Scale bar represents 100 µm. 
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Figure 4.21 – Quantification of PFF-induced α-synuclein aggregates in fibroblasts 
transfected with GFP-α-synuclein. GFP (A and B) and α-synuclein (C and D) 
aggregates were numerous in transfected fibroblasts treated with PFFs, but only observed 
in small numbers in other groups. Statistical significance indicated by asterixes as 
determined by one-way ANOVA with post-hoc Tukey analysis. Abbreviations: Alpha-
syn = α-synuclein; GFP = green fluorescent protein; PFF = pre-formed fibrils. 
 
The dynamic nature of the iN culture system meant that application of PFFs at different 
time points could alter the degree of α-synuclein aggregation. In the early stages of 
conversion, endogenous α-synuclein levels are low, theoretically resulting in a reduction 
in aggregate burden. In contrast, application at too late a stage may preclude culture for 
sufficient duration for aggregates to form. In order to assess the optimal timeframe for 
application of PFFs during the conversion, iNs from two iPD lines were generated, with 
PFFs applied at five different time points (day 3, 5, 10, 17 or 22 post-transduction). Cells 
were then fixed at day 27 for analysis. 
 
In keeping with the idea that early application of PFFs would limit the development of 
aggregates, the number of aggregates was low in the wells treated at three and five days, 
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and was greatest in the wells treated at day 17, which reached statistical significance when 
compared to treatment at day five (p=0.045). The number was also lower in the wells 
treated at day 22, suggesting that at least five days of further culture is required for PFF-
induced aggregates to accumulate in the greatest numbers. These data suggest that the 
optimal point of PFF-application in terms of induction of α-synuclein aggregation is 
between 10 and 17 days post-transduction. Interestingly, the aggregates derived from day 
10 PFF administration were largest, suggesting that culture for 17, rather than 10 days 
post-PFF exposure allows for the aggregates to mature to a greater extent. There were no 
differences in neuronal purity between the different time points of PFF-administration, 
suggesting that the changes in aggregate burden were not due to differences in the number 
of iNs in the well, and that the timing of exposure did not affect differentiation or neuronal 
death (Figure 4.22 and Figure 4.23). 
 
 
Figure 4.22 – Effect of time of PFF exposure on PFF-induced α-synuclein aggregate 
development. iNs were generated from two iPD lines, and PFFs applied at day 3, 5, 10, 
17 or 22 post-transduction, before α-synuclein aggregate count (A) and area (B) per cell, 
and aggregate size (C), were quantified with immunocytochemistry. The number and area 
of PFF-induced aggregates were greatest at day 17 and day 10 respectively. Neuronal 
purity was calculated based on β3-tubulin expression. Error bars represent standard error 
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of mean. Statistical significance indicated by asterixes as determined by one-way 
ANOVA with post-hoc Tukey analysis. Abbreviations: iN = induced neuron; PFF = pre-
formed fibrils. 
 
Figure 4.23 – Effect of time of PFF exposure on PFF-induced α-synuclein aggregate 
development. When PFFs were applied at days 3 and 5 post-transduction few aggregates 
developed. The number of aggregates was greatest when PFFs were applied at day 17. 
Images acquired at day 27 post-transduction. Scale bar represents 100 µm. 
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In order to assess the ability of the PFF-induced aggregates to propagate pathology, iNs 
were generated from an iPD cell line which consistently developed high numbers of 
aggregates. Given that the majority of observed aggregates are extracellular, it was 
assumed that some would be present in the cell culture medium. The cell culture medium 
from iNs exposed to PFFs for 11 days was transferred to a second plate, containing iNs 
from the same cell line that were at day 16 post-transduction. These cells were then 
cultured for a further 11 days, and immunocytochemistry was performed to see if the 
PFF-induced aggregates could propagate pathology. No aggregates were observed in the 
recipient plate of the transferred medium, suggesting that the aggregates themselves did 
not propagate pathology (Figure 4.24). However, it should be noted that the concentration 
of aggregates in the medium was probably very low, considering the fact that aggregates 
are not observed in areas of the well in which there are no cells. To investigate whether 
the aggregates can propagate pathology, it will therefore probably be necessary to purify 
the aggregates prior to transmission to ensure comparable concentration to the application 
of PFFs. 
 
Figure 4.24 – Ability of PFF-induced aggregates to propagate pathology. A) PFF-
induced aggregates after PFF exposure in plate one. B) Absence of aggregates after 
transfer of medium from plate one to plate two. Scale bar represents 100 µm. 
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iNs were generated from iPD and GBA1-PD cell lines to assess whether or not PFF 
treatment induced an autophagy response. PFFs were applied at day 17, and protein was 
harvested after a further 72 hours for Western blot analysis. Though 
immunocytochemistry for neuronal markers was not performed, cells had taken on a 
typical neuronal morphology, with no overt differences between the cell lines 
(Supplementary Figure 7.5). In all cell lines LC3b-II levels increased following treatment 
with PFFs, suggesting that they induced an autophagy response, either directly or through 
the generation of α-synuclein aggregates. The increase in autophagosomes was significant 
in both the iPD group (p=0.036) and the GBA1-PD group (p=0.041), suggesting that the 
GBA1-PD group retained the ability to mount an autophagy response in this circumstance. 
P62/SQSTM1 levels were also reduced suggesting that the increase in autophagosome 
numbers was accompanied by an increase in autophagic flux, though this reduction was 
lower in the GBA1-PD group in which it failed to reach significance (p=0.101) suggesting 
that this response is reduced in this group (Figure 4.25). 
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Figure 4.25 – Impact of PFF treatment on autophagy in iNs. A) Western blot for LC3b 
in iNs from patients with GBA1-PD (n=3) and iPD (n=3) with or without PFF treatment. 
B) Western blot for P62/SQSTM1 in iNs from patients with GBA1-PD (n=2) and iPD 
(n=3) with or without PFF treatment. C) and D) Quantification of above. PFF treatment 
increased the numbers of autophagosomes in iPD and GBA1-PD iNs. P62/SQSTM1 
levels were reduced only in iPD iNs but not in GBA1-PD iNs. Error bars represent 
standard error of the mean. Statistical analysis comparing mean values for each group 
based on independent samples T tests, with significant differences indicated by asterixes. 
Abbreviations: iNs = induced neurons; PFF = Pre-formed fibrils. 
 
4.4.5 α-synuclein pre-formed fibril-induced mitochondrial pathology 
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PFF treatment had no effect on neuronal purity (Supplementary Figure 7.6). In order to 
explore whether treatment with PFFs resulted in mitochondria dysfunction a TMRE assay 
for mitochondrial membrane potential was performed in iNs derived from GBA1-PD and 
iPD patients that had been exposed to low or high dose PFF for 10 days. Interestingly, the 
GBA1-PD group demonstrated a statistically significant dose-dependent fall in 
mitochondrial membrane potential as judged by TMRE signal, in response to PFF-
exposure. TMRE signal fell by approximately 34.5 % (95 % confidence interval 24.6 % 
to 106.4 %) with the lower PFF dose (p=0.019), and by 46.2 % (95% confidence interval 
31.3 % to 76.4 %) with the higher dose (p=0.005). The mitochondrial membrane potential 
in the iPD group was reduced with PFF treatment by approximately 12 %, but this was 
not statistically significant (Figure 4.26). 
 
It was subsequently noted during further trials that in the iPD group, PFFs generally 
induced a decline in the mitochondrial membrane potential, but that this effect was less 
than that seen in GBA1-PD, such that it did not usually reach statistical significance. To 
further characterise the effect of PFFs on mitochondrial membrane potential, a 
retrospective analysis of all trials was performed in which the mean value for relative 
change in TMRE signal was determined for each cell line. This revealed a significant 
decline in mitochondrial membrane potential in the GBA1-PD group (p=0.015), with a 
non-significant decline in the iPD group. 
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Figure 4.26 – Mitochondrial membrane potential in iNs after treatment with PFFs. 
A) Treatment with α-synuclein resulted in a dose-dependent reduction in mitochondrial 
membrane potential in GBA1-PD (n=3) but not in the iPD group (n=3). B) A retrospective 
analysis of all trials of TMRE membrane potential in iNs from healthy controls (n=2), 
and patients with iPD (n=5) and GBA1-PD (n=3) revealed that GBA1-PD was the only 
group to develop a significant reduction in mitochondrial membrane potential. C) 
Representative images from analysis. Asterixes indicate statistically significant 
differences from vehicle control condition. Error bars represent standard error of the 
mean. Scale bar represents 200 µm. 
 
To further evaluate the susceptibility of GBA1-PD iNs to α-synuclein PFFs, caspase 
activity was assessed 10 days post-exposure to PFFs. Whilst there were no differences in 
caspase activity in the iPD group, the GBA1-PD lines demonstrated significantly 
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increased caspase activity (p<0.001 for 0.4 µg/µl PFF dose and p=0.002 for 1.5 µg/µl 
PFF dose), compared to those treated with vehicle control) (Figure 4.27). 
 
Figure 4.27 – Total caspase activity in iNs after treatment with PFFs. Caspase activity 
was increased in GBA1-PD (n=2) following PFF-exposure, but not in the iPD group. 
Asterixes indicate statistically significant differences from vehicle control condition as 
determined by one-way ANOVA with post-hoc Tukey analysis. Error bars represent 
standard error of the mean. Abbreviations: PFF = pre-formed fibrils. 
   
4.5 Discussion 
 
4.5.1 Lysosome-autophagy system dysfunction in GBA1 mutation-
associated Parkinson’s disease 
 
Abnormalities in the lysosome-autophagy system have consistently been observed in 
models of GBA1-PD, though the mechanisms by which autophagy is dysfunctional is not 
clear. Because macroautophagy is a dynamic process in continuous flux, it is a 
challenging system to study. Most studies in GBA1-PD observe changes in numbers of 
the constituents of the pathway (i.e. autophagosomes and lysosomes), but are unable to 
accurately define where the site of dysfunction lies. 
 
In this study, P62/SQSTM1 has been used as a measure of autophagy. LC3b was also 
studied, but it was not possible to obtain images of sufficient resolution to accurately 
count puncta in immunocytochemistry analyses.  P62/SQSTM1 levels following 
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starvation were significantly higher in the GBA1-PD fibroblasts than in healthy controls 
and in iPD patients, suggesting that autophagy activity was reduced in this group. 
 
Having found that autophagy activity was reduced in GBA1-PD fibroblasts, this was 
investigated further through inhibition of the late and early parts of the autophagy 
pathway using bafilomycin A1 and wortmannin respectively. Bafilomycin A1 blocks the 
fusion between lysosomes and autophagosomes, which, under normal circumstances 
would be expected to increase the numbers of autophagosomes (due to their reduced 
clearance), and to reduce the degradative capacity of macroautophagy (through reduced 
flux) (Klionsky et al. 2016). In the healthy control group bafilomycin treatment did indeed 
reduce autophagic degradative capacity, as evidenced by a significant increase in 
P62/SQSTM1 levels. There was a similar rise in the iPD group though this did not reach 
significance. In contrast, there was only a small change in P62/SQSTM1 levels in GBA1-
PD with bafilomycin treatment. Taken alone, this could be interpreted to suggest that 
there is a pre-existing block in the fusion stage of the autophagy pathway, such that 
introducing an inhibitor of this step causes no additional detriment to the pathway. 
Alternatively, if there is a problem at the earlier parts of the pathway (i.e. those involved 
in autophagosome formation), blockade of the fusion stages would have little impact on 
the degradative capacity of autophagy, because the pathway is already impaired upstream 
of this. 
 
Although the overall P62/SQSTM1 levels were not significantly altered in GBA1-PD, the 
number of P62/SQSTM1 puncta did rise significantly in this group after bafilomycin 
treatment, as in both of the other groups. There were no differences in autophagic flux, 
as determined by the difference between the number of P62/SQSTM1 puncta with 
bafilomycin treatment or vehicle control between any of the groups. It has been shown 
that most P62/SQSTM1 puncta represent autophagosomes or late endosomes (Bjørkøy et 
al. 2005). However, P62/SQSTM1 puncta may also represent sequestosomes – protein 
collections presumed to be targets for autophagic degradation, which accumulate under 
conditions in which autophagy is impaired (Klionsky et al. 2016). It would therefore be 
necessary to perform additional studies, for example visualisation of LC3b, to confirm 
that the increase in P62/SQSTM1 puncta witnessed with bafilomycin treatment does 
indeed represent preserved flux in the GBA-PD lines. This was attempted, but it was not 
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possible to visualise LC3b puncta in this project. Whilst the possibility that some 
P62/SQSTM1 puncta were sequestosomes remains, this data is most in keeping with the 
site of dysfunction being at the early steps of the autophagosome pathway, with GBA1-
PD being associated with a failure in the initiation of autophagy. 
 
Furthermore, when GBA1-PD lines were treated with the PI3K inhibitor wortmannin, 
there was a reduction in autophagic flux as evidenced by increased P62/SQSTM1 levels 
and increased P62/SQSTM1 puncta. In this instance, the puncta could clearly be seen to 
be relatively large in size, and to resemble sequestosomes. In contrast, there were no 
changes in these parameters in the other groups, suggesting that the GBA1-PD group were 
particularly susceptible to PI3K inhibition. In the healthy controls and iPD groups there 
was therefore sufficient reserve in the capacity for autophagy activation through PI3K-
dependent or independent pathways, despite wortmannin treatment. In contrast, the 
GBA1-PD group were unable to compensate for this insult, suggesting that they are 
particularly dependent on the PI3K-mediated pathway for autophagy activation, perhaps 
due to dysfunction in other PI3K-independent autophagy activation pathways, which are 
active in the other groups. Alternatively, it may be that there is a pre-existing partial 
deficit in PI3K-mediated autophagosome formation, such that wortmannin treatment 
caused complete failure of this process in GBA1-PD. 
 
Overall, this data suggests that the major problem with autophagy in GBA1-PD is most 
likely to be in the autophagosome formation stages of autophagy. A previous study using 
fibroblasts from many of the same cell lines used here was consistent with this idea. In 
contrast to healthy controls and iPD patients, in GBA1-PD patients there was no increase 
in autophagosome numbers (as determined by LC3b Western blot) after starvation, or 
with bafilomycin treatment (Collins et al. 2017). Drugs that are able to restore the process 
of autophagosome formation would therefore be of potential therapeutic interest in the 
subgroup of PD patients carrying GBA1 mutations. Lysosome numbers were also 
increased in GBA1-PD cell lines compared to healthy controls and iPD patients. This 
could occur due to a block in autophagosome-lysosome fusion, but alternatively could 
reflect a compensatory increase in chaperone-mediated autophagy activity, to compensate 
for a defect in the macroautophagy pathway. 
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It must be acknowledged that these experiments were performed in patient fibroblasts, 
rather than iNs. When P62/SQSTM1 staining was performed in iNs, there were no 
differences between any of the disease groups at baseline. However, a similar observation 
was made in the fibroblasts, in which the differences in autophagy function only became 
apparent when inducing autophagy through starvation, or when inhibiting various stages 
of the pathway. When LC3b-II levels were quantified after starvation, they were non-
significantly lower in iNs derived from GBA1-PD lines compared to healthy control and 
iPD lines, supporting the idea that initiation of autophagy is impaired in GBA1-PD. It 
would however, be useful for these experiments to be repeated in iNs with and without 
bafilomycin A1 and wortmannin treatment. Although the autophagy machinery behaves 
differently in different cell types (Menon, Kotlyarov and Gaestel 2011), the structures 
involved in autophagy are the same in fibroblasts as in neurons, and it is therefore 
reasonable to assume that the autophagy defect of GBA1-PD is present in neuronal cells 
also, although it is not known how the process of neuronal reprogramming itself affects 
the lysosome-autophagy pathway. During the reprogramming process, as the cell 
switches from one cell programme to another, there is likely to be an increase in protein 
and/or organelle turnover, which may result in altered lysosome-autophagy activity. 
Investigation of protein-clearance mechanisms in iNs may therefore be misleading, at 
least up to the point at which fibroblast properties have been fully eradicated, and a mature 
neuronal phenotype has been reached. Of course, the consequences of a dysfunctional 
lysosome-autophagy system will differ in relatively short-lived fibroblasts, to those in 
post-mitotic neurons in which there is the potential for abnormal protein aggregation. iNs 
were therefore employed to set up a model in which the potential consequences of 
neuronal autophagy dysfunction on protein aggregation could be investigated, with a view 
to using this for drug-screening. This model is discussed in section 4.5.3. 
 
4.5.2 Mitochondrial dysfunction in GBA1 mutation-associated Parkinson’s 
disease 
 
Mitochondrial dysfunction is thought to be important in PD pathogenesis, due to the facts 
that several of the hereditary forms of PD occur due to mutations in genes involved in 
mitochondrial health, and that mitochondrial toxins such as MPTP and rotenone can 
produce PD-like pathology in some models (Testa et al. 2005, Schapira 2008). The 
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lysosome-autophagy system is important in the turnover and removal of dysfunctional 
mitochondria, through the specific process of mitophagy (Geisler et al. 2010). GBA1 
mutation-associated autophagy dysfunction could therefore potentially allow for the 
persistence of abnormal mitochondria that would normally be removed, and mitophagy 
has indeed been shown to be impaired in the context of GBA1 mutation (Li et al. 2018).  
 
In this project, three parameters were used as indicators of mitochondrial health – 
mitochondrial superoxide production, mitochondrial membrane potential, and ATP 
production (with the latter only assessed in fibroblasts). However, no impairments in the 
GBA1-PD lines were detected in comparison to healthy controls or iPD patients at 
baseline. However, the sample size here was probably too limited to detect any small 
biological differences. Previous studies in which mitochondrial abnormalities have been 
detected in the context of GBA1 abnormalities have largely involved enzyme suppression, 
or transgenic rodents or cell lines with severe mutations (Cleeter et al. 2013, Xu et al. 
2014, Osellame et al. 2013). In contrast, the cell lines used in this project had mild 
mutations or variants, which may explain why no deficits in mitochondrial function were 
detected at baseline. 
 
As is discussed in section 4.5.3, mitochondrial dysfunction was identified specifically in 
GBA1-PD following treatment with α-synuclein PFFs. It is possible that PFF-induced 
aggregates result in mitochondrial dysfunction through an undefined process, with 
persistence of these depolarised mitochondria in the GBA1-PD group in which autophagy 
is defective. 
 
4.5.3 Treatment of induced neurons with α-synuclein pre-formed fibrils 
 
iNs offer a novel model for the study of pathology in neurodegenerative diseases. As 
discussed in chapter 3, there are challenges in working with iNs, including limited long-
term survival in culture. During the time-frame that iNs could be kept in culture in this 
study, no spontaneous formation of α-synuclein aggregates was observed. Other culture 
systems have required the introduction of a significant insult in order for α-synuclein 
aggregates to develop, such as overexpression of aggregate-prone mutant α-synuclein, or 
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inhibition of the ubiquitin-proteasome system (Rideout et al. 2001, El-Agnaf et al. 1998). 
Any manipulation of the system takes the model further away from the in vivo processes 
involved in pathogenesis in patients, so it is desirable to minimise such insults as much 
as possible. In this study, treatment with a single dose of α-synuclein PFFs were used to 
seed pathology in the recipient cell (Figure 4.28). PFFs have been used in other systems 
to result in aggregation of endogenous α-synuclein (Luk et al. 2009, Volpicelli-Daley et 
al. 2011). Whilst this acute dose of PFFs is not representative of the pathogenic processes 
occurring in patients, it allows for the generation of α-synuclein pathology in vitro, 




Figure 4.28 – PFF-induced α-synuclein aggregation in iNs. Treatment of iNs with α-
synuclein PFFs results in accumulation of extracellular aggregates, with smaller numbers 
of intracellular aggregates observed. It is presumed that PFFs seed aggregation of 
endogenous α-synuclein, and that the cell is able to clear the majority of these through 
exocytosis. 
 
The PFF-induced aggregates observed in this iN model were predominantly found 
extracellularly, situated adjacent to cells, with small numbers of intracellular aggregates 
observed. It was first important therefore to exclude the possibility that the observed 
aggregates in fact represented persisting PFFs. The observations that the aggregates were 
situated adjacent to cells, and not found in acellular regions within the well suggested that 
they were arising from the cells. Additionally, PFFs did not adhere to the culture matrix, 
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and fluorescent-tagged PFFs were cleared within a few days. These findings were in 
keeping with the hypothesis the α-synuclein content in the PFF-induced aggregates 
consisted of endogenous α-synuclein arising from the cells. This was supported by that 
fact that PFFs did not result in aggregates in fibroblasts (in which α-synuclein is not 
expressed), and confirmed through the transgenic expression of α-synuclein in 
fibroblasts, following which similar aggregates to those seen in iNs could be induced 
through PFF treatment. 
 
The nature by which the aggregates form remains unclear. It is possible that PFFs are 
taken up into the iNs, serving as a seed for aggregation of endogenous α-synuclein. A 
proportion of these aggregates may then be released by exocytosis, resulting in the 
accumulation of extracellular aggregates. The release of α-synuclein aggregates in the 
context of GBA1 dysfunction has been described in other in vitro models (Bae et al. 2014, 
Papadopoulos et al. 2018). The alternative possibility is that iNs release endogenous α-
synuclein into the culture medium, and PFFs lead to formation of the aggregates outside 
the cell. The latter explanation seems less likely given that: 
 
i. Aggregates are only observed adjacent to cells, and not in empty areas of the well. 
Whilst α-synuclein concentration in the medium may be greatest in the vicinity of 
cells, one would expect to see aggregates in all areas of the well if they were 
formed from extracellular α-synuclein 
ii. Some aggregates are observed intracellularly 
iii. There are downstream consequences of PFF treatment in intracellular processes 
(including a reduction in mitochondrial membrane potential and elevation of 
caspase activity). 
 
The PFF-induced aggregates do not resemble the Lewy bodies seen in patients with PD, 
but they potentially serve as a surrogate marker for the way in which the patient-derived 
iNs cope with α-synuclein aggregation. Additionally, the downstream consequences of 
PFF-induced aggregation can provide information about the vulnerability of a particular 
cell line to α-synuclein pathology. It has been argued that the progressive nature of PD 
occurs due to transmission of pathology between cells in a prion-like fashion, and the 
presence of the PFF-induced extracellular aggregates could relate to the degree to which 
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pathology would spread between cells in a particular cell line (Bae et al. 2014, Angot et 
al. 2010). As such, a reduction in the number of external aggregates would be a useful 
outcome measure when testing putative disease-modifying treatments. This is speculative 
however, and it should be acknowledged that transfer of medium from PFF-treated cells 
did not result in propagation of pathology (although it would be desirable to have purified 
the aggregates before attempting propagation, so that adequate concentrations could be 
used). 
 
The burden of PFF-induced aggregates was consistently higher in PD lines when 
compared to healthy controls, occurring in greater numbers and with lower concentrations 
of PFFs. This could mean that they are inherently more prone to the development of α-
synuclein aggregation, but the formation of these PFF-induced structures is dependent on 
a range of factors which will be discussed here. It is possible that variation in any of these 
factors could account for differences in the number of PFF-induced aggregates between 
cell lines. 
 
4.5.3.1 Factors relating to α-synuclein pre-formed fibril administration 
 
The extent of PFF aggregate accumulation in part depends on technical factors. These 
factors are consistent for all cell lines, so do not account for differences in the burden of 
aggregates between different groups. It is important to consider however, the timing of 
administration and duration of culture following administration of PFFs. At the early 
stages of conversion, only a limited number of cells will have progressed in their 
reprogramming to the point that α-synuclein is expressed at sufficiently high levels for 
PFFs to seed pathology. Application of PFFs at an early stage therefore results in only 
low levels of aggregate formation. Another requirement for the generation of aggregates 
is allowing sufficient time for endogenous α-synuclein to aggregate. Given that analyses 
in this system were generally performed between day 25 and 30 due to poor survival at 
later time points, application of PFFs at too late a stage will limit the time that cells can 
be cultured following PFF exposure, and therefore limit the formation of these aggregates.  
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The optimum time point of PFF administration is therefore a balance such that it is late 
enough for α-synuclein to be expressed at sufficient levels, and early enough to allow 
culture to continue for a sufficient duration. On testing different time points of 
administration, day 17 yielded the greatest number of aggregates, whilst administration 
at day 10 resulted in larger aggregates. Administration at day 22, which only allowed for 
five days of further culture reduced the number of aggregates that formed in comparison 
to early time points. Therefore, the optimal time for PFF administration is between day 
10 and day 17 in this system. 
 
4.5.3.2 Cell-related factors 
 
The significant variation that is observed in the number of aggregates between different 
lines could be due to a number of intrinsic factors related to the cell. Firstly, uptake of 
PFFs into the cell is likely to vary between different cell lines, which would influence the 
seeding effect, and the number of aggregates that form. Perhaps the most important 
variable in determining the number of aggregates is the ability of the particular cell line 
to reprogram, and to induce α-synuclein expression. Cell lines in which reprogramming 
is more effective will have greater levels of endogenous α-synuclein, and therefore a 
greater potential for aggregate development. In contrast, cell lines which reprogram 
poorly will have more limited expression of endogenous α-synuclein, and a lower 
capacity to generate aggregates. It is also possible that variations in the splicing of α-
synuclein or polymorphisms in the SNCA gene alter the propensity for aggregate 
formation between different cell-lines (Beyer 2006). 
 
Additionally, the activity of intracellular protein clearance mechanisms including the 
ubiquitin-proteasome and lysosome-autophagy systems is important. The rate by which 
cells clear PFFs, PFF-induced aggregates and any potential intermediate structures will 
influence the degree to which aggregates are able to accumulate. It is feasible that the 
trend towards higher PFF-induced aggregate counts in GBA1-PD is due to the fact that 
autophagy is impaired in these lines, but there are clearly several confounders. Even the 
GBA1-PD lines were able to initiate autophagy in response to PFF-treatment as evidenced 
by an increase in LC3b-II levels, though this response appeared diminished in comparison 
to the iPD group in which a decline in P62/SQSMT1 levels were also detected. The 
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relationship between PFF treatment and the lysosome-autophagy system is complex. The 
observed increase in LC3-II and reduction in P62/SQSTM1 levels imply that PFF 
treatment leads to activation of macroautophagy. It should be noted that these experiments 
were performed at an early stage following PFF-exposure, at a point when PFF-induced 
aggregates are not seen in high numbers. It is therefore likely that the autophagy response 
observed was against the PFFs themselves, potentially being important in their clearance. 
It has also been noted that PFF-induced aggregates in cell models impair autophagosome-
lysosome-fusion, and that the aggregates are resistant to degradation through autophagy 
(Tanik et al. 2013, Redmann et al. 2017). There seems therefore to be a picture in which 
the autophagy system is important in the clearance of exogenous PFFs, but that the 
proteasome is more important in the clearance of the PFF-induced endogenous α-
synuclein aggregates, which themselves impair function of the autophagy system. The 
apparent increase in vulnerability of GBA1-cell lines to PFF treatment could therefore 
either be due to a reduction in clearance of PFFs, or due to an aggregate-induced insult to 
an already impaired lysosome-autophagy system. 
 
Given these variables, it is not possible to say what the significance of a high number of 
aggregates is. Paradoxically, healthy cell lines which may be more likely to reprogram 
well may have higher levels of endogenous α-synuclein, and may therefore actually 
manifest a higher number of the aggregates. The relative degree to which each of these 
influences the accumulation of aggregates is not clear, and this is an area for further 
characterisation in the future. Having said this, the number of PFF-induced aggregates 
can be a useful marker for the handling of α-synuclein when comparing different 
conditions within the same line – for example determining the ability of a drug to reduce 
the number of aggregates. This system was therefore used for drug-screening, which is 
discussed in the next chapter. 
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Technical Factors Cell-Related Factors 
- Concentration of PFFs 
- Timing of PFF exposure 
- Duration of culture post-PFF 
- Uptake of PFFs 
- Endogenous α-synuclein levels 
- α-synuclein splicing pattern 
- Activity of intracellular protein-
clearance mechanisms 
- Ability to secrete via exocytosis 
- Vulnerability to α-synuclein-induced 
dysfunction 
- Disease-related factors 
- Health of cells in culture 
Table 4.2 – Variables contributing to burden of PFF-induced pathology in iN model. 
Abbreviations: PFF = Pre-formed fibrils. 
 
Furthermore, treatment with PFFs resulted in mitochondrial abnormalities in the GBA1-
PD group, in the form of reduced mitochondrial membrane potential. The effect in iPD 
was less, with this group developing smaller declines in mitochondrial membrane 
potential, which generally failed to reach statistical significance. One could speculate that 
the PFF-induced aggregates (or an unseen intermediate) result in mitochondrial 
dysfunction, with abnormal mitochondria being cleared in healthy controls and iPD cell 
lines. With the autophagy, and presumably mitophagy, defect associated with GBA1-PD 
these unhealthy mitochondria may persist in the cell. Furthermore, there was an increase 
in caspase activity following PFF-treatment in the GBA1-PD group, with no change in 
the iPD group, supporting the fact that the GBA1-PD group are more susceptible to PFF-
induced pathology than the iPD group. Whilst caspase activity was elevated in GBA1-PD 
after treatment with PFFs, this effect was not dose-dependent, with a smaller increase 
after exposure to the higher dose. This may be explained by increased prior cell death 
after exposure to the higher dose, and it would be useful to test this after exposing iNs to 
multiple intermediate doses of PFFs. iNs seemed to mount an autophagy response 
following PFF treatment, as evidenced by increased LC3b-II levels. This happened in 
GBA1-PD iNs as well as iPD iNs, suggesting that dysfunction of autophagy initiation 
does not fully explain the increased susceptibility of GBA1-PD iNs to PFF-treatment. It 
could be speculated that dysfunction of mitophagy specifically (of which there is evidence 
in GBA1-PD (Li et al. 2018)), accounts for the increased vulnerability to PFF-induced 
pathology in GBA1-PD, though this has not been investigated here.  
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The relationship between PFF-induced aggregates and mitochondrial function would be 
interesting to characterise further, for example through the determination of other 
mitochondrial parameters including ATP production and oxygen consumption, following 
PFF treatment. In particular, it would be interesting to see whether the PFF-induced 
aggregates themselves were pathological (which could be achieved by purifying these 
and applying them to the cells), or whether this was due to an alternative mechanism. 
 
4.5.4 Concluding remarks 
 
In this study, abnormalities in the function of the lysosome-autophagy system have been 
demonstrated in GBA1-PD fibroblasts, in keeping with previous evidence. In order to 
develop a drug-screening model using a relevant cell type, iNs were generated as 
described in chapter 3. Because no spontaneous α-synuclein aggregates were observed, a 
single dose of α-synuclein PFFs was used to induce aggregate formation, without 
interfering with biochemical pathways within the cells. This resulted in the formation of 
aggregates, and the development of relevant downstream pathology, which was much 
greater in the GBA1-PD group compared to healthy controls and iPD patients. These 
objective and reproducible outcome measures were used as the basis for drug-screening 
studies in GBA1-PD which are discussed in the next chapter.
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There are currently no disease-modifying treatments for PD, with medical treatment 
focussing on the control of motor symptoms through restoration of striatal dopamine 
levels. The failure of promising pre-clinical results to translate to clinical benefit in trials 
is in part due to limitations of our existing experimental models, which rely on the use of 
transgenic animals or cell lines, or neurotoxins, which fail to mimic the pathogenic 
processes occurring in patients. In this study, patient-derived iNs have been used to 
provide a source of adult human neurons, which retain the age signature and genetic risk 
profile of the host. Four agents were tested for their ability to reduce pathology in this 
system. Of these, trehalose significantly reduced the burden of α-synuclein PFF-induced 
pathology in the GBA1-PD group, whilst nortriptyline produced similar results in the iPD 
group. These drugs are therefore of interest for further testing, and consideration of 
trialling in patients. 
 
5.2 Introduction to chapter 
 
There are currently no disease-modifying treatments for PD, with pharmaceutical 
treatment being limited to dopaminergic drugs which improve some of the motor 
symptoms without altering the course of disease or treating many of the non-motor 
manifestations. Discovery of novel putative disease-modifying treatments has been 
hindered by the lack of a truly representative model for PD. Animal models involve a 
significant insult (often acutely), such as overexpression of mutant SNCA or the use of 
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toxins, to yield a clinical phenotype or relevant pathology, which does not reflect the 
pathogenic mechanisms seen in patients, so even if an agent is shown to be beneficial in 
these systems, the ability to translate it to a clinical setting will remain uncertain (Beal 
2001). As is discussed in chapter 3, iPS-derived neuronal in vitro models essentially 
represent embryonic neurons, so it is likely that the effect of a drug in these cells will 
differ to that in the cells affected in PD (aged neurons), so that these models may also 
have a limited ability to predict clinical utility of a drug (Horvath 2013, Lapasset et al. 
2011, Prigione et al. 2011). As well as the development of novel agents, there is much 
recent interest in the repurposing of existing drugs for their possible use in 
neurodegenerative diseases, meaning that there are potentially large libraries of 
compounds that may be considered for trials. Given the expense associated with 
conducting clinical trials, an effective drug-screening model would be invaluable in 
prioritising the choice of drugs for entry into the clinical setting. Demonstration of 
efficacy in a number of model systems including in vitro and animal models is likely to 
be required for progression of a novel agent to clinical trials, but for existing drugs in 
which safety data is well established, efficacy in a representative in vitro system may be 
sufficient to proceed to clinical testing. 
 
iNs theoretically offer a useful in vitro system for drug screening. iNs are patient-derived, 
so retain the intracellular environment associated with PD risk determined by as yet 
poorly understood polygenic risk factors, and also retain the effects of age (Mertens et al. 
2015, Kim et al. 2018, Huh et al. 2016) . In doing so, the effect of a drug in an iN system, 
may more closely represent the effect that the drug will have in an aged neuron in a 
patient. iNs may therefore be more useful in predicting the utility of a drug than existing 
models are. The use of iNs for drug screening to date has however been limited to only a 
small number of studies (Liu et al. 2016b). In this project, iNs have been used to screen a 
number of agents for their ability to reduce pathology in GBA1-PD neurons. 
 
5.3 Drug screening models for Parkinson’s disease 
 
Translation of promising experimental results to clinical trials in PD has been 
disappointing, with no disease modifying treatments identified (Stocchi and Olanow 
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2003, Elizan et al. 1989). This is in part due to the fact that existing disease models fail 
to truly reflect the pathogenic processes occurring in patients. Here, the main established 
models for drug screening in PD are discussed. 
 
Transgenic or neurotoxin-based animal models are frequently used to investigate the 
potential neuroprotective effects of drugs in PD. Ideally, these animal models should 
possess a relevant phenotype (a slowly progressive motor disorder with non-motor 
features such as cognitive impairment), neurodegeneration of relevant brain regions, and 
relevant pathology in the form of α-synuclein inclusions. However, most published 
models fail to recapitulate at least one of these features, and reproducibility is often a 
problem. The use of MPTP in non-human primates is perhaps the most representative 
model for drug screening, in that animals develop the cardinal motor features of PD, in 
addition to non-motor features including constipation and cognitive impairment, 
associated with neurodegeneration at relevant sites (Varastet et al. 1994, Forno et al. 1986, 
Bergman, Wichmann and DeLong 1990, Kowall et al. 2000). However, Lewy body 
inclusions are not consistently observed, and the neurodegeneration occurs acutely, which 
is not representative of PD. Furthermore, the way in which a drug behaves and is 
metabolised in a non-human cell may be significantly different to the way in which it acts 
in a human cell, which may partly explain why clinical trials have so far been 
disappointing. The use of transgenic animals in which mutant, aggregation-prone forms 
of α-synuclein or supraphysiological levels of wild-type α-synuclein are expressed are 
limited by the fact that these insults fail to provide any insight into the upstream processes 
that lead to α-synuclein accumulation under physiological circumstances, and that they 
do not recapitulate the cardinal features of PD (Beal 2001). 
 
While animal models will continue to play an important role in pre-clinical studies of 
putative treatments for PD, a human model would potentially more faithfully represent 
the ability of a drug to impact on relevant pathological pathways. Given the emerging 
interest in the potential for repurposing drugs, it is also important for a model to be 
scalable, to allow for large numbers of drugs to be easily tested, and prioritised for entry 
to clinical trials. Overexpression of wild-type or mutant α-synuclein in standard human 
cell lines, such as neuroblastoma cells, potentially allows for investigation of the effects 
of test drugs on α-synuclein homeostasis and aggregation (Bar-On et al. 2008). However, 
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an immortal cell line is inherently different to the post-mitotic neurons in which PD 
pathology occurs, so the relevance of findings in these models is questionable, when it 
comes to deciding which drugs are likely to herald a clinical benefit. 
 
In order to more closely recapitulate the environment in which PD pathology occurs in 
patients, iPSC-derived neurons have also been employed (Cooper et al. 2012). This 
approach uses cells from PD patients, so retains the currently poorly defined polygenic 
risk profile associated with the development of PD. Additionally, it allows for the 
investigation of drugs in human post-mitotic, subtype-specific neurons, potentially 
providing a more relevant intracellular environment for the study of pathology and drug 
effects. However, as discussed in chapter 3, the neurons derived from iPSCs are 
embryonic, and given that embryonic neural cells do not develop PD pathology in vivo, 
these cells may miss important contributors to PD pathogenesis. Indeed, the induction of 
α-synuclein aggregates has not been possible without introducing additional insults, such 
as proteasome inhibition (Rideout et al. 2001). 
 
A potential novel alternative system for screening drugs in human neurons is to use iNs. 
As well as retaining inherent genetic risk factors, iNs also retain the effects of ageing on 
intracellular processes such as mitochondrial function and protein-clearance mechanisms, 
so may have a greater value in terms of predicting the behaviour of a drug on protein 
aggregation and related pathology (Mertens et al. 2015, Kim et al. 2018, Huh et al. 2016). 
However, to date the use of iNs for drug screening has been limited to only a few studies, 
which are discussed in chapter 3, and the practicality of using iNs as a drug-screening 
model for PD has not been clearly established. 
 
5.4 Overview of putative disease-modifying 
approaches in Parkinson’s disease 
 
For a drug to have a disease-modifying effect in PD, it will need to slow or stop the death 
of affected neurons in the substantia nigra, as well as the other sites of pathology such as 
the cortex. Given the importance of α-synuclein in PD pathology, most proposed disease-
modifying approaches centre on reducing production or aggregation of α-synuclein, 
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enhancing clearance of α-synuclein, or limiting the consequences of α-synuclein 
aggregation on intracellular processes and pathways (Figure 5.1) (Brundin et al. 2017). 
In addition, there are subgroups of PD patients, for example GBA1-PD, in which a specific 
genetic abnormality may be targeted. Here, the existing experimental therapeutic 
approaches are introduced. 
 
5.4.1 Approaches involving reduction of α-synuclein 
 
The pathogenic potential of α-synuclein may be reduced at several levels: 
 
i. Reduced synthesis of α-synuclein 
ii. Reduced aggregation of α-synuclein 
iii. Enhanced clearance of α-synuclein through intracellular pathways 
iv. Removal of extracellular α-synuclein (Stoker et al. 2018b) 
 
One approach to reducing α-synuclein synthesis is to inhibit transcription of the SNCA 
gene. α-synuclein expression is reduced by the β2-adrenergic receptor agonist clenbuterol 
in neuroblastoma cells and rat cortical neurons, and the use of such agonists has been 
associated with a reduced risk of PD in a large epidemiological study (Mittal et al. 2017). 
α-synuclein production may also be targeted at the level of translation, through RNA 
interference technologies, using synthetic RNA molecules to trigger degradation of the 
SNCA mRNA. Lentiviral delivery of a shRNA targeting α-synuclein suppressed α-
synuclein expression in neuroblastoma cells and in a rodent model (Sapru et al. 2006), 
while infusion of a short-interfering RNA (siRNA) reduced α-synuclein levels in mice 
and non-human primates (Lewis et al. 2008, McCormack et al. 2010). It should be noted 
that the normal function of α-synuclein is not known, and there are concerns about the 
potential effects of loss of the physiological function of α-synuclein, with some studies 
reporting significant neurotoxicity when α-synuclein expression is suppressed 
(Gorbatyuk et al. 2010, Robertson et al. 2004, Kanaan and Manfredsson 2012). 
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The clearance of α-synuclein may potentially occur through intracellular or extracellular 
mechanisms. A number of α-synuclein immunotherapies have entered clinical trials, 
which are designed to reduce extracellular α-synuclein and hence prevent propagation of 
pathology – these treatments are not discussed in detail here, given that they are not 
suitable for trialling in the iN model (Stoker et al. 2018b). Drugs that enhance 
macroautophagy, chaperone-mediated autophagy or proteasome activity (pathways all 
known to be involved in α-synuclein clearance (Webb et al. 2003)) would potentially 
reduce baseline levels of α-synuclein within the cell. In particular, in groups such as 
GBA1-PD in which there is an inherent autophagy deficit, targeting the lysosome-
autophagy system may offer the optimal approach to reducing α-synuclein pathology. 
Indeed, some chaperone molecules which facilitate the transfer of GCase to the lysosome, 
and hence restore GCase enzyme activity have entered clinical trials (Bendikov-Bar et al. 
2013, McNeill et al. 2014, Stoker et al. 2018b). 
 
5.4.2 Other putative disease-modifying approaches 
 
Other experimental treatments in PD have involved delivery of genes or molecules 
thought to be protective. For example, GDNF and its naturally occurring analogue, 
neurturin, have been found to enhance survival of dopaminergic neurons in animal 
models of PD (Eslamboli et al. 2005, Gash et al. 1996, Gasmi et al. 2007, Kordower et 
al. 2006). However, clinical trials have yielded disappointing results so far (Marks et al. 
2010, Whone et al. 2019). 
 
Because mitochondrial dysfunction has been implicated in PD, mitochondrial oxidant 
stress has also been considered as a target for treatment in PD. Results have however, 
been inconsistent with no clear benefit demonstrated. Co-enzyme Q10 (an antioxidant 
molecule) was reported to reduce accumulation of disability in a small study (Shults et al. 
2002), though this could not be reproduced in other trials (Storch et al. 2007). Similarly, 
the antioxidants mitoquinone (a compound designed to enhance delivery of ubiquinone 
(the active element of Co-enzyme Q10) to mitochondria) and tocopherol failed to show 
any clinical benefit (Snow et al. 2010, Parkinson_Study_Group 1993). 
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Figure 5.1 – Experimental disease-modifying strategies for PD. Adapted from (Stoker 
et al. 2018b) 
 
5.4.3 Introduction to drugs investigated in the induced neuron model 
 
It is likely that the PD population consists of subgroups of patients in whom different 
pathogenic mechanisms predominate. As such, the optimal disease-modifying approach 
may differ in different groups, and as disease-modifying treatments emerge, precision 
medicine may mean that patients receive tailored treatment regimes in which the 
predominant pathogenic mechanisms are targeted. The use of iNs, in which the hosts 
genetic susceptibility factors are retained, allows for the investigation of, and targeting of 
the most relevant pathogenic processes in individual patients or specific groups of 
patients. Here, iNs have been used to screen drugs for their ability to reduce pathology in 
GBA1-PD. Since GBA1-PD pathology has been consistently shown to involve lysosome-
autophagy dysfunction, drugs potentially augmenting autophagy have been selected. 
Additionally, because mitochondrial dysfunction was evident in the PFF-model in GBA1-
PD iNs, drugs with putative effects on mitochondrial health have also been tested in this 
model. 
 
5.4.3.1 Drugs targeting the lysosome-autophagy system 
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In this project, trehalose and nortriptyline have been tested in the iN model, both of which 
have been shown to increase autophagy activity in experimental models. Trehalose is a 
naturally occurring non-mammalian disaccharide which plays an important role against 
cellular stresses, such as temperature aberrations, oxidation and dehydration, which has 
in particular been characterised in yeast (Kandror et al. 2004, Chen and Haddad 2004). 
Trehalose reduces in vitro formation of amyloid from bovine insulin (Arora, Ha and Park 
2004) and aggregation of amyloid-β (Liu et al. 2005), prompting interest as a putative 
therapeutic agent for neurodegenerative disorders associated with protein aggregation. 
Similarly, trehalose reduced the aggregation of aggregation-prone tau (with the fronto-
temporal dementia with Parkinsonism-associated with chromosome 17 (FTDP-17) 
mutation ΔK280) (Krüger et al. 2012). In these in vitro studies it was suggested that 
trehalose was able to reduce aggregation by stabilisation of hydrophilic groups on the 
protein, allowing for the normal structure to be maintained (Arora et al. 2004). 
 
In another study of neuroblastoma cells expressing huntingtin with 60 or 150 
polyglutamine tracts, trehalose led to a dose-dependent reduction in huntingtin aggregate 
formation, and increase in cell viability (Tanaka et al. 2004). The authors suggested that 
the mechanism of action was the binding of trehalose to the expanded polyglutamine 
repeats, stabilising the partially unfolded protein. Trehalose also reduces the aggregation 
of poly-A-binding nuclear protein-1 (PABPN1) – another protein containing an abnormal 
trinucleotide repeat (Davies, Sarkar and Rubinsztein 2006). 
 
These studies all provided some evidence that trehalose directly reduces the aggregation 
of proteins. However, in addition to reducing the formation of aggregates, trehalose has 
also been shown to increase their clearance through activation of autophagy, and it is 
possible that it acts through multiple mechanisms (Table 5.1). In Cos-7 cells expressing 
huntingtin with a 74 polyglutamine repeat, trehalose reduced the burden of huntingtin 
aggregates – an effect that was abrogated by concomitant treatment with the autophagy 
inhibitor three-methyladenine (3-MA). The therapeutic role of autophagy was supported 
by the fact that trehalose could not induce clearance of aggregates in autophagy 
incompetent murine fibroblasts. Trehalose also increased autophagosome formation as 
demonstrated by increased LC3b-II levels and puncta in a number of cell types, including 
primary cortical neurons (Krüger et al. 2012, Sarkar et al. 2007). mTOR activity was not 
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affected by trehalose treatment, suggesting that trehalose activated autophagy in an 
mTOR-independent manner (Sarkar et al. 2007). Trehalose has also been shown to 
increase autophagy in vivo, using a PD mouse model, in which decreased P62/SQSTM1 
levels were detected after 2.5 months of treatment, along with increased LC3b-II levels 
indicative of increased autophagosome numbers (Rodríguez-Navarro et al. 2010). 
Increased LC3b-II levels have also been seen in primary mouse cortical neurons after 
treatment with trehalose, with this effect increasing with time over 14 days of treatment 
(Redmann et al. 2017). However, in this latter study in which α-synuclein PFFs were used 
to induce formation of phosphorylated α-synuclein aggregates in primary cortical neurons 
trehalose did not alter the number of aggregates that accumulated (Redmann et al. 2017). 
 
Clinical benefits have also been noted with trehalose treatment in animal models of 
neurodegenerative diseases. Trehalose led to preserved strength in transgenic mice 
expressing mutant PABPN1 in a model of oculopharyngeal muscular dystrophy (Davies 
et al. 2006). It has also been shown to reduce weight loss and improve motor function in 
the R6/2 model of Huntington’s disease, as well as pathology including striatal atrophy 
and intranuclear protein inclusions (Tanaka et al. 2004). Motor function was also 
improved, and loss of TH-positive neurons prevented with trehalose in transgenic and 
neurotoxin rodent models of PD (Rodríguez-Navarro et al. 2010, Sarkar et al. 2014). 
Striatal dopaminergic neurons and dopamine metabolites were also increased by 
treatment in this model, suggesting a neuroprotective effect for trehalose.
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Study Protein Model Effect of trehalose 
Arora et al. 2004 Insulin In vitro purified protein aggregation Reduced aggregation 
Liu et al. 2005 Amyloid-β In vitro purified protein aggregation Reduced aggregation 
Tanaka et al. 
2004 
Myoglobulin (35 polyQ repeat) In vitro purified protein aggregation Reduced aggregation 
Huntingtin (60 or 150 polyQ 
repeats 
Neuroblastoma neuro2A cells Reduced aggregation 
Increased cell viability 
Huntingtin (expanded polyQ 
repeat) 
R6/2 transgenic mice Reduced weight loss 
Reduced striatal atrophy 
Reduced intranuclear aggregates 
Improved motor function and survival 
Davies et al. 2006 PolyA binding protein nuclear 1 
(17 polyA repeat)  
Cos7 cells Reduced proportion of cells containing aggregates 
Transgenic mice Improved motor performance 
Reduced intranuclear aggregates 
Sarkar et al. 2007 Huntingtin (74 polyQ repeat) Cos7 cells 
SK-N-SH cells  
Reduced aggregate numbers 
Reduced cell death 
Inducible PC12 cells Increased clearance of soluble and insoluble Huntingtin polyQ74 
Reduced aggregate numbers 
α-synuclein (A53T and A30P) Inducible PC12 cells Increased clearance of mutant α-synuclein 
Sarkar et al. 2014 N/A MPTP-treated mice Reduced loss of nigral and striatal dopaminergic neurons and terminals 
Reduced astroglial and microglial activation 
Rodríguez-
Navarro et al. 
2010 
Tau Transgenic mice overexpressing human tau 
with double knock-out of parkin  
Improved motor and cognitive performance 
Reduced levels of tau 
Reduced numbers of tau neuritic plaques 
Reduced astrogliosis 
Preservation of TH+ neurons and fibres in midbrain and striatum 
(benefits only short-term in striatum) 
Krüger et al. 
2012 
Tau Primary rat cortical neurons Reduced levels of tau 
Transgenic N2A cells with pro-aggregant 
tau 
Reduced proportion of cells with tau aggregates 
Reduced cytotoxicity 
In vitro protein aggregation Reduced aggregation 
Redmann et al. 
2017 
α-synuclein Primary mouse cortical neurons treated 
with α-synuclein PFFs 
No change in number of aggregates 
 Table 5.1 – Effects of trehalose in studies of protein aggregation and neurodegenerative disease. Abbreviations: polyA = polyalanine, polyQ = 
polyglutamine.
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Nortriptyline is a tricyclic antidepressant drug used predominantly to treat depression and 
neuropathic pain. It has been used in clinical practice since the 1960s and is commonly 
prescribed, meaning that its safety profile is well known. Several studies have shown 
nortriptyline and the tricyclic antidepressant drug amitriptyline (of which nortriptyline is 
the active metabolite) to increase autophagy activity. In neuronal and astrocytic cultures, 
amitriptyline was shown to increase autophagosome levels within 12 hours. The increased 
LC3b puncta were found to co-localise with acidic vesicles suggesting that the increase 
was due to activation of autophagy rather than a fusion block. The use of bafilomycin A1 
had an additive effect, supporting the fact that amitriptyline was leading to increased 
autophagosome formation (Zschocke and Rein 2011). LC3b puncta have also been seen 
to increase in HeLa cells treated with nortriptyline (Rossi et al. 2009). Similar findings 
have been reported in vivo, after injection of amitriptyline into mice, where increases in 
beclin, and the autophagy-related protein atg12 were observed. However, it should be 
noted that atg12 is also known to promote apoptosis, and it is possible that activation of 
apoptotic pathways could account for this. Increased LC3b-II to LC3-I ratio was seen in 
the prefrontal cortex of mice injected with amitriptyline, suggesting that autophagosome 
numbers were increased (Gassen et al. 2014). 
 
In another study, a high-throughput assay was developed, in which mycobacterial 
survival in macrophages was measured and used to test 2000 compounds from a bioactive 
library (Sundaramurthy et al. 2013). Autophagy is impaired by mycobacteria – an 
adaptation of the microorganisms that facilitates intracellular survival (Gutierrez et al. 
2004). Three agents were found to reduce mycobacterial survival, one of which was 
nortriptyline. The reduction in mycobacterial survival was brought about by the ability of 
nortriptyline to overcome the arrest in phagosome maturation induced by mycobacteria. 
Nortriptyline resulted in increased delivery of mycobacteria into late endocytic 
compartments, increased  autophagosome numbers, and a reduction in the number of 
surviving mycobacteria, which was reversed by the autophagy inhibitor 3-MA. Combined 
with the fact that fusion blocking agents (bafilomycin and chloroquine) led to a further 
increase in autophagosome numbers, this data supports the suggestion that nortriptyline 
is able to increase autophagy activity. It should be noted that the effective concentrations 
were higher than that achieved in the serum of patients currently treated with 
nortriptyline, so more potent preparations may be necessary for nortriptyline to be 
clinically useful with regard to interaction with autophagy and the treatment of PD. 
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Finally, it is also possible that nortriptyline could reduce α-synuclein pathology through 
other mechanisms. In a recent study involving numerous models, nortriptyline was found 
to reduce aggregation of α-synuclein, rather than increase its clearance. This included a 
dose-dependent delay in aggregation of recombinant α-synuclein, thought to be due to 
interaction with monomeric α-synuclein and prevention of the formation of high-
molecular weight species. In neuroblastoma cells overexpressing mutant aggregation-
prone α-synuclein, nortriptyline at a concentration of 3 µM led to a reduction in 
inclusions, without reducing overall protein levels. Aggregate numbers were also reduced 
in the brains of rats injected with α-synuclein PFFs, and neuronal survival was improved 
in the nigra of rats, and the retina of drosophila expressing mutant α-synuclein (Collier et 
al. 2017). 
 
5.4.3.2 Drugs targeting mitochondrial function 
 
Two drugs were investigated in the iN model, due to previous studies suggesting that they 
had beneficial effects on mitochondrial homeostasis – metformin and ghrelin. 
 
Metformin (1,1-dimethylbiguanide hydrochloride) is a drug widely used in the treatment 
of diabetes mellitus type two. It has been shown to affect a number of intracellular 
pathways, and has been suggested to have beneficial effects on mitochondrial function, 
and has thus been considered to be of potential interest in targeting PD pathogenesis. 
 
Clinical data regarding the effect of metformin on PD is very limited. In a retrospective 
cohort of patients with type two diabetes, it was found that sulphonylurea drugs increased 
the risk of PD, but concomitant treatment with metformin abrogated this risk, with the 
authors suggesting that metformin potentially played a protective role against the 
development of PD (Wahlqvist et al. 2012). In MPTP-treated mice, metformin has been 
found to have neuroprotective effects and improved motor performance (Lu et al. 2016, 
Patil et al. 2014). Similar findings have been reported in mice treated with 3,4-
methylenedioxymethamphetamine (MDMA), in which metformin prevented loss of 
nigral and striatal TH-positive neurons and fibres (Porceddu et al. 2016). 
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Metformin has been found to correct mitochondrial abnormalities in LRRK2 G2019S 
transgenic Drosophila (Ng et al. 2012), reduce oxidative stress in MPTP-treated mice 
(Patil et al. 2014), and reduce reactive oxygen species, and correct mitochondrial 
membrane potential in SH-SY5Y cells treated with MPP+ (Lu et al. 2016). Additionally, 
metformin reduces levels of phosphorylated α-synuclein in SH-SY5Y cells 
overexpressing human α-synuclein, and in primary hippocampal neurons and normal 
mouse brain (Pérez-Revuelta et al. 2014).  
 
Though the mechanisms through which metformin may act remain unclear, it is known 
to activate AMPK (Zhou et al. 2001, Lu et al. 2016), which results in changes to a number 
of intracellular processes with the aim of conserving and generating energy (Hardie 2004, 
Amato and Man 2011). As has been discussed in section 4.2.1.1 AMPK is also involved 
in the initiation of autophagy, directly or through inhibition of mTOR, and metformin has 
been shown to increase autophagy activity in MPTP-treated mice (Lu et al. 2016) and 
PC12 cells treated with rotenone (Hou et al. 2015). Metformin has also been reported to 
inhibit mitochondrial complex one, thereby causing a reduction in oxidative 
phosphorylation (El-Mir et al. 2000). Whilst a reduction in mitochondrial energy 
production may seem detrimental, it is possible that this action of metformin leads to a 
reduction in reactive oxygen species and subsequent oxidative stress. To summarise, 
metformin alters mitochondrial biology in a number of models, and has been reported to 
have beneficial effects on PD-relevant pathology. However, the mechanisms through 
which it acts remain poorly defined. 
 
Ghrelin is a growth hormone secretagogue produced predominantly in the gastric mucosal 
cells, with its main biological function being to increase appetite (Stoyanova 2014). It 
exists in the plasma in acylated and de-acylated forms, and acts on the growth hormone 
secretagogue receptor one-a (GHSR1a), which is expressed abundantly in the substantia 
nigra (Jiang et al. 2008, Moon et al. 2009). The post-prandial ghrelin response has been 
reported to be altered in PD patients compared to healthy controls, prompting some 
interest that ghrelin may play a role in PD (Unger et al. 2011). 
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Several studies have found that ghrelin protects against loss of TH-positive neurons in 
the substantia nigra, and dopaminergic terminals in the striatum in mice treated with 
MPTP (Bayliss et al. 2016b, Andrews et al. 2009, Jiang et al. 2008, Moon et al. 2009). 
Similar results have been seen in a cell model, in which ghrelin prevented MPP+ induced 
cell death (Dong et al. 2009). Additionally, ghrelin knock-out mice are more susceptible 
to MPTP-induced neurodegeneration than their wild-type counterparts (Andrews et al. 
2009). Ghrelin treatment has also been associated with improved motor performance in 
MPTP-treated mice (Bayliss et al. 2016b, Moon et al. 2009). 
 
Several potentially important mechanisms have been identified that may contribute to 
ghrelin’s protective effect. Microglial activation is reduced by ghrelin in MPTP-treated 
mice (Bayliss et al. 2016a, Moon et al. 2009). Other studies have found ghrelin to reduce 
levels of the pro-apoptotic protein Bcl-2, and reduce caspase-3 activity indicating reduced 
levels of apoptosis, following MPTP treatment (Jiang et al. 2008, Dong et al. 2009). An 
important effect of ghrelin in these neurotoxin models is improvements in mitochondrial 
function. Mitochondrial numbers and functional capacity have been noted to be improved 
by ghrelin treatment, including in the substantia nigra of mice, possibly due to increased 
expression of the transcription factor nuclear respiratory factor 1 (Nrf1) which is known 
to be important in mitochondrial biogenesis (Andrews et al. 2008, Andrews et al. 2009). 
In cells treated with MPP+, ghrelin led to restoration of mitochondrial membrane 
potential, and reduced reactive oxygen species production (Dong et al. 2009). These 
effects are dependent on the expression of the mitochondrial uncoupling protein UCP-2, 
which is known to be important in neuronal survival following MPTP treatment (Andrews 
et al. 2005, Andrews et al. 2008, Andrews et al. 2009). Similarly to metformin, ghrelin is 
known to activate AMPK (Andrews et al. 2008, Bayliss et al. 2016b, Andersson et al. 
2004), which has been suggested to have an effect upstream of UCP-2 (Andrews et al. 
2008). 
 
The protective effects of ghrelin also appear to be dependent on GHSR1a, as they are 
diminished in transgenic animals deficient of this receptor, and when GHSR1a 
antagonists are employed (Andrews et al. 2008, Moon et al. 2009, Jiang et al. 2008). 
Another point of note is that acylated ghrelin is required to convey protection in MPTP-
treated mice, with deacylated ghrelin being ineffective (Bayliss et al. 2016a). 
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Here, four drugs have been tested in the iN model of PFF-induced α-synuclein 
aggregation. Two of these, trehalose and nortriptyline, were selected for their previously 
reported ability to enhance autophagy and potentially enhance the clearance of PFFs and 
induced aggregates. Metformin and ghrelin where also selected for their beneficial effects 
on mitochondrial function, with the hypothesis that they would reduce the downstream 
consequences of PFF treatment. 
 




Immunocytochemistry was performed as described in section 4.3.1. Primary antibodies 
used were anti-P62/SQSTM1 (1:500; abcam 91526), anti-β3 tubulin mouse (1:1000; 
abcam 78078), anti-β3 tubulin rabbit (1:1000; abcam 18207), and anti-α-synuclein mouse 
(1:1000; BD biosciences 610787). High-throughput analysis using the CellomicsTM XTI 
microscope was used to determine mean intensity and spot count data using the spot count 
and cell health profiling protocols. When assessing the effect of nortriptyline treatment 
on PFF-induced α-synuclein spot count, images were acquired manually using the Leica 
DMi8 epifluorescence platform microscope. Five images per condition were acquired, 
and spot analysis was performed using ImageJ software, with the mean value for the five 
fields used for statistical analysis. 
 
5.5.2 Western blot analysis 
 
Western blot analysis was performed as described in section 4.3.9 
 
5.5.3 Treatments and Reagents 
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Trehalose (Sigma T0167) was dissolved directly into fibroblast or neuronal medium to 
give a working concentration as indicated below. Nortriptyline (Sigma N7261) was 
dissolved in ultrapure water to give a 10mM stock solution. Metformin hydrochloride 
(Sigma BP2227) was dissolved in ultrapure water to give a 200 mM stock solution. 
Recombinant human ghrelin (Tocris 1463) was dissolved in ultrapure water to give a 1 
mM stock solution. Stock solutions of nortriptyline, metformin or ghrelin were diluted to 
the appropriate concentration in cell culture medium. All treatments were passed through 
a sterile 0.2 µm filter prior to application to cells. Bafilomycin A1 was prepared as 
described in section 4.3.1. 
 
5.5.4 TMRE assay for mitochondrial membrane potential 
 
TMRE assays were performed as described in section 4.3.4. 
 
5.5.5 LysotrackerTM red DND-99 assay 
 
Fibroblasts from GBA1-PD (n=3) and iPD (n=4) patients were passaged and plated at a 
density of 3000 cells per well in a 96-well plate (Ibidi).Cells were resuspended in medium 
containing no treatment, trehalose 25 mM or 100 mM, or notrtiptyline 0.5 µM or 2 µM 
prior to plating. The cells were incubated at 37OC for four days. The plate was then 
washed with HBSS before 25 nM LysotrackerTM DND-99 and DAPI 1 µg/ml in HBSS 
with Ca2+ and Mg2+ was added and the cells incubated at 37OC for 15 minutes. The cells 
were then fixed in 4 % paraformaldehyde for 15 minutes, and spot analysis was performed 
using the CellomicsTM XTI microscope. 
 
5.5.6 Statistical analysis 
 
Statistical analysis was performed as described in section 3.3.10 
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5.6.1.1 Effect of trehalose on lysosome-autophagy system 
 
To first investigate whether trehalose was able to increase autophagic activity in patient 
cells, fibroblasts were plated from healthy controls (n=2), and patients with GBA1-PD 
(n=3), and then treated with low dose (10 mM) and high dose (100 mM) trehalose for 
four days. In both groups, trehalose increased the P62/SQSTM1 spot count, though this 
only reached significance in the GBA1-PD group (p=0.006 for the 100 mM dose 
compared to vehicle control). The rise in spot count was largest in the healthy control 
group though this did not reach statistical significance, probably due to the smaller sample 
size (Figure 5.2). Surprisingly, P62/SQSTM1 intensity was significantly increased with 
trehalose treatment in both the healthy control (p=0.026 and p=0.001 for trehalose 10 mM 
and 100 mM compared to vehicle control respectively) and the GBA1-PD group 
(p<0.0001 for both trehalose 10 mM and 100 mM compared to vehicle control). 
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Figure 5.2 – P62/SQSTM1 immunocytochemistry in fibroblasts after treatment with 
trehalose. Fibroblasts from healthy controls (n=2) and patients with GBA1-PD (n=3) 
were treated with vehicle control, or low or high dose trehalose for four days. 
P62/SQSTM1 spot count (A) and intensity (B) increased with trehalose treatment. Error 
bars show standard error of mean. Statistically significant differences indicated by 
asterixes as determined by one-way ANOVA with post-hoc Tukey analysis. Scale bar 
represents 50 µm. Abbreviations:  Tre = trehalose. 
 
As has been discussed previously, the increase in P62/SQSTM1 spot count could 
represent an increase in autophagosome numbers, or an increase in sequestosomes due to 
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a block in autophagy. To investigate this further, fibroblasts were treated with vehicle 
control, trehalose 50 mM, bafilomycin A1 100 nM or both trehalose and bafilomycin A1. 
As expected, blockade of autophagy with bafilomycin A1 increased P62/SQSTM1 spot 
count in both healthy controls and GBA1-PD. Trehalose and bafilomycin had an additive 
effect, with a dramatic increase in the observed spot count, which was statistically 
significant in the GBA1-PD group (p=0.001). This suggests that the rise in P62/SQSTM1 
spot count seen with trehalose was not due to a blockage in autophagy, but more likely 
due to an increase in autophagosome numbers. These changes were not statistically 
significant in the healthy control group, which is most likely due to the small sample 
sizes, but a clear trend was seen (Figure 5.3 and Figure 5.4). 
 
Figure 5.3 – P62/SQSTM1 spot count in fibroblasts after treatment with trehalose 
and bafilomycin A1. Fibroblasts from healthy controls (n=2) and patients with GBA1-
PD (n=3) were treated with vehicle control, or trehalose 50 mM with or without 
bafilomycin A1 100 nM.  As seen previously, P62/SQSTM1 spot count and total area per 
cell increased with trehalose treatment. The presence of bafilomycin A1 increased 
P62/SQSTM1 spot count further. Error bars show standard error of mean. Statistical 
significance indicated by asterixes as determined by one-way ANOVA with post-hoc 
Tukey analysis for each group.  Abbreviations: Baf = bafilomycin A1; Tre = trehalose. 
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Figure 5.4 – P62/SQSTM1 immunocytochemistry in fibroblasts after treatment with 
trehalose and/or bafilomycin A1. Bafilomycin A1 and trehalose increased the number 
of small P62/SQSMT1 puncta. The use of both trehalose and bafilomycin A1 had an 
additive effect. Scale bar represents 50 µm. Abbreviations: Baf = bafilomycin A1; Tre = 
trehalose. 
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The effect of trehalose on P62/SQSTM1 levels was also assessed in iNs from healthy 
controls, and patients with iPD and GBA1-PD after treatment with trehalose 100 mM for 
48 hours. The observed changes in P62/SQSTM1 were smaller than those previously seen 
in the fibroblasts (possibly due to the shorter duration of treatment). The P62/SQSTM1 




Figure 5.5 – P62/SQSTM1 immunocytochemistry in iNs following treatment with 
trehalose 100mM. iNs were generated from healthy control (n=2), iPD (n=2) and GBA1-
PD (n=3) fibroblast lines. At day 27 trehalose 100 mM was added to the medium and the 
cells were cultured for a further 48 hours before fixation. Trehalose resulted in a non-
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significant increase in P62/SQSTM1 intensity all groups. Bars represent mean values for 
iNs, defined as those cells expressing the neuronal marker β3-tubulin, with error bars 
representing the standard error of the mean. Scale bar represents 100 µm. Abbreviations: 
Tre = trehalose. 
 
To confirm the finding of increased autophagosome numbers associated with trehalose 
treatment, western blotting was performed for the autophagosome marker LC3b, after 
treatment of fibroblasts with 25 mM or 100 mM trehalose, or vehicle control for four days 
(Figure 5.6). This was initially performed with a healthy control, as well as two iPD cell 
lines. There was an increase in LC3b-II (the autophagosome-associated form of LC3b) 
levels with trehalose 25 mM compared to vehicle control, with a further increase at the 
higher dose (p=0.004) (Figure 5.6). LC3b-I signal was too low to allow one to accurately 
determine LC3b-II:LC3b-I ratios. The increase in LC3b-II was seen in the healthy control 
as well as both iPD lines (Supplementary Figure 7.8). Western blot analysis for LC3b-II 
following trehalose treatment was subsequently performed on three GBA1-PD cell lines, 
which demonstrated a similar increase in LC3b-II:β-actin ratio (p=0.018) and LC3b-
II:LC3b-I ratio (p=0.002) at the higher dose (Figure 5.6 and Supplementary Figure 7.9). 
Taken together with the finding that trehalose had an additive effect on the number of 
P62/SQSTM1 puncta with bafilomycin A1, these data suggest that trehlaose does indeed 
increase the formation of autophagosomes, including in the context of GBA1-PD. 
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Figure 5.6 - LC3b Western blot following trehalose treatment in fibroblasts. 
Trehalose led to a dose-dependent increase in autophagosome numbers in fibroblasts 
from iPD and GBA1-PD patients. A) Western blot for LC3b on fibroblast lysate from a 
healthy control and two iPD cell lines treated with vehicle control, or trehalose 25 mM or 
100 mM for four days. Quantification of this is shown in B), with bars representing the 
mean value for LC3b-II to β-actin ratio of all three lines. C) Western blot for LC3b on 
fibroblast lysate from three GBA1-PD cell lines treated with vehicle control, or trehalose 
25 mM or 100 mM for six days. The mean LC3b-II to β-actin from all three lines is shown 
in D). Error bars represent standard error of the mean. Statistical significance indicated 
by asterixes as determined by one-way ANOVA with post-hoc Tukey analysis. 
Abbreviations: Tre = trehalose. 
 
To further explore the impact of trehalose on the lysosome-autophagy system, lysosomal 
mass was quantified through staining of fibroblasts from patients with iPD (n=4) or 
GBA1-PD (n=3) with LysotrackerTM DND-99 after treatment with vehicle control, or 
trehalose 25 mM or 100 mM for four days. Trehalose treatment was associated with a 
dose-dependent significant reduction in LysotrackerTM spot count and area per cell in both 
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the iPD and GBA1-PD groups, which would be consistent with their increased clearance 
(Figure 5.7). 
 
Figure 5.7 – LysotrackerTM DND-99 staining following trehalose treatment in 
fibroblasts. Trehalose reduced lysosomal mass in iPD and GBA1-PD fibroblasts. 
LysotrackerTM DND-99 spot count (A) and spot area (B) per cell after four days treatment 
with vehicle control, or trehalose 25 mM or 100 mM. Images for vehicle control and high-
dose trehalose are shown in (C). Statistical significance indicated by asterixes as 
determined by independent-samples T tests. Error bars represent standard error of the 
mean. Scale bar represents 100 µm. Abbreviations: Tre = trehalose. 
 
Clinical aspects and in vitro modelling of GBA1 variant-associated Parkinson’s disease 
194 Thomas Stoker – September 2019 
5.6.1.2 Ability of trehalose to impact on α-synuclein-induced pathology 
 
As discussed above, trehalose significantly altered the function of the lysosome-
autophagy system, with the aforementioned findings being most consistent with an 
increase in activation of autophagy. This was seen in GBA1 mutation-carrying lines as 
well as wild-type GBA1 lines, suggesting that its action on the autophagy system was not 
significantly altered by the underlying autophagy defect of GBA1-PD. In order to 
investigate whether these effects of trehalose could potentially benefit neuronal 
pathology, the impact on PFF-induced pathology in iNs was assessed. 
 
iNs were generated from three GBA1-PD lines. At 15 days post-transduction trehalose or 
vehicle control, was added to the cell culture medium, to give final concentrations of 2.5 
mM or 10 mM. Higher doses, such as those used over short durations in the fibroblasts, 
had a detrimental effect resulting in abnormal cell morphology, with swollen cell bodies, 
presumably due to osmotic forces, when used for longer periods (Supplementary Figure 
7.10). Cells were treated with α-synuclein PFFs on day 17, and analysed at day 27 post-
transduction. 
 
Trehalose led to a dose-dependent reduction in PFF-induced α-synuclein aggregates per 
cell, which was statistically significant when normalised to the PFF only condition 
(p=0.001) (Figure 5.8 and Supplementary Figure 7.7). The total spot area per cell was 
also lower following trehalose treatment, though this was just short of statistical 
significance (p=0.053). Additionally, trehalose restored the mitochondrial membrane 
potential level following PFF treatment to that seen at baseline, in a dose-dependent 
fashion. However, trehalose alone resulted in a non-significant increase in mitochondrial 
membrane potential in the absence of PFF, so it is not clear whether the restoration of 
membrane potential following PFF treatment is specific to α-synuclein-induced 
pathology.  Neither PFFs nor trehalose significantly altered neuronal purity (Figure 5.8). 
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Figure 5.8 – Impact of trehalose on PFF-induced pathology in iNs of GBA1-PD 
patients. Trehalose treatment led to a reduction in the number (A) and total area (B) of 
PFF-induced α-synuclein aggregates per cell. C) Trehalose led to a restoration of 
mitochondrial membrane potential following PFF treatment. D) Neither trehalose nor 
PFFs had a significant impact on neuronal purity. E) Representative images of PFF-
induced α-synuclein aggregates. Statistical significance determined by independent 
samples T tests is indicated by asterixes. Scale bar represents 100 µm. Abbreviations: 
PFF = pre-formed fibrils; Tre = trehalose. 
 
In order to study whether trehalose could augment the autophagy response to PFFs in iNs, 
immunocytochemistry for P62/SQSTM1 was performed in iNs from three GBA1-PD 
patients following treatment with PFFs. As seen before, treatment with PFFs led to an 
increase in autophagy as evidenced by a small reduction in P62/SQSTM1 intensity 
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(p=0.028). Trehalose treatment led to a greater decline in P62/SQSTM1 intensity after 
treatment with PFFs suggesting that it was able to augment the autophagy response in this 
setting, though this only reached significance with the smaller dose (p=0.001). The 
decline in P62/SQSMT1 intensity brought on by PFF treatment was significantly greater 
in the trehalose 2.5 mM group compared to vehicle control (p=0.011), suggesting that the 
autophagy response to PFFs was enhanced by trehalose. 
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Figure 5.9 – Effect of trehalose on autophagy response to PFFs. iNs were generated 
from three GBA1-PD cell lines. At day 15 post-transduction vehicle control or trehalose 
2.5 mM or 10 mM was added to the cells. At day 17, PFFs (0.5 ng/µl) were added, and 
the cells were cultured for a further seven days, before immunocytochemistry for 
P62/SQSTM1 was performed. Representative images shown in A) and quantification of 
P62/SQSTM1 intensity relative to the no PFF condition shown in B). Statistical 
significance determined by independent samples T tests indicated by asterixes. Scale bar 
represents 50 µm. Abbreviations: iN = induced neurons; PFF = pre-formed fibrils; Tre = 
trehalose. 
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5.6.2.1 The effects of nortriptyline on the lysosome-autophagy system 
 
To first assess whether nortriptyline could affect the lysosome autophagy system, 
fibroblasts from two iPD cell lines were treated with vehicle control, or 2 µM or 5 µM 
nortriptyline for six days, and autophagosome numbers were quantified with LC3b 
Western blot (Figure 5.10). Nortriptyline treatment led to a dose dependent increase in 
LC3b-II, though this did not reach statistical significance, probably due to the low number 
of cell lines. This was repeated in fibroblasts from GBA1-PD cell lines (n=3), in which 
there was no increase in LC3b-II levels with nortriptyline treatment (Figure 5.10 and 
Supplementary Figure 7.11). It had been found that prolonged culture of iNs with doses 
of 5 µM or higher resulted in poor cell survival, so the lower maximum dose of 2 µM was 
employed for this repeat experiment with GBA1-PD lines.  
 
Figure 5.10 LC3b Western blot in iPD and GBA1-PD lines after treatment with 
nortriptyline. Nortriptyline increased autophagosome numbers in iPD, but not GBA1-
PD fibroblasts. A) Western blot for LC3b on fibroblast lysate from two iPD cell lines 
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treated with vehicle control, or nortriptyline 2 µM or 5 µM for one week. Quantification 
of this is shown in B), with bars representing the mean value for LC3b-II to β-actin ratio 
of both lines. C) Western blot for LC3b on fibroblast lysate from three GBA1-PD cell 
lines treated with vehicle control, or nortriptyline 0.5 µM or 2 µM for one week. The 
mean LC3b-II to β-actin for these lines is shown in D). Error bars represent standard error 
of the mean. Abbreviations: Nor = nortriptyline. 
 
The effect of nortriptyline in iNs was then assessed with immunostaining for 
P62/SQSTM1, after 48 hours treatment. Only cells that expressed β3-tubulin were 
included in the analysis. Nortriptyline resulted in a reduction in P62/SQSTM1 intensity 
in all groups to similar extents, suggesting an increase in autophagic flux, which reached 
significance in the GBA1-PD group (p=0.021). 
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Figure 5.11. P62/SQSTM1 immunocytochemistry in iNs after treatment with 
nortriptyline. Fibroblasts from healthy control (n=2), iPD (n=2) and GBA1-PD (n=3)] 
individuals were reprogrammed to iNs. At day 27, iNs were treated with nortriptyline 10 
µM or vehicle control for 48 hours, before immunocytochemistry for P62/SQSTM1 was 
performed. A) and B) P62/SQSTM1 levels were non-significantly reduced in iNs from 
all groups, which reached significance in the GBA1-PD group (p=0.021) (Only cells 
expressing β3-tubulin were included in the analysis). C) Images for GBA1-PD cell line at 
20X magnification. Scale bar represents 100 µm. Asterix indicates statistical significance 
as determined by independent samples T tests. Abbreviations: Nor = nortriptyline. 
 
In order to assess whether or not nortriptyline altered the lysosome count, fibroblasts from 
patients with GBA1-PD (n=3) and iPD (n=4) were incubated with nortriptyline 0.5 µM or 
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2 µM, or vehicle control for four days, before staining with LysotrackerTM DND-99. In 
the iPD group the lysosome count (p=0.01) and area (p=0.023) were significantly 
increased with nortriptyline, with further increased with the higher dose (p=0.003 and 
0.019 for lysosome count and area respectively). In the GBA1-PD group there was a 
smaller rise in lysosome count and area which only reached significance for the higher 
dose p<0.0001 and p=0.001 respectively).  (Figure 5.12).  
 
 
Figure 5.12. Effect of nortriptyline treatment on lysosomal mass in fibroblasts. 
Fibroblasts from patients with GBA1-PD (n=3) and iPD (n=4) were stained with 
LysotrackerTM DND-99. In both groups there were significant increases in lysosomal 
count and total lysosomal area. Statistical significance indicated by asterixes as 
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determined by independent samples T-tests. Scale bar represents 100 µm. Abbreviations: 
Nor = nortriptyline. 
 
5.6.2.2 Ability of nortriptyline to impact on α-synuclein-induced pathology 
 
Having found that nortriptyline resulted in changes to the lysosome-autophagy system, it 
was then tested in the PFF model, to see whether it could impact on α-synuclein 
pathology. Initially, iNs from GBA1-PD cell lines were treated with nortriptyline 0.5 µM 
or 2.5 µM from day 15 post-transduction, with addition of PFFs at day 17. As with 
previous experiments, half medium changes were then carried out until day 27 before 
analysis. In the GBA1-PD lines, nortriptyline had no effect on the number of PFF-induced 
α-synuclein aggregates. Neither nortriptyline treatment, nor PFF treatment had any 
significant effect on neuronal purity. The effect of nortriptyline on mitochondrial 
membrane potential was also assessed after PFF exposure, using a TMRE assay. 
Nortriptyline alone did not significantly alter mitochondrial membrane potential in the 
GBA1-PD iNs. The decline in mitochondrial membrane potential with PFFs was less than 
that previously seen, such that it did not reach significance. It was therefore not possible 
to comment on whether the nortriptyline protected against the PFF-induced decline in 
mitochondrial membrane potential. Nevertheless, nortriptyline did not seem to offer any 
significant benefit in the GBA1-PD iNs in terms of reducing PFF-induced pathology. 
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Figure 5.13 – Effect of nortriptyline on PFF-induced α-synuclein aggregates in 
GBA1-PD. Nortriptyline treatment did not reduce the burden of α-synuclein aggregates 
in GBA1-PD iNs (n=3). There were no significant differences in mitochondrial membrane 
potential with nortriptyline treatment. Asterixes indicate statistical significance as 
determined by one-way ANOVA with post-hoc Tukey analysis. Scale bar represents 100 
µm. Abbreviations: PFF = pre-formed fibrils; Nor = nortriptyline. 
 
Because nortriptyline seemed to have a more significant effect on autophagy in the iPD 
lines in comparison to the GBA1-PD lines, the effect of nortriptyline on PFF-induced 
pathology was also assessed in iPD iNs (n=5). Two healthy control lines were also 
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included. As had previously been observed, the number of PFF-induced α-synuclein 
aggregates was low in the healthy controls, and nortriptyline did not significantly alter 
the number of these. In contrast, in the iPD group, nortriptyline led to a dose-dependent 
reduction in the number of α-synuclein spots (p=0.048 and p=0.021 for the low and high 
dose respectively). The effect on TMRE signal was then assessed. Nortriptyline treatment 
alone did not alter the mitochondrial membrane potential in either group. PFFs resulted 
in a reduction in mitochondrial membrane potential in the iPD group (p=0.003), which 
was partially corrected with nortriptyline treatment. In the healthy control group PFF 
treatment did not alter the mitochondrial membrane potential. 
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Figure 5.14. Effect of nortriptyline in iNs from healthy control and iPD individuals. 
A) and C) Nortriptyline reduced PFF-induced aggregates in iPD but not in healthy 
controls (n=2). B). Nortriptyline led to a restoration in mitochondrial membrane potential 
after PFF treatment in iNs from iPD lines (n=5). Asterixes represent statistically 
significant differences determined by one-way ANOVA with post-hoc Tukey analysis. 
Scale bar represents 100 µm. Abbreviations: Nor = nortriptyline; PFF = pre-formed 
fibrils. 
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5.6.3 Other Drugs 
 
Metformin and ghrelin were also tested in the iN model given that they have been 
suggested to have beneficial effects on mitochondrial function. iNs were generated from 
three GBA1-PD lines, which were treated with 1 mM or 4 mM metformin, or 1 µm or 5 
µm ghrelin from day 15. As before, PFFs were added at day 17 post-transduction, and 
analyses performed after a further 10 days. Neither metformin nor ghrelin had a 
significant effect on neuronal purity or the number or area of PFF-induced α-synuclein 
aggregates, when compared to the PFF only condition. Metformin was associated with a 
dose-dependent increase in mitochondrial membrane potential (p=0.003 and p=0.001 for 
the low and high dose respectively). It also corrected the decline in mitochondrial 
membrane potential induced by PFFs to baseline levels. Ghrelin had no effect on 
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Figure 5.15 – Impact of metformin on PFF-induced pathology in iNs of GBA1-PD 
patients. The number (A) and total area (B) of PFF-induced α-synuclein aggregates per 
cell was not significantly altered by metformin treatment. C) Metformin increased 
mitochondrial membrane potential alone, and following PFF treatment. D) Neither 
metformin nor PFFs had a significant impact on neuronal purity. E) Representative 
images of PFF-induced α-synuclein aggregates. Asterixes indicate statistically significant 
differences as determined by one-way ANOVA with post-hoc Tukey analysis. Scale bar 
represents 100 µm.  Abbreviations: Met = metformin; PFF = pre-formed fibrils. 
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Figure 5.16– Impact of ghrelin on PFF-induced pathology in iNs of GBA1-PD 
patients. The number (A) and total area (B) of PFF-induced α-synuclein aggregates per 
cell was not significantly altered by ghrelin treatment. C) Ghrelin did not significantly 
alter mitochondrial membrane potential alone, or following PFF exposure. D) Neither 
ghrelin nor PFFs had a significant impact on neuronal purity. E) Representative images 
of PFF-induced α-synuclein aggregates. Asterixes indicate statistically significant 
differences as determined by one-way ANOVA with post-hoc Tukey analysis. Scale bar 
represents 100 µm.  Abbreviations: Ghr = ghrelin; PFF = pre-formed fibrils. 
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5.7 Discussion 
 
Here, the abilities of putative disease-modifying treatments to reduce α-synuclein-
induced pathology in GBA1-PD have been tested in a novel iN model. This focus of this 
study was predominantly on two drugs purported to enhance activity in the lysosome-




Trehalose has previously been shown to reduce the burden of protein aggregates and 
improve clinical features in models of a number of neurodegenerative disorders (Davies 
et al. 2006, Sarkar et al. 2007, Rodríguez-Navarro et al. 2010). The mechanism by which 
trehalose achieves this is not clear, and may be multi-modal. Some studies have suggested 
that trehalose binds to and stabilises mutant proteins, preventing aggregation (Tanaka et 
al. 2004, Davies et al. 2006). Others have demonstrated that trehalose affects the activity 
of the lysosome-autophagy system, and it has been suggested to activate autophagy in an 
mTOR-independent manner (Sarkar et al. 2007, Rodríguez-Navarro et al. 2010, Redmann 
et al. 2017). It was therefore selected for investigation as a potential treatment for GBA1-
PD in which the autophagy system is dysfunctional. 
 
Trehalose clearly had an effect on the lysosome-autophagy system, which was similar in 
GBA1-PD to that in iPD. An increase in LC3b-II levels demonstrates that trehalose 
increased autophagosome numbers, either through increased activation of autophagy, or 
a fusion block. Taking into account the previous literature, the former is more likely, and 
this is supported by the fact that trehalose had an additive effect on the number of 
P62/SQSMT1 puncta induced by bafilomycin A1 treatment. Trehalose also led to a 
reduction in lysosome numbers, whereas one would expect an increase in lysosome count 
in the context of a fusion block in the autophagy pathway. The reduction in lysosome 
numbers would be consistent with their increased clearance due to increased flux through 
the lysosome-autophagy system. In order to more fully classify the mechanism by which 
trehalose altered autophagosome numbers it would be useful to perform LC3b-II and 
P62/SQSMT1 Western blot analysis in the context of autophagy inducing conditions (e.g. 
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starvation) and with blockers of the fusion stage. The mean intensity of P62/SQSTM1 in 
fibroblasts and iNs increased with trehalose (though the effect was much lower, and not 
significant in the latter). Increased P62/SQSTM1 levels normally indicate a reduction in 
autophagy flux, which conflicts with the prior literature and the other findings here. It 
should be acknowledged that immunocytochemistry is only semi-quantitative, and the 
increase in mean intensity may not represent an increase in P62/SQSTM1 levels. The 
apparent increase in P62/SQSTM1 intensity may have been a limitation of the analysis 
protocol, and it is possible that in conditions in which high numbers of brightly 
fluorescent puncta are present (such as with bafilomycin or trehalose treatment), that the 
mean intensity is raised. Furthermore, there are some circumstances in which increased 
P62/SQSTM1 levels have been associated with increases in autophagy activity (Colosetti 
et al. 2009, Toepfer et al. 2011). 
 
Inhibition of PI3K selectively led to impairment in autophagy activity in GBA1-PD as 
discussed in chapter 4. Trehalose is known to activate autophagy in an mTOR-
independent manner (Sarkar et al. 2007), and it would be interesting to determine if it is 
activating autophagy through PI3K-dependent pathways, thus overcoming the autophagy 
dysfunction of GBA1-PD. 
 
Importantly, trehalose led to a significant reduction in the burden of PFF-induced α-
synuclein aggregates, and was also able to prevent the PFF-induced reduction in 
mitochondrial membrane potential. Though the mechanisms behind this have not been 
investigated, PFF treatment induced an autophagy response, which was augmented by 
trehalose in the GBA1-PD group (section 4.4.4), and it is therefore plausible that trehalose 
was able to reduce the number of PFF-induced aggregates through an induction of 
autophagy. The restoration of mitochondrial membrane potential could be explained 
through clearance of depolarised mitochondria via a restored mitophagy pathway, or 
through a reduction in aggregate-induced mitochondrial dysfunction. Although 
investigation of these mechanisms would be important, the fact that trehalose is able to 
reduce this α-synuclein-related pathology, even in the context of GBA1 abnormalities 
makes this an interesting agent for further therapeutic testing. 
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5.7.2 Nortriptyline 
 
In this study, the ability of nortriptyline to alter the function of the lysosome-autophagy 
system was first assessed in fibroblasts and iNs from PD patients, before being tested in 
the PFF-iN model, to see if it was able to reduce α-synuclein pathology. 
 
Nortriptyline was found to increase autophagosome numbers in iPD cell lines, but not in 
GBA1-PD cell lines. As discussed above, the increase in autophagosome numbers could 
be explained by increased activation of macroautophagy, or by a blockade in the fusion 
steps of the pathway. The subsequent observation that nortriptyline resulted in increased 
autophagic flux, as demonstrated by reduced P62/SQSTM1 levels in iNs, suggests that 
increased activation of autophagy is the more likely explanation. In order to confirm this 
suspicion, it would be necessary to perform this experiment with the addition of blockers 
of the lysosome-autophagosome fusion stage, such as bafilomycin A1. 
 
Additionally, nortriptyline led to an increase in lysosome numbers in the iPD lines, and 
to a lesser extent in the GBA1-PD group. It is not possible to comment on whether the 
increase in lysosomes is due to their increased biosynthesis or reduced clearance, but it 
raises the possibility that nortriptyline may have multiple actions on the lysosome-
autophagy system. 
 
In fibroblasts, nortriptyline had a much lesser effect on autophagy parameters in GBA1-
PD than in iPD, suggesting that it is acting via a mechanism that is not able to fully 
overcome the autophagy deficit of GBA1-PD, and that it is probably acting upstream of 
the site of dysfunction in GBA1-PD. However, when tested in iNs rather than fibroblasts, 
nortriptyline did significantly increase autophagy activity, which may be a reflection of 
the fact that autophagy activity is different in different cell types, and consequently the 
effect of drugs on this system differs between cell types. Having said this, nortriptyline 
did not offer any significant benefit in reducing PFF-induced pathology in the GBA1-PD 
iNs. In contrast, in the iPD group in which nortriptyline clearly increased autophagy 
activity, treatment resulted in a reduction in PFF-induced α-synuclein aggregates, and 
restoration of mitochondrial membrane potential following PFF-treatment. Taken 
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together, this data suggests that nortriptyline may have a beneficial effect in iPD through 
action on the lysosome-autophagy pathway, but that this effect is probably reduced in 
GBA1-PD. 
 
5.7.3 Other Drugs Tested 
 
Metformin and ghrelin were tested in the iN system given that they have previously been 
suggested to have beneficial effects on mitochondrial health, with the aim of targeting the 
presumed downstream pathology in the PFF model. Unsurprisingly, neither treatment 
significantly altered the burden of PFF-induced aggregates. In fact, there was a non-
significant trend towards an increase in these structures with metformin. As is discussed 
in section 4.5.3, this apparent increase could be due to a number of potential factors, such 
as increased expression of α-synuclein or a detrimental effect on protein-clearance 
systems. 
 
Treatment with metformin did however result in an increase in the mitochondrial 
membrane potential, suggesting that it did have a beneficial effect on mitochondria in the 
iNs. Whilst metformin did seem to restore the mitochondrial membrane potential to 
baseline levels following PFF treatment, it had the same effect in the absence of PFFs. It 
is not known therefore whether or not metformin is altering the relationship between PFF-
induced aggregates and mitochondrial health, and it would be useful to perform a cell 
viability or caspase activity assay, to determine whether or not this effect was truly 
beneficial. Ghrelin did not significantly affect mitochondrial membrane potential. 
 
5.7.4 Induced Neurons for drug testing in Parkinson’s disease 
 
As has been mentioned, the use of iNs for drug screening studies has been very limited 
to date, and this study is possibly the largest in which iNs have been used for this purpose. 
Of the four drugs tested here, trehalose treatment yielded some promising results in the 
context of GBA1-PD, in which it reduced the number of PFF-induced α-synuclein 
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aggregates and also corrected the decline in mitochondrial membrane potential, with 
similar results occurring with nortriptyline treatment in the iPD group. 
 
One particular aspect of this model was that the pathological insult was relatively minor 
– a single dose of α-synuclein PFFs. Of course, this acute dose of PFFs is not reflective 
of the chronic degenerative process of PD, but the purpose of this is to induce the 
development of endogenous α-synuclein pathology, more closely representing the 
presumed pathogenic process in patients. However, the fact that this insult was minor 
posed limitations, in that the pathology that developed in the iNs was relatively mild, and 
that the significance of the (predominantly extracellular) α-synuclein aggregates was of 
uncertain significance (discussed in section 4.5.3). As has been discussed, the decline in 
mitochondrial membrane potential following PFF treatment was a consistent finding in 
the GBA1-PD cell lines. However, the biological effect of this was relatively small, and 
therefore often did not reach statistical significance for individual experiments, 
sometimes precluding any firm conclusions about the effects of a drug on this pathology. 
Future exploration of this model will require work with a greater number of cell lines so 
that findings regarding the effects of drugs on pathology are more robust. Additionally, 
other than the development of the PFF-induced aggregates, there were little pathological 
findings in the iPD group, making this model of more limited use in studying the effects 
of drugs in this population. Having said this, when a greater number of cell lines were 
employed (Figure 5.3) when testing the effects of nortriptyline in iPD, the decline in 
mitochondrial membrane potential was statistically apparent. 
 
Going forward, the utility of this model would be significantly enhanced by using a 
greater number of cell lines, both in the iPD and GBA1-PD group. It would also be useful 
to search for and test additional outcome measures, such as PFF-induced impairments in 
ATP production or oxygen consumption, or increases in mitochondrial superoxide 
formation for example. Additionally, PFF-treatment resulted in an increase in caspase 
activity in the GBA1 group (Figure 4.27), and it would be useful to test whether or not 
trehalose (or other drugs) prevented this. In addition, a greater degree of pathology would 
be desirable for future studies, which would best be achieved through increased culture 
time, so studies in which the culture conditions are optimised may facilitate this. 
Alternatively, pathology could be exaggerated by knocking-in mutant forms of, or 
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overexpressing wild-type α-synuclein, but these approaches would take the model further 
away from the pathogenic processes occurring in patients, thus negating one of the 
advantages of this model.
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6 DISCUSSION 
 
6.1 Clinical significance of GBA1 variants in 
Parkinson’s disease 
 
The aim of the first study in this project was to better characterise the natural history of 
GBA1-PD, using a study population of incident PD patients. Though the sample size was 
a limiting factor, the long follow-up time meant that most participants were followed-up 
from the time of diagnosis, to the time to development of dementia, postural instability 
and death – three critical milestones in the evolution of PD. This meant that is was 
possible to establish a clear picture of the clinical course of GBA1-PD, and contrast it to 
that in PD patients without GBA1 variants. 
 
This study replicated the findings of most previous studies, in that it demonstrated an 
increased risk of motor progression and dementia in association with GBA1 variants. In 
contrast to most other studies, the long follow-up period in this analysis allowed for the 
impact of GBA1 variants on mortality to be determined. It was found that carrying a 
pathogenic mutation or polymorphism increased the risk of death, which occurred 
approximately a year earlier in comparison to non-carriers – an effect that was 
independent of the development of dementia. 
 
The other main conclusion from this study, is that GBA1 polymorphisms (in addition to 
GD-causing pathogenic mutations) such as the E326K variant, adversely affect the course 
of PD. This finding is important for two reasons in particular. Firstly, this approximately 
doubles the proportion of PD patients in which GBA1 abnormalities potentially play a 
pathogenic role, such that around 10 % of PD patients will carry a relevant GBA1-variant. 
As such, as targeted disease-modifying therapies becomes available, and as regenerative 
therapies begin to enter clinical trials, testing for GBA1 variants may have important 
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implications for practice. Secondly, the fact that these polymorphisms do not predispose 
to GD implies that their pathogenic consequences are unique to GBA1-PD (and 
potentially other α-synucleinopathies such as DLB). Experimental therapies that augment 
GCase activity are likely therefore to be of limited use in this population, and the focus 
should be on restoring correct folding of GCase or targeting the dysfunctional 
intracellular pathways associated with GBA1 variants. 
 
6.2 A novel model for drug testing in GBA1 variant-
associated Parkinson’s disease 
 
The second arm of this project was the establishment of a novel model using iNs that 
could be used for drug-screening studies. iNs were chosen because of the fact that they 
retain the age signature of the host, meaning that they uniquely offer a source of aged, 
adult human neurons – a relevant cell-type when studying neurodegenerative diseases. 
Despite having first been described almost a decade ago, the application of iNs to answer 
questions about disease processes has been limited to a small number of studies, and to 
answer questions about putative treatments has been confined to an even smaller number 
of studies. The focus of this study was on developing a model in which iN technology 
could be applied to answer clinically relevant questions. 
 
The baseline pathology in the iNs was limited, and in order to manifest α-synuclein-
related pathology, a single dose of pathogenic α-synuclein PFFs was necessary. Though 
this represented an artificial insult, the PFFs were cleared quickly, and subsequent 
pathology therefore came from endogenous processes. Treatment with PFFs yielded some 
reproducible outcome measures, such as the accumulation of α-synuclein aggregates and 
reduction in mitochondrial membrane potential which were used for drug testing studies 
here, as well as other outcome measures such as elevated caspase activity, which could 
be used for future projects. Effects such as the decline in mitochondrial membrane 
potential tended to be of low magnitude, and future studies should employ a greater 
number of cell lines to ensure that they are adequately powered to determine differences. 
As is discussed in detail in chapter 4, the significance of the PFF-induced, predominantly 
extra-cellular aggregates is not known, but they were considered to serve as a surrogate 
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marker for α-synuclein accumulation. Further characterisation of this system will be 
useful in future studies. 
 
Though a number of challenges with the use of iNs remain, such as variability in 
reprogramming potential between cell lines, limited culture longevity, and impurities in 
cell populations as unconverted or partially converted cells persist, this study 
demonstrates that iNs can potentially be applied, and play an important role, in disease-
modelling studies. 
 
6.3 Putative disease-modifying treatments 
 
A series of experiments were performed as part of this study in which the lysosome-
autophagy system and mitochondrial health were assessed, to explore whether GBA1-
variants were associated with dysfunction in these systems. Though the exact nature of 
dysfunction was not studied in depth, it was clear that there were differences in the 
lysosome-autophagy system in GBA1-PD compared to iPD and healthy controls. These 
studies, along with the existing literature, were useful in providing some rationale for the 
initial selection of drugs to test in the iN model. Trehalose and nortriptyline were therefore 
chosen, for their previously reported ability to augment autophagy activity in a number 
of models. Because mitochondrial dysfunction had been identified in the iN model 
following PFF treatment, metformin and ghrelin were also tested in this system. 
 
When testing the two drugs targeting autophagy, both yielded interesting results. Only 
trehalose was found to enhance autophagy in GBA1-PD, with no changes in LC3b-II 
levels associated with nortriptyline treatment. Trehalose, but not nortriptyline, was 
associated with a reduction in PFF-induced pathology in the iN system in GBA1-PD. In 
contrast, nortriptyline reduced pathology in the iPD group. Both of these drugs readily 
cross the blood-brain-barrier, and safety data for nortriptyline which is already widely 
used for other conditions is well established. Trehalose is not currently used in a clinical 
setting, but early clinical trials have begun to confirm its safety (clinicaltrials.gov 
identifier NCT02725957). Both drugs therefore could potentially be prioritised for entry 
into clinical trials, if they continue to show promise in experimental models. 
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6.4 Further Work 
 
Going forward with this work, a number of other studies would be useful. With regard to 
the iN system, the most important aim will be to increase the longevity of the cell culture, 
to potentially allow for the development of relevant intracellular pathology. Of course, 
limitations in the survival of cells in the culture system may relate to underlying disease-
related factors, but a systematic assessment of the different culture matrices to determine 
the optimal culture conditions would be useful. 
 
In this study, the use of α-synuclein PFFs in iNs provided a number of outcome measures 
that could be used for drug screening. It would however, be useful to characterise the PFF 
pathology further. One of the outcome measures used for drug testing in this project was 
a reduction in mitochondrial membrane potential after PFF treatment. It is important to 
assess other mitochondrial parameters including ATP production and oxygen 
consumption following PFF exposure, to further quantify the effect on mitochondrial 
function. Caspase activity was also increased following PFF exposure in this study, and 
it would be useful to perform a cell death assay to explore this further. PFF-induced 
changes in any of these parameters could be used for further drug testing. 
 
The nature of the PFF-induced aggregates, and the intracellular α-synuclein pathology 
has not been established. It would therefore be interesting to perform 
immunoprecipitation assays to determine the effect of PFFs on the accumulation of 
pathogenic α-synuclein species. Immunocytochemistry failed to detect any serine-129 
phosphorylated α-synuclein, but it is possible that the levels of phosphorylated α-
synuclein were below the detection limit for this assay. Immunoprecipitation would allow 
for a greater sensitivity in detecting phosphorylated and high molecular weight α-
synuclein species. If such α-synuclein pathology is detected on immunoprecipitation, 
these would provide further useful outcome measures for drug screening. 
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Preliminary results suggested that trehalose and nortriptyline reduced PFF-induced α-
synuclein pathology in different groups. Whilst both drugs altered autophagy parameters, 
the mechanisms by which they do this have not been established, and it is not clear 
whether or not the reduction in PFF-induced pathology is due to an effect on the 
lysosome-autophagy system. It would therefore be useful to visualise autophagosomes 
and lysosomes following treatment with these drugs to explore whether or not they are 
affecting autophagosome formation or the fusion stage of the pathway. It would also be 
useful to see whether or not autophagy inhibitors such as 3-MA diminish the effects of 
trehalose and nortriptyline in the PFF model. 
  
6.5 Concluding remarks 
 
GBA1-PD continues to be a PD subpopulation of considerable interest. GBA1-variants 
are common in PD, occurring in approximately 10 % of patients, and it is increasingly 
clear that they adversely affect clinical course. Targeting this population therefore could 
have a significant impact on the overall burden of PD-related morbidity and mortality. 
Furthermore, in this group of patients there are specific pathogenic processes, and 
experimental therapies should target these. iNs offer a means of rapidly generating aged 
adult neurons, which can be used for disease-modelling and drug screening. As with all 
models, there are disadvantages to the use of iNs, but they potentially offer a useful in 
vitro system for the study of neurological disease, and future studies should focus on the 
applicability of these cells for this purpose.
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7 SUPPLEMENTARY MATERIAL 
 
Plasmid Size (kb) Restriction Endonuclease Splice Site Fragment Sizes 




















Supplementary Table 7.1 – Restriction endonucleases used for agarose gel plasmid 
verification. 
 
Gene Primer / Probe Sequence 
Albumin Forward primer 5'-TGAAACATACGTTCCCAAAGAGTTT-3' 
Reverse primer 5'-CTCTCCTTCTCAGAAAGTGTGCATAT-3' 
Probe 5'Fam-TGCTGAAACATTCACCTTCCATGCAGA-Tamra-3' 
WPRE Forward primer GGCACTGACAATTCCGTGGT 
Reverse primer AGGGACGTAGCAGAAGGACG 
Probe 5'Fam-ACGTCCTTTCCATGGCTGCTCGC -Tamra-3' 
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Target Species Supplier Catalogue 
Number 
Dilution 
Tau Mouse Thermo Fisher MN1000 1:500 
Map2 Rabbit EMD Millipore AB5622 1:500 
α-synuclein-42 Mouse BD Biosciences 610787 1:1000 
Neurofilament-200 Mouse Sigma N0142 1:1000 
MAP2 Chicken Abcam Ab5392 1:100 
LC3B Rabbit Sigma L7543 1:500 
P62/SQSTM1 Mouse Genetex GTX629890 1:500 
P62/SQSTM1 Rabbit Abcam Ab91526 1:500 
β3-tubulin Mouse Abcam Ab78078 1:1000 
β3-tubulin Rabbit Abcam Ab18207 1:1000 
NCAM Mouse Abcam Ab9018 1:1000 




Mouse Millipore MABN826 1:1000 





Supplementary Table 7.3 – Primary antibodies used in immunocytochemistry and 
Western blot analyses. 
 
 
Supplementary Figure 7.1 – P62/SQSTM1 immunocytochemistry in iNs under 
baseline conditions. iNs from healthy controls (n=2) and patients with iPD (n=2) and 
GBA1-PD (n=3) were fixed at day 29 post-transduction and immunocytochemistry for 
P62/SQSMT1 was performed. There were no significant differences in P62/SQSTM1 
intensity or P62/SQSTM1 spot count as determined by one-way ANOVA and post-hoc 
Tukey analysis. Error bars represent standard error of the mean. 
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Supplementary Figure 7.2 – Immunocytochemistry for phosphorylated serine 129 
α-synuclein. iNs from a GBA1-PD line were generated. PFFs were applied at day 17 and 
the cells were fixed nine days later. Confocal microscopy images were obtained at 20x 
magnification. No phosphorylated α-synuclein was detected. Scale bar represents 200 
µm. Abbreviations: p-α-syn ser-129 = phosphorylated serine 129 α-synuclein. 
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Supplementary Figure 7.3 – Brightfield images of starved iNs prior to lysing for 
protein harvest for LC3b and P62/SQSTM1 Western blots. Scale bar represents 200 
µm. 
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Supplementary Figure 7.4 – LC3b quantification in iNs under baseline conditions. 
iNs were generated from healthy controls (n=2), and patients with iPD (n=4) and GBA1-
PD (n=3). At day 22 post-transduction protein was harvested in 5 M urea lysis buffer for 
Western blot analysis. Graph shows quantification of LC3b-II levels showing no 
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Supplementary Figure 7.5 – Brightfield images of iNs treated with PFFs or vehicle 
control prior to lysing for protein harvest for LC3b and P62/SQSTM1 Western 
blots. Scale bar represents 200 µm. 
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Supplementary Figure 7.6 – Effect of PFF-treatment on neuronal purity. Post-hoc 
analysis of 12 conversions involving 14 cell lines. PFF treatment did not alter neuronal 
purity. Abbreviations: PFF = pre-formed fibrils.  
 
 
Supplementary Figure 7.7 – Effect of trehalose on PFF-induced α-synuclein 
aggregate count and area. Trehalose led to a dose-dependent trend in the numbers and 
area of PFF-induced aggregates per cell. Statistical significance indicated by asterixes as 
determined by one-way ANOVA with post-hoc Tukey analysis. Abbreviations: PFF = 
pre-formed fibrils. Tre = trehalose. 
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Supplementary Figure 7.8 – LC3b-II levels in individual cell lines after treatment 
with trehalose. Trehalose increased autophagosome numbers in all three cell lines. 
Abbreviations: Tre = trehalose. 
 
 
Supplementary Figure 7.9 – Western blot analysis of LC3b-II:LC3b-I ratio in 
GBA1-PD cell lines after trehalose treatment. Trehalose led to a dose-dependent 
increase in autophagosome numbers in GBA1-PD fibroblasts. Statistical significance 
indicated by asterixes as determined by one-way ANOVA with post-hoc Tukey analysis. 
Abbreviations: Tre = trehalose. 
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Supplementary Figure 7.10 – Morphology of iNs after treatment with high-dose 
trehalose. iNs from an iPD line were generated and at day three post-transduction, 
trehalose 100mM was added. Images obtained at day 10 post-transduction demonstrated 
abnormal cell morphology associated with high-dose trehalose treatment. Scale bar 
represents 200 µm. 
 
 
Supplementary Figure 7.11 – Western blot analysis of LC3b-II:LC3b-I ratio in 
GBA1-PD cell lines after nortriptyline treatment. Nortriptyline did not alter LC3b-
II:LC3b-I ratio in fibroblasts from GBA1-PD iNs. Abbreviations: Nor = nortriptyline.
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